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ABSTRACT 
THE ROLE OF THE TOLL-LIKE RECEPTOR PATHWAY IN 
SUSCEPTIBILITY TO INFLAMMATORY BOWEL DISEASE 
Nigel Crawford, B.Sc. (HODS), M.B. Ch.B. 
February 16th, 2004 
Inflammatory bowel disease (IBD) is a chronic autoimmune disorder that is 
subdivided into Crohn's disease (CD), ulcerative colitis (UC), and indeterminate colitis 
(IC). Epidemiological studies have proven that genetic variation increases susceptibility 
to IBD, with multiple abnormal genes combined with environmental factors being 
responsible for disease development. Characterization of these susceptibility genes 
remains of critical importance to improving understanding of IBD pathogenesis. 
The overall aim of this study is to discover new IBD susceptibility genes. The 
initial approach was to study a number of previously described IBD susceptibility loci 
through characterization of peak LOD score short tandem repeat markers using 
population- and family-based methods. The IBD 1, IBD2, and IBD5 loci were shown to 
be associated with different forms of IBD in the study cohort. This work formed the basis 
of the next series of experiments, where the IBD2 locus was mapped in detailed. IBD2 
was shown to be associated with IC, colonic CD and to some extent UC. 
Focus of this study then turned to two candidate genes: interleukin-l receptor-
associated kinase-M (IRAK-M), an inhibitor of the strongly pro inflammatory Toll-like 
VI 
receptor pathway, and myeloid differentiation factor 88 (MyD88), an adaptor protein 
involved in macrophage apoptosis. These genes were selected on the basis of their 
biological plausibility and genomic location (within IBD2 and IBD9 respectively). The 
first phase of this study was to define candidate gene colonic mucosal expression levels 
in IBD, and to screen coding and regulatory regions for polymorphisms. Both genes were 
significantly over-expressed in IBD-affected mucosa, and contained a total of seven 
commonly occurring single nucleotide polymorphisms (SNPs). 
These polymorphisms were then characterized in the entire population to define 
disease-associations. SNPs within the 3' -untranslated region of MyD88 were associated 
with late onset CD in patients with a family history of IBD. However, a number of 
concerns do exist regarding the low statistical power of these analyses. In contrast, lRAK-
M is unlikely to playa role in IBD susceptibility in this population. 
In conclusion, preliminary evidence is presented to show that MyD88 may be an 
IBD susceptibility gene. Its precise role in CD development will be clarified in further 
studies. 
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Almost all human disorders are affected to some extent by genetic factors. Such 
hereditary influences will tend to predispose to the development of either individual 
diseases (e.g. rheumatoid arthritis) or specific disease types (e.g. autoimmune disease). 
Consideration of such factors allows diseases to be broadly classified into 'Mendelian' or 
'complex' based on their inheritance pattern. 
Mendelian or single-gene traits are directly related to distinct genetic or 
biochemical defects. This type of inheritance pattern is rare and is only apparent in a 
small number of human disorders. Complicating factors, such as incomplete penetrance 
(that is, not all genetically predisposed individuals will develop the disease) and variable 
age of onset are often evident in this type of disease, but all show basic Mendelian 
inheritance patterns (1). 
In contrast to Mendelian disorders, complex diseases are highly prevalent within 
human populations. Common examples include essential hypertension, osteoarthritis and 
schizophrenia. These types of disorders differ in that the influence of genetic factors is 
much less well defined. Overall, the influence of hereditary factors appears to be much 
more subtle, and rather than being overtly involved in pathogenic processes as is the case 
with Mendelian disorders, genetic variation within a population causes susceptibility to a 
wide variety of different disorders. 
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Genetic predisposition to complex disease development is likely caused by the 
presence of multiple variant or abnormal genes within an individual's genome. The effect 
of such abnormalities may be small in isolation, and an individual possessing a single 
variant copy of such a gene may lead a perfectly normal existence. However, it is the 
combination of variant genes within in a genome, and how such genes interact both with 
each other and disease-specific environmental stimuli that lead to the development of a 
particular disorder. Differential rates of complex diseases in monozygotic as compared to 
dizygotic twins, as well as a higher frequency of disease in first-degree relatives of 
affected individuals when compared to the general population, have conclusively proven 
that genetic, as well as environmental factors, contribute to complex disease pathogenesis 
(1 ). 
Considerable effort has been made to define the genetic basis of many Mendelian 
disorders, with a number of approaches being commonly used to elucidate disease-
causing genes. One of the most frequently employed techniques is the candidate gene 
approach, where the biochemical nature of a disease is to some extent understood. 
Candidate gene studies have proven successful in a number of instances. For example, a 
small subset of type 2 diabetes has been shown to be caused by mutation of genes 
encoding insulin and the insulin receptor (1). An alternative method for defining disease-
causing genes is positional cloning. This type of approach is typically used when the 
biochemical nature of a disease is unknown. This method was successfully applied in the 
cloning of the cystic fibrosis gene on chromosome 7, as well as the Huntington's disease 
gene on chromosome 4 (2). It must be noted that relatively few genes have been 
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identified using either of these approaches, and much work remains in defining those 
genetic abnormalities underlying other Mendelian disorders. 
Similar approaches can be employed to define genetic abnormalities in complex 
diseases. However, despite extensive efforts, relatively few genetic regions and even 
fewer genes have been positively implicated in complex disease pathogenesis (1). Some 
of the most successful examples include mapping of complex disease susceptibility to the 
human leukocyte antigen (HLA) region of chromosome 6, which has been shown to be 
an etiological factor in many human disorders (3). Examples ofHLA-associated diseases 
include a number of inflammatory diseases like rheumatoid arthritis (4), ankylosing 
spondylitis and inflammatory bowel disease (5). Despite these successes, limited progress 
has been made in elucidating non-HLA genes involved in complex diseases pathogenesis. 
The outcomes of on-going studies in a variety of diseases are eagerly anticipated in many 
quarters since knowledge of the genetic basis of complex disease susceptibility is likely 
to lead to a greater overall understanding of the numerous biological steps and 
interactions that must occur for an individual to develop a disease. Such knowledge may 
have a profound impact on how complex diseases are managed in the clinical setting. For 
instance, knowledge of specific disease-causing genetic abnormalities may lead to 
development of novel therapies that may alleviate symptoms. Additionally, it may 
become possible to define an individual's susceptibility to developing a specific disease, 
thus enabling such an individual to minimize exposure to environmental factors involved 
in the pathogenesis of the disorder. 
The focus of this dissertation will be inflammatory bowel disease (IBD). IBD is a 
debilitating chronic inflammatory autoimmune disorder of the gastrointestinal tract. It has 
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a relatively high frequency, affecting approximately one million Americans (6). 
Symptoms tend to first occur in early adulthood and are often debilitating, with surgery 
frequently being required to provide alleviation. Additionally, patients have a 
significantly increased risk of developing colorectal cancer (7). 
IBD is known to have a complex, non-Mendelian form of inheritance. The overall 
aim of this dissertation is to define IBD susceptibility genes, firstly by defining genomic 
regions of susceptibility in the study population, and secondly by performing candidate 
gene studies. The nature of IBD and the candidate gene pathway that will be the focus of 





Inflammatory bowel disease (IBD) encompasses a number of chronic 
inflammatory disorders of the gastrointestinal tract that share a variety of clinical 
characteristics, the most notable of which are profuse diarrhea and abdominal pain. 
Symptoms are frequently debilitating, and multiple surgical procedures may be required 
if medical treatment fails. Patients are generally sub-classified as suffering from either 
Crohn's disease (CD) or ulcerative colitis (UC) on the basis of clinical, radiological and 
histological grounds. However, approximately 15% of colonic IBD cases display 
ambiguous disease features, and a definitive diagnosis of either UC or CD cannot be 
made. In such instances, individuals are diagnosed as suffering from 'indeterminate 
colitis' (IC) (8). Inflammation in UC and IC is limited to the colon and rectum, whereas 
inflammation in CD, although most frequently affecting the terminal ileum, can involve 
any part ofthe gastrointestinal tract. Additionally, all forms ofIBD may be associated 
with extra-intestinal manifestations such as arthritis, cholangitis, iritis and dermatological 
problems. 
It is estimated that IBD affects up to one million Americans (6), with the 
prevalence ofUC being slightly higher than that of CD. On a global scale, IBD is 
predominantly found in areas of the developed world (historically Scandinavia, the 
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United Kingdom, and the United States), although the mid-I980s and 1990s did see a 
dramatic increase in incidence in continental Europe, the Middle East, the Pacific Rim, 
Africa and Latin America (9). In general, however, IBD is considered to be a disease of 
urban areas, with its prevalence typically being low in rural regions. Epidemiological 
studies have shown that IBD tends to develop in early adulthood: CD is diagnosed most 
frequently in individuals in their 20's and UC in individuals in their 30's. Approximately 
10% to 15% of individuals are diagnosed as suffering with IBD before adulthood (9). The 
sex-distribution of this disease is also different, with all forms ofIBD being slightly more 
prevalent in females (9). 
It is widely accepted that lBD, like all complex non-Mendelian disorders, 
develops in a genetically susceptible individual in response to exposure to environmental 
stimuli (10). Despite the fact that a both genetic and environmental factors have been 
implicated in the pathogenesis ofIBD (11), the precise mechanisms of action of such 
factors, and more importantly, how environmental and genetic determinants interact to 
produce specific IBD phenotypes remain largely unknown. Similarly, the pathologic 
mechanism underlying the development of the chronic inflammation seen in IBD 
continues to be elusive. Many models of IBD pathogenesis have been suggested, 
although none has yet been proven correct. One of the most persuasive models postulates 
that IBD develops as a consequence of an abnormal host response to normal intestinal 
bacterial flora (12). 
Environmental factors implicated in IBD pathogenesis are diverse, and are for the 
most part associated with Western lifestyles of the second half of the twentieth century. 
Environmental factors that have been proposed as increasing the risk of developing IBD 
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include cigarette smoking, oral contraceptive use, breast-feeding and the measles vaccine 
to name but a few (13). The most heavily studied of such environmental factors is 
cigarette smoking, which has been shown to have opposite effects on disease activity in 
VC and CD. Symptoms of CD are exacerbated by exposure to tobacco, whereas 
symptoms ofVC are actually alleviated (14). Although, elucidation of such 
environmental stimuli is of interest, such studies do have one notable drawback i.e. they 
do not provide a clear mechanism of action as to how the specific factor(s) leads to IBD 
development. 
IBD Genetics 
Numerous epidemiological studies have conclusively demonstrated that IBD 
pathogenesis has a prominent genetic component and that certain individuals are more 
prone to developing IBD. Twin concordance rates ofIBD have been used to estimate the 
relative effect of genetic factors in IBD pathogenesis and have proven a powerful tool in 
determining the relative roles of genetic and environmental influences in IBD. Such 
studies have demonstrated a greater concordance of IBD in monozygotic twin pairs 
compared to a dizygotic twin pairs (11;15). Additionally, these effects appear to be more 
prominent in CD than in VC. Assuming that each twin-pair has been subject to the same 
environmental stimuli, it must be concluded that genetic factors are responsible for this 
difference in disease concordance. 
The findings of twin studies have been augmented by observations of ethnic 
differences in disease frequency. Such studies have illustrated that IBD is primarily a 
disease of Caucasians (9), with its prevalence being highest in Jewish populations (16). 
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Additional compelling evidence is provided by familial aggregation studies, which have 
estimated that between 6% and 32% of patients with IBD have an affected first- or 
second-degree relative (17). 
Consideration of both genetic and environmental factors has led many to postulate 
that the classification ofIBD into UC and CD is too narrow. Many genetic studies have 
led researchers to suggest that IBD actually represents a heterogeneous group of 
inflammatory disorders, and that different clinical subgroups are caused by different 
genetic defects. Exposure to environmental stimuli is, however, required for the disease 
process to become active (17). An individual with a specific IBD phenotype will 
probably carry some susceptibility genes that are common to all types ofIBD, and a 
number of others that confer susceptibility to a specific IBD sub-phenotype. This 
assumption has been supported by genetic linkage studies, which are discussed in greater 
detail below. 
Genome-wide scans have been a particularly useful tool in defining genetic 
regions that confer increased susceptibility to developing IBD. These studies employ 
short tandem repeat (STR) markers, which are a type of variable-number tandem repeat 
marker, consisting of2-6 nucleotides, repeated a variable number of times. STRs have 
proven extremely useful tools for a number of reasons: first, they show large variation 
within any population; second, they are widely dispersed throughout the genome; and 
finally, if an STR is in close physical proximity to a disease gene, meiotic recombination 
between the marker and disease gene is highly unlikely to occur, meaning that a specific 
STR allele will be co-inherited with the disease gene. Therefore, markers closest to the 
disease gene would show the strongest correlation with disease patterns. Hundreds of 
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STRs are employed in genome-wide scans. The outcome of these scans has been to 
define genomic regions with a high degree of STR allele sharing among disease-affected 
sibling-pairs. In other words, IBD-affected sibling-pairs share STR marker alleles that are 
in close physical and genetic proximity to the same (shared) disease gene. Genomic 
regions that demonstrate a high frequency of STR allele sharing are termed 'susceptibility 
loci'. A number of such susceptibility loci have been defined in IBD, the most well 
characterized of which have been termed IBDl-9 (18-25). These loci tend to confer 
susceptibility to different IBD phenotypes. For example, IBDI has been demonstrated to 
be important in susceptibility primarily CD, whereas IBD2 confers susceptibility to both 
UCandCD. 
There are a number of obvious drawbacks when one defines the heritable 
component of a disease in terms of susceptibility loci. The most notable of these is that 
although these loci do represent a genetic region of susceptibility, they do not give any 
information as to the nature of the susceptibility gene contained within. The overall aim 
of studying the genetics of complex disease must be to elucidate susceptibility genes. 
Therefore, susceptibility loci only serve to direct researchers to genomic regions that will 
contain susceptibility gene(s). Another important problem with susceptibility loci is that 
they are very large in both physical and genetic terms. They span many millions of base 
pairs and contain hundreds of genes. Finding the one disease-causing gene within such a 
large genetic region therefore presents considerable challenges. 
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NOD2: The IBD Susceptibility Gene 
Only one gene has thus far been conclusively implicated in IBD susceptibility 
(26;27). This gene, nucleotide oligomerization domain 2 (NOD2), is located on 
chromosome 16q12 and is likely to account for the majority, but not all, of the linkage 
observed within the IBD1 susceptibility locus (24). The biological function ofNOD2 has 
been a matter of great interest since the discovery of its role in CD susceptibility, and 
strong arguments exist to support its role in both up-regulation of the pro-inflammatory 
transcription factor NF -KB and induction of apoptosis in macrophages (28). It is known 
that expression of NOD2 is limited to monocytes and dendritic cells, and that it acts as an 
intracellular pattern recognition receptor for bacterial peptidoglycan (28). Stimulation of 
NOD2leads to NF-KB up-regUlation and apoptosis. NOD2 disease-causing mutations 
(DCMs) have been shown to interfere with the ligand recognition process and results in 
impaired NOD2-mediated NF-KB activation. This finding presents somewhat ofa 
paradox given that CD is associated with increased NF-KB activity. Further work is 
therefore required to clarify the mechanism by which NOD2 mutations cause 
susceptibility to CD. 
Three independent DCMs within NOD2 (one frame-shift mutation [1007fs] and 
two missense mutations [R702W and G908RD have been shown to be associated with 
CD. These three mutations are estimated to be carried by 25-35% of CD patients and 7-
15% healthy controls (29). The relative risk for CD development has been estimated as 
approximately 2-3 in individuals carrying one DCM and 20-40 in individuals who are 
homozygous mutants or compound heterozygotes (30;31). 
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Investigation of NOD2 mutations in different CD phenotypic subgroups has 
proved extremely worthwhile. NOD2 mutations have been shown to be associated with 
inflammatory processes localized to the terminal ileum, fibrostenotic disease behavior 
and early age of onset (31-36). Additionally, carriage of these mutations only appears to 
be of significance in Caucasian populations, with NOD2 not being involved in 
susceptibility to CD in Chinese (37) and Japanese populations (38). 
Gastrointestinal Immunological Dysfunction and Inflammatory Mediators in IBD 
There is accumulating evidence to suggest that both UC and CD develop as a 
consequence of an abnormal host response to normal intestinal bacteria (12;39). Rodent 
models of IBD have demonstrated that the presence of luminal flora is necessary for the 
development of intestinal inflammation. Mutant rat and mouse strains prone to 
developing "spontaneous colitis" do not develop intestinal inflammation when bred in a 
germ-free environment (40). The nature of defects underlying development of 
inflammation in IBD remains unclear. It is probable that inflammation either develops 
because of intrinsic defects in gastrointestinal immunoregulation or defects in bowel 
mucosal barrier function, leading to continued immune effector cell stimulation. There is 
compelling evidence for both theories. Monocytes within the lamina propria of 
individuals with CD are spontaneously activated, possibly by gram-negative bacteria 
(41). Such spontaneous activation of phagocytes can directly cause significant alterations 
in barrier function (41). 
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Mixed leukocytic infiltration of gastrointestinal mucosa is a prominent feature of 
lBD. CD4+ T -cells are the most common form of activated mononuclear cells infiltrating 
the gut (42). Enhanced adhesion molecule and chemokine expression in inflamed IBD 
tissue promotes recruitment of these cells to the intestinal mucosa. These CD4 + T -cells 
play an important role in the pathogenesis of tissue damage in lBD, especially in CD (42-
44). Different T-cell subsets appear to predominate in CD and UC, with Thl T-cells 
being more common in inflamed CD mucosa, and atypical Th2 T -cells being more 
common in inflamed UC mucosa (39). 
Both CD and UC are characterized by infiltration of the bowel mucosa by 
activated macrophages, in addition to this lymphocytic infiltrate. It is believed that this 
occurs as a consequence of lymphocyte Th1 cytokine production in CD (e.g. interferon-
gamma [lFNy] and lL-2), although how this cell population becomes active in UC is less 
certain. Activated macrophages, along with other mucosal cell types, produce a wide 
range of pro-inflammatory cytokines, including TNFu, lL-1P, lL-6, lL-8, and lL-16. 
Production of vast quantities of such broadly active cytokines, together with enhanced 
expression of a wide variety of inflammatory mediators, exacerbates the inflammatory 
process, eventually leading to the clinical manifestations of disease (39). Other pro-
inflammatory agents include chemokines, arachidonic acid metabolites (e.g. 
prostaglandins and leukotrienes) and reactive oxygen metabolites (43;45). The precise 
nature of elements controlling transcription of these inflammatory mediators is for the 
most part unknown. It is almost certain, however, that their expression is primarily 
controlled by transcription factors that act by binding to the promoter regions of 
inflammatory genes. Nuclear factor-KB (NF-KB), an inducible nuclear trans-acting factor 
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known to playa key role in regulating expression of many inflammatory mediators, is the 
most strongly implicated of such transcription factors. Hyperactivity ofNF-KB has been 
implicated in a wide variety of chronic inflammatory diseases including asthma, 
rheumatoid arthritis and IBD (reviewed by Barnes and Karin (46)). 
A wide variety of stimuli have been shown to activate NF-KB, including 
cytokines, activators of protein kinase C, viruses, and oxidants (46). Some of the most 
well-characterized activation pathways appear to involve receptor-mediated events. 
Notable examples include signaling through the IL-l and TNFa cytokine receptors, as 
well as microbial pattern recognition receptors, including Toll-like receptors and the 
intracytoplasmic bacterial peptidoglycan receptor, NOD2. 
NF-KB is highly up-regulated at sites of inflammation, and its activation induces 
transcription of pro-inflammatory cytokines, chemokines, adhesion molecules, matrix 
metalloproteinases, cyclo-oxygenase-2, and inducible nitric oxide synthase (47). The role 
ofNF-KB in IBD is well defined. Lamina propria macrophages display inappropriate 
activation of a number of NF -KB subunits including NF -KB 1, c-ReI, and especially RelA 
(48). Treatment of a macrophage cell line derived from inflamed IBD mucosa with a 
specific NF-KB p65 subunit antisense phosphorothioate oligonucleotide results in a 
significant reduction in pro-inflammatory cytokine production (48). 
Innate immunity and a prominent component of this system that activates NF-KB 
and other proinflammatory mediators, the Toll-like receptor (TLR) pathway will now 
examined. TLR stimulation induces a strongly pro-inflammatory intracellular signaling 
pathway. The possible role that this pathway may play in IBD pathogenesis will then be 
assessed in depth. 
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Innate Immunity 
Vertebrate host defense mechanisms can be broadly divided into two systems: 
'adaptive' immunity and 'innate' immunity. Both serve to recognize and respond to 
invading pathogens by initiating host defenses. How each of these systems react and 
respond to different pathogenic threats are markedly dissimilar. 
Adaptive immune recognition relies on generating a random and highly diverse 
repertoire of antigen receptors, the T - and B-cell receptors. This is followed by clonal 
expansion of receptors with pathogen-specific recognition abilities (49). Although this is 
an extremely powerful immunological defense mechanism, it has a number of prominent 
limitations, the most notable of which is that responses are slow. The lag-time for an 
effective response to a pathogen through adaptive immune mechanisms is typically 4-7 
days. The primary reason for this slow response time is that activation of adaptive 
immunity requires signals from a variety of sources. Such signals provide information 
regarding the nature of the pathogenic threat, and serve to direct the type of response 
mounted to any given pathogen. These signals primarily originate from the innate 
immune system (50). 
The innate immune system comprises an evolutionarily ancient host defense 
mechanism that shows a great deal of molecular conservation between plants to 
mammals. Innate and adaptive immunity differ in two broad respects. First, innate 
immunity comprises a system of effector mechanisms that, when activated, often lead to 
the swift destruction of an invading organism (typically within a matter of hours). 
Second, rather than mounting responses to a specific antigen, innate immune mechanisms 
respond to structures present on large groups of microorganisms and are distinct from 
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molecular patterns found in vertebrates (51). The targets of innate immune recognition 
are highly conserved molecular structures known as pathogen-associated molecular 
patterns (PAMPs) (49). The principal cells involved in initiating and mediating these 
responses are phagocytes such as neutrophils and macrophages, as well as a wide variety 
of other cells derived from non-leukocytic tissue. Once the phagocytic cell has reached 
the site of infection, microbial P AMPs are recognized by innate immune system 
receptors, so-called pattern-recognition receptors (PRRs) (52). The phagocyte then sets in 
motion a number of mechanisms that ultimately lead to the destruction of the pathogen 
and/or activation of the adaptive immune system. 
Toll-Like Receptors 
The Drosophila Toll protein and its mammalian homologues, the Toll-like 
receptors (TLRs), are evolutionarily conserved forms of PRR, and are essential 
components the innate immune system. They are expressed on a broad range of immune 
and non-immune system effector cells, and possess the ability to recognize a wide variety 
of microbial P AMPs. TLR stimulation activates a number of interlinked intracellular 
signaling pathways, all of which lead to innate and ultimately adaptive immune system 
activation (53). 
Toll-like receptors are a family often structurally related type-l transmembrane 
proteins (TLRl-l 0) (49). The TLR extracellular region contains multiple leucine-rich 
repeats (LRRs), a ligand recognition and signal transduction motif found in a diverse 
range of proteins (54). The LRR domains consist ofa varying number of repeats of 24-29 
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amino acids in length, containing the motifxxLxLxx and other conserved leucines (55). 
The cytosolic region of TLRs is called the Toll/interleukin-l receptor (TIR) motif owing 
to the structural homology of a 200 amino acid conserved domain found in both TLRs 
and interleukin-l receptors (IL-IR) (56). TIR motifs are conserved protein-protein 
interaction domains that are found in both plant and animal transmembrane and cytosolic 
proteins (57). TIR domain-containing proteins have been shown to have a role in host 
defense in both plants and animals. 
Toll-like receptors form a powerful means for innate immune effector cells to 
differentiate foreign versus host molecular patterns. More specifically, TLRs recognize a 
broad range of conserved molecular motifs found in microorganisms but not in 
vertebrates (56). The range of ligands recognized by TLRs is very diverse. For example, 
TLR2, TLR3, TLR4, TLR5, TLR6 and TLR9 recognize peptidoglycan, double stranded 
RNA, lipopolysaccharide (LPS), flagellin, mycoplasmal macrophage-activating 
lipopeptide-2kDa (MALP-2) and CpO bacterial DNA respectively (58-63). Ligand 
specificities for a variety of TLRs are shown in Figure 1. The main strategies for 
increasing the range of ligands recognized include formation of heterodimers (e.g. 
between TLR2 and TLR6) and the use of accessory molecules (e.g. TLR4 requires the 
accessory molecule MD-2 for recognition of gram negative bacterial LPS). 
Tissue expression patterns ofTLRs vary, with most tissues expressing at least one 
TLR and several expressing all ten (e.g. spleen, peripheral blood leukocytes) (64). 
Analysis ofTLR expression in fractionated primary human leukocytes (CD4+, CD8+, 
CDI9+ monocytes and granulocytes) indicates that professional phagocytes express the 
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Figure 1. Ligand specificities for different TLRs. TLRs recognize a variety of P AMPs in 
vivo by forming homo- and heterodimers. Note that TLR2 forms a heterodimer with 
either TLRI or TLR6. Such strategies increase the nwnber of recognized PAMPs by 
allowing for more combinations of TLRs than would be possible if TLRs acted in 
isolation or only formed homodimers. Note that some TLRs can utilize accessory 
molecules (e.g. MD-2 with TLR4). The precise role of such accessory proteins is unclear 
in many instances. G+, gram-positive; G-, gram-negative; GPI, glycophosphoinositol; 
RSV, respiratory syncytial virus. From Medzhitov R, 2001. Toll-like receptors and innate 
immunity: Nat.Rev.Immunol., v. I , p. 135-145. 
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B cells, suggesting additional, and as yet poorly defined, roles for TLRs in adaptive 
immunity. 
TLR Family Signaling Pathways 
TLR stimulation leads to up-regulation of a number of cytokines involved in 
processes such as inflammation and chemotaxis. Much work has focused on defining 
specific intracellular signaling pathways that mediate such innate immune system effector 
cell responses. As with many other cell signaling pathways, a great deal of complexity is 
evident, with multiple connections to different cell signaling components as well as 
'cross-talk' with other receptor-mediated pathways. 
Characterization of the TLR signaling pathway leading to up-regulation ofNF-KB 
owes a great deal to the discovery of structural homology between the intracellular 
domains of the IL-IR and TLRs (53). The IL-IR pathway was reasonably well 
characterized when Medzhitov et al (50) described the human homolog of the Drosophila 
Toll protein (65;66). Indeed, the primary signaling pathways induced by activation of 
either IL-IR or TLRs appear to have the same end-points. These well-described signaling 
pathways are shown in Figure 2. 
Both IL-IR and TLR stimulation lead to the recruitment of MyD88, a cytoplasmic 
adaptor protein that can interact with every member of the TLR family, as well as the IL-
lR (65;67-69). MyD88 is essentially a C-terminal TIR motif, connected to another 
structurally conserved signaling motif, a death-domain (DD), which is located at its N-
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Figure 2. The interleukin-I receptor (IL-lR)/Toll-Iike receptor (TLR) signaling pathway. 
Adapted from Akira S. and Sato S., 2003 . Toll-like Receptors and Their Signaling 
Mechanisms, Scand. J. Infect. Dis. 35:555-562. 
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TIR domain ofligand-bound TLRs (or IL-1R). Once recruited to the receptor complex, 
MyD88 binds the serine/threonine kinases IL-IR associated kinase-l (lRAK-1) and 
IRAK-4 through DD-DD interactions. This subsequently causes IRAK-4 to 
hyperphosphorylate IRAK -1, which induces interaction with another adaptor protein, 
tumor necrosis factor receptor-associated factor 6 (TRAF6) (55). The association of these 
molecules presumably causes conformational changes, and the signaling module IRAK-
4/IRAK-lITRAF-6 dissociates from TLRlMyD88 (55). The downstream targets for this 
three-molecule complex include mitogen-activated protein kinase kinase kinase 
(MAP3K), transforming growth factor-~-activated kinase-1 (TAKl), and two adaptor 
proteins, TAK1-associated binding proteins-1 and -2 (TAB1 & 2). 
Thus IRAK-4/IRAK-1/TRAF-6 interacts with membrane bound TAB2, and then 
the TAB2/TAKlITABl/TRAF6 complex translocates to the cytosol, leaving the IRAKs 
to be degraded. TAK1 is subsequently activated, which in turn leads to activation of yet 
another protein kinase, IKB kinase (lKK) (51). IKK phosphorylates the Inhibitor of KB 
(lKB) proteins, which are bound to NF-KB and inhibit its action in the un-stimulated state. 
Phosphorylation of IKB targets it for ubiquitination and proteosomal degradation 
allowing NF-KB to translocate into the nucleus where it induces the transcription of 
inflammatory and immune response genes. Activation ofTAK1 also results in activation 
of MAP kinases. 
This pathway is by no means the only signaling transduction cascade that may be 
induced through TLR stimulation. Much attention has recently focused on those TLR 
signaling pathways that are independent of the adaptor protein MyD88. This has 
stemmed from observations that MyD88 knockout mice are still able to activate NF-lCB 
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and MAP kinases in response to LPS, albeit in a delayed fashion (70). MyD88-
independent pathways have been shown to activate interferon-inducible genes and 
promote LPS-mediated maturation of dendritic cells (56). These pathways do, however, 
remain of secondary importance to the MyD88-dependant pathway that is essential for 
induction of inflammatory responses to LPS. 
Another interesting phenomenon elicited by macrophage TLR stimulation is the 
induction of apoptosis. Specifically, it has been observed that bacterial lipoprotein-
stimulated TLR2 can either induce apoptosis or activate NF-KB in macrophage cell lines 
(71). TLR signaling pathways leading to either inflammation or apoptosis appear to 
bifurcate at the level of MyD88. TLR2 has been shown to bind Fas-associated death 
domain protein (F ADD) in a MyD88-dependant fashion (72). F ADD is a universal 
apoptotic adapter protein that mediates signaling between all known death-domain-
containing members of the TNF receptor super-family. The implications ofTLR-
mediated apoptosis are especially intriguing. One possible explanation is that activation 
of programmed cell-death may serve to limit inflammatory responses. That is, to resolve 
inflammation, immune effector cells must be eliminated through apoptosis (73). 
The function of a number of TLR signaling pathway components will now 
considered. Discussion will concentrate on two IBD candidate genes within this pathway, 
lRAK-M and MyD88. The possible roles of these genes in the pathogenesis ofIBD will be 
discussed in Chapter III. 
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Interleukin-l Receptor-Associated Kinases 
Interleukin-1 receptor associated kinases (IRAKs) are a family of serine/threonine 
kinases that are integral components of the IL-1 R and TLR signaling pathways. The first 
member of this family to be described was IRAK -1, which shares a significant deal of 
homology with the Drosophila protein Pelle, a kinase that is essential for activating the 
Drosophila NF-KB homolog Dorsal (74). In addition to IRAK-1, three further IRAKs 
have been identified in vertebrates: IRAK-2, IRAK-4 and IRAK-M (69;74-76). All 
IRAKs share two structural domains: a centrally located serine/threonine-rich kinase 
domain and an N-terminal death-domain (DD). 
Activation of either the TLR or IL-1 R pathway induces the recruitment of IRAK-
1 to the receptor through a homophilic interaction with the DD of the adaptor protein 
MyD88 (56). MyD88 also binds IRAK-4, which is brought into close proximity to 
IRAK-1. IRAK-4 is thus allowed to phosphorylate critical residue(s) in the kinase 
activation loop ofIRAK-1, triggering the kinase activity ofIRAK-l. This causes IRAK-1 
to autophosphorylate residues at its N-terminus (56), which leads to the recruitment of the 
adaptor protein TRAF6 to the receptor complex. 
Early studies implied that there might be a degree of functional redundancy 
between individual IRAK family members. This stemmed from the observation that all 
IRAKs act downstream of MyD88 and can bind to TRAF6. However, although different 
IRAK isoforms share a degree of structural homology, functional differences are apparent 
between individual family members. One of the most important differences is their 
varying kinase activity. IRAK-4 has been shown to have a similar level of kinase activity 
as IRAK-1 (75). However, IRAK-2 and IRAK-M both lack the kinase activity ofIRAK-1 
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and IRAK-4. Furthermore, their ability to become activated through auto-
phosphorylation is practically zero, and they only possess a partial ability to stimulate 
NF-KB when over-expressed in 293T cells, and restore IL-l signaling in IRAK-1- cells 
(69;76). IRAK-2 and IRAK-M presumably lack kinase activity because they have an 
asparagine and serine residue, respectively, in their kinase domains in place of an 
aspartate residue shown to be critical for the kinase activity of other IRAKs (56). 
It has been postulated that IRAK -4 is the central TIR -signaling mediator in innate 
immunity (77). This has stemmed from a number of observations including that IL-l R 
and TLR signaling are inhibited by expression of an IRAK-4 kinase-inactive mutant, with 
IRAK-4 deficient animals displaying severely impaired responses to viral and bacterial 
challenges. The same cannot be said ofIRAK-l, where gene-targeting studies have 
shown that it is only partially required for IL-IR and TLR signaling (75;78). Similar 
kinase domain point mutations of other IRAKs do not lead to a similar severe degree of 
impairment ofNF-KB activation as that which occurs following point-mutation ofIRAK-
4. Suzuki et al (78) showed that IRAK-4 is necessary to functionally modify IRAK-l and 
other signal transducing substrates. In addition to these observations, tissue expression 
patterns of the IRAKs differ with IRAK-l and IRAK-4 being expressed ubiquitously 
(69;75), IRAK-2 having a narrower cellular distribution, and expression ofIRAK-M 
being limited to myeloid cells (76). 
The mechanisms underlying regulation of IRAK function are only just becoming 
apparent. IRAK-l is known to be quickly degraded following TLRlIL-IR stimulation 
(79;80). It is likely that IRAK-l is degraded through a phosphorylation-induced 
ubiquitinlproteosome pathway (80). Hu et al (81) demonstrated that LPS-induced 
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degradation ofIRAK-1 requires a 186 amino acid residue region located at the N-
terminal. Conversely, lRAK-2 was not degraded when THP-1 cells were exposed to LPS, 
suggesting complex regulation of innate immunity upon microbial stimulation. 
IRAK-M: An Inhibitor of TLR Signaling 
Kobayashi et al (58) described the apparent function ofIRAK-M in a mouse 
strain that expressed functionally inactive lRAK-M. A surprising result was obtained 
upon TLR stimulation of macro phages derived from these mice, with lRAK-M-1-
macrophages displaying increased cytokine production and inflammatory responses. 
Two approaches were used to determine the function oflRAK-M. First, murine 
lRAK-M-1- macrophages were stimulated with either live or heat-killed bacteria. These 
cells displayed increased pro-inflammatory cytokine production in comparison to 
wildtype macrophages. Second, in vivo studies utilized lRAK-M-1- mice infected with the 
enteric pathogen, Salmonella typhimurium. Such mice exhibited an exaggerated 
gastrointestinal inflammatory response, which again, is likely due to enhanced TLR 
signaling. These studies concluded that lRAK-M is a negative regulator ofTLR signaling 
and is thus a key component in the regulation of the innate immune response. 
Another interesting concept to consider in light of this work is the phenomenon of 
lipopolysaccaride (LPS) tolerance. When an individual is repeatedly exposed to LPS, the 
threshold of LPS response is increased (82), representing a form of negative feedback 
that presumably has evolved to protect the organism against excessive cytokine 
production, and the potentially fatal endotoxic shock (83). The exact mechanisms 
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involved in this phenomenon remain uncertain. However, several factors have been 
proven to be involved in this process. For instance, TLR4 is down-regulated following 
chronic LPS exposure (84), as well as repression of transcription and rapid degradation of 
pro-inflammatory cytokine mRNAs in LPS-tolerant cells (85). The elucidation ofthe 
function IRAK-M by Kobayashi et al (58) has added another dimension to the 
mechanism of endotoxin tolerance. Kobayashi et al (58) found that IRAK-M-1-
macrophages have diminished ability to develop LPS tolerance after repeated exposure to 
LPS. There was also increased expression oflRAK-M following exposure of wild type 
macrophages to high levels ofLPS. IRAK-M-1- macrophages did retain some capacity to 
develop LPS tolerance at late time points. It was thus concluded that IRAK-M up-
regulation in response to high LPS loads is partially responsible for inducing endotoxin 
tolerance. 
The gene encoding IRAK-M was isolated from a full-length cDNA clone by 
Wesche et al (65). The protein itself is 596aa in length and has 30-40% overall sequence 
similarity with IRAK-l and IRAK-2. lRAK-Mis located on chromosome 12q13.13 and is 
in extremely close proximity to the peak region of linkage within the IBD2 susceptibility 
locus. The gene itself consists of 12 exons and spans approximately 60kbp. 
Mechanism of Action oflRAK-M 
Kobayashi et al (58) proposed a mechanism of action for IRAK-M, and although 
by no means biologically implausible, it is somewhat a matter of speculation. The 
proposed mechanism of action oflRAK-M is shown in Figure 3. The action oflRAK-M 
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Figure 3. Proposed mechanism of action ofIRAK-M 
A: Uninhibited TLR4 signaling. Following stimulation by a PAMP, MyD88 binds the 
TLR (TLR4 in this instance) through a TIR interaction, and recruits kinases IRAK-I and 
IRAK-4 to form an active signaling complex. The proximity of these two kinases causes 
hyper-phosphorylation and a subsequent conformational change in IRAK-l. IRAK-II-4 
binds the adaptor protein TRAF -6, which causes IRAK -I lIRAK -4/TRAF -6 to be released 
from TLR4/MyD88 and to interact with downstream molecules. Note that IRAK-I is 
bound to TOLLIP. The function of this molecule is unknown, although it seems likely 
that it is either an inhibitor ofunphosphorylated IRAK-I or another adaptor protein. 
B: Inhibition ofIRAK-l by IRAK-M. In the presence ofIRAK-M, TLR stimulation 
again leads to the formation of the TLR-MyD88-IRAK-I/-4 complex. However, on this 
occasion IRAK-M also joins the complex. This has two proposed effects: it either 
stabilizes the signaling complex, preventing dissociation ofIRAK-l from MyD88, or 
inhibits phosphorylation ofIRAK-l by IRAK-4. Thus IRAK-l is not freed to interact 
with downstream signaling intermediaries. 
Adapted from Janssens S. and Beyaert R., 2003. Functional Diversity of Different 
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was proposed on the basis of three observations: 1) the presence oflRAK-M enhanced 
the interaction between lRAK-1 and MyD88; 2) the auto-phosphorylative capacity of 
lRAK-1 was significantly diminished by lRAK-M; and 3) lRAK-M could inhibit the 
interaction oflRAK-1 with its downstream target TRAF6. The proposed primary mode 
of action ofIRAK-M was by binding to the TLR-MyD88-IRAK-l/-4 signaling module. 
This would have dual effects: to stabilize the signaling complex, preventing lRAK-1/-4 
from being released to act on its downstream substrates; and to inhibit the auto- or cross-
phosphorylation ofIRAK-1/-4, thus preventing activation. Additionally, lRAK-M has 
previously been shown to be capable of binding TRAF6 (76). It is plausible that lRAK-M 
may compete with lRAK-l/-4 by binding to this adaptor protein. 
However, the example shown above is certainly not the definitive explanation for 
the mechanism of action of lRAK -M. Mak and Yeh (86) implied that the findings of 
Kobayashi et al (58) raise a number of other important questions. Pro-inflammatory 
signaling pathway activation following IL-1R1TLR stimulation is limited by the rapid 
degradation of phosphorylated lRAK-1 (79), thus quickly depleting the intracellular pool 
ofIRAK-l. Consideration of Kobayashi's data leads to the question of whether 
phosphorylation ofIRAK-1, its activation status and its ability to be degraded are altered 
by the presence ofIRAK-M. These questions remain unanswered. 
MyD88 and TLR-Mediated Apoptosis 
MyD88 is an essential component of a number of receptor-mediated cascades 
including the IL-1R and TLR pathways. Bums et al (67) showed that IL-1-induced NF-
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KB activation was inhibited by transfecting cells with a dominant negative mutant form of 
MyD88. Furthermore, they illustrated that over-expression of MyD88 led to NF-KB 
activation. The role ofMyD88 in TLR signaling was initially described by Medzhitov et 
al (68), where it was found to mediate activation ofNF-KB via lRAK-l and TRAF6. 
Further evidence was provided by Kawai et al (70), who demonstrated that MyD88-
deficient mice are unresponsive to LPS. 
MyD88 is a 296-amino acid polypeptide with a predicted mass of 33 kD (87) 
consisting of a carboxyl-terminal TIR motif, connected to an amino-terminal death-
domain (DD) (68). The TIR domain ofMyD88 enables it to interact with the 
complementary TIR domain of ligand-bound TLRs (or IL-l R). Once ligand-activated 
TLR has bound MyD88, the serine/threonine kinases lRAK-l and lRAK-4 are recruited 
through a DD-DD interaction with MyD88. The MyD88 gene consists of 5 exons and is 
located on chromosome 3p22-3p21.3. This is a noteworthy point; chromosome 3p has 
been previously linked to IBD susceptibility (IBD9 susceptibility locus) (19;22;88). 
MyD88 is not only involved in NF-KB activation following TLR and/or IL-IR 
stimulation. It has also been shown to be an intermediary in a pathway leading to 
macrophage apoptosis. This was concluded from experiments that involved exposing 
TLR2-expressing macrophages to the TLR2 ligand, bacterial lipoprotein. These cells 
would either produce inflammatory responses via the familiar NF-KB pathway, or would 
undergo apoptosis (71). TLR2 signaling appears to bifurcate at the level of MyD88. 
Additionally, TLR2 has been shown to bind Fas-associated death domain protein 
(F ADD) in a MyD88-dependant fashion (72). F ADD is a universal apoptotic adapter 
protein that mediates signaling between all known death domain-containing members of 
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the TNF receptor superfamily. Inhibition of the inflammatory pathway appears to 
enhance activation of the apoptotic pathway and vice versa. Regulation of the balance 
between these differing pathways in vivo is, however, poorly understood. 
The implications ofTLR-mediated apoptosis are especially intriguing. One 
possible explanation is that the activation of programmed cell-death may serve to limit 
the inflammatory response. That is, to resolve inflammation, immune effector cells must 
be eliminated through apoptosis (73). The role of MyD88 in apoptotic and inflammatory 
TLR-activated pathways is shown in Figure 4. 
Further evidence for the existence of apoptotic pathways reliant on MyD88 have 
been provided by a number of studies. The phenomenon ofTLR-mediated macrophage 
apoptosis (71) was verified by Ruckdeschel et al (89) who investigated the mechanisms 
by which the Yersinia enterocolitica outer protein P (Y opP) interferes with the host 
immune response. They demonstrated that not only did YopP inhibit activation ofNF-KB 
in macrophages, but also induced a pro-apoptotic signal relay through MyD88 and 
IRAK-2, which potentially targets the FADD/caspase-8 apoptotic pathway. Conversely, 
IRAK-1 and TRAF6 were shown to counteract the bacterially induced cytotoxic response 
by signaling macrophage survival. 
In addition to these studies, ectopic expression of MyD88 in human cervical 
carcinoma HeLa cells induced apoptosis, thus further emphasizing the unusual role that 
this protein assumes in transduction of programmed cell death signaling pathways 
(90;91). Recently, MyD88 was also documented to mediate signaling in Taxol-induced 
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Figure 4. TLR-activated inflammatory and apoptotic pathways bifurcate at the level of 
MyD88 in macrophages. The death domain (DD) of MyD88 most often interacts with the 
DD ofIRAK-II-4, thus causing NF-K13 up-regulation and inflammation. Alternatively, in 
certain circumstances, MyD88 can interact with the DD of Fas-associated death domain 
protein (FADD). F ADD in turn interacts with caspase 8 through its death effector domain 
(DED) motif. Caspase activation initiates apoptotic signaling cascades within the 
macrophage. Solid line = Direct protein-protein interaction. Broken line = Indirect 
interaction. 
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In conclusion, MyD88 appears to be involved in induction of apoptosis in 
macrophages as a consequence of TLR stimulation, as well as playing a significant role 
in inflammatory responses through activation of transcription factors such as NF-KB. This 
TLR-induced apoptosis is of somewhat unclear biological significance, but is likely 
involved in resolution of the inflammatory response. It is therefore quite evident that 





IBD develops in a genetically susceptible individual in response to environmental 
stimuli. This type of inheritance pattern is described as 'complex' or 'non-Mendelian'. 
That is, a genetically susceptible individual will carry multiple abnormal genes, which in 
isolation may have little or no phenotypic effect. However, it is the combination of these 
variant genes, and how they interact that determines phenotype. 
Progress in defining IBD susceptibility genes has proven extremely difficult. This 
situation is not unique to IBD and can generally be considered to be the case for all 
complex diseases. Despite elucidation of multiple IBD susceptibility loci, only one IBD 
susceptibility gene, NOD2, has thus far been identified (18-25). NOD2 is a component of 
the innate immune system, the body's first line of defense against invading pathogens. 
Mutations within NOD2 increase susceptibility to a number of distinct CD phenotypes in 
Caucasian populations (26;27;31-36). 
This dissertation primarily focuses on defining new IBD susceptibility genes. The 
candidate genes to be studied are components of the Toll-like receptor pathway, an 
integral component of the innate immune system. The innate immune system has the 
capacity to induce powerful inflammatory responses when provoked, and there is 
accumulating evidence to suggest that innate immune dysfunction may be a key initiating 
factor in IBD pathogenesis. TLR stimulation activates a strongly proinflammatory 
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intracellular signaling pathway that leads to up-regUlation ofNF-tcB, a nuclear trans-
acting factor induced upon stimulation of the innate immune system. NF-tcB is known to 
playa key role in regulating expression of many inflammatory mediators, and 
hyperactivity of this transcription factor has been implicated in a wide variety of chronic 
inflammatory diseases including asthma, rheumatoid arthritis and IBD (46). Additionally, 
in certain circumstances, TLR stimulation cause programmed cell death in macrophages, 
presumably as a measure initiated to limit the duration and intensity of inflammatory 
responses. 
Defining susceptibility genes in IBD, as in all complex diseases, is of paramount 
importance. Elucidation of such genes will improve our understanding of 
pathophysiologic mechanisms underlying disease development, and may enable the 
development of novel therapeutic interventions or more efficient means of diagnosis. 
Proposed Concepts 
This dissertation addresses six proposed concepts: 1) Not all of the nine or more 
previously described IBD susceptibility loci will be associated with disease susceptibility 
in any given population. This is primarily due to intrinsic population differences. 2) The 
high consistency of reliable phenotyping in the study population will allow for more 
accurate assessment of disease associations. Previous IBD susceptibility loci linkage 
studies have produced variable results either because of inconsistent phenotyping of 
disease populations, or because IBD populations have been considered as large, 
heterogeneous groups (i.e. not considering sub-phenotypes). 3) IBD susceptibility loci are 
34 
associated with disease because they contain susceptibility genes. 4) TLR signaling 
pathway dysfunction is an integral component of IBD pathogenesis since inappropriate 
activation of these receptors may have wide-ranging effects, including hyper-stimulation 
of inflammatory and apoptotic signaling cascades. 5) lRAK-M, a gene that lies within a 
previously described IBD susceptibility locus whose product is a potent inhibitor of TLR 
signaling, is a biologically plausible IBD candidate gene. 6) Given the importance of the 
TLR pathway in innate immune system homeostasis, other components of the 
intracellular signaling are system biologically plausible candidates, the most notable of 
which is the adaptor protein MyD88. 
To address these six concepts, a series of experiments were designed to test the 
following hypotheses. 
Hypothesis #1 
A variable number of IBD susceptibility loci will be associated with disease in 
this popUlation. That is, due to intrinsic popUlation differences and high consistency 
of phenotyping, not all of the nine or more loci described in different populations 
will have an apparent role is disease susceptibility here. 
Some susceptibility loci have been described in very small, isolated populations. 
For example, the strongest evidence for linkage of the IBD710cus on chromosome Ip36 
has been described in an American Chaldean population, a Roman Catholic group from 
Iraq (93). Other susceptibility loci have been described in broad, somewhat different 
populations than is the case in this study. Examples of such loci include the IBD9 locus 
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on chromosome 3p which was described in a Northern European Caucasian population 
derived from many countries (88). Furthermore, some loci have only been described in 
one study, and have never been replicated. For example, the locus on chromosome 4q has 
only been described once, in a North American Caucasian population (23). 
Such inconsistent findings from linkage studies have proved a prominent 
confounding factor in the search for susceptibility genes. To test this hypothesis, 
experiments will be designed to define disease associations for a number of susceptibility 
loci in the patient population. This will be achieved by characterizing peak LOD score 
STR markers from previous studies (i.e. those STRs most highly linked to disease). 
Genotype and allele frequencies will be compared between disease and control 
populations through the use of population- and family-based statistical approaches. 
This approach will have distinct advantages over these linkage studies. Firstly, 
individuals within this IBD population generally have a severe affection status, and are 
from the relatively small geographic region of Kentucky and Southern Indiana. The study 
population is therefore more clinically homogenous when compared to other cohorts. 
Secondly, disease groups will be analyzed at the sub-phenotype level. Experience with 
NOD2 has shown that higher degrees of association are achieved using this approach, 
than when considering unstratified IBD groups. Finally, both population- and family-
based methodology will be employed to analyze STR data. These approaches are 
complementary and can be considered different means of approaching the same problem. 
Family-based approaches account for population substructure, a significant confounding 
variable that can cause type 1 statistical error in population-based studies. 
36 
Hypothesis #2 
The IBD2 susceptibility locus is associated with disease in the Kentucky and 
Southern Indiana IBD patient population. Furthermore, this disease association is 
due to the presence of lRAK-M within IBD2. 
Previous studies of IBD2 in this patient population have demonstrated that IBD2 
appears to be associated with UC (94). The aim here is essentially to extend the previous 
study by performing a more detailed characterization of the IBD2 locus, thereby 
determining the role it plays in IBD susceptibility. Three STR markers will be 
characterized in the same severely affected population in distinct phenotypic groups. The 
experimental procedure and the approach to analysis ofSTR data will essentially be the 
same as used in Hypothesis #1. 
The IBD candidate gene lRAK-Mlies within 5Mb of the peak region oflinkage of 
IBD2 (both are located on chromosome 12q13). The finding ofIBD2 disease association 
will be seen as providing evidence to suggest that lRAK-M is a prudent choice as an IBD 
candidate gene. Detailed characterization of IBD2 is therefore considered as an essential 
preliminary step prior to assessing lRAK-M an IBD candidate gene. 
Hypothesis #3 
Mutation of IRAK-M, a potent inhibitor of TLR signaling, lessens its ability 
to negatively regulate this signaling pathway in IBD. Bowel luminal contents 
therefore over-stimulate TLRs present on bowel lamina propria macrophages, 
which in turn produce excessive amounts of proinflammatory mediators through 
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activation of NF -Jill and other transcription factors. Prolonged over-production of 
proinflammatory cytokines, chemokines and other inflammatory mediators in the 
gastrointestinal tract will eventually cause the type of chronic inflammation 
characteristic of IBD. 
lRAK-M is a biologically plausible IBD candidate gene. When considering the 
work of Kobayashi et al (58) that demonstrated the apparent importance ofIRAK-M in 
regulation of innate immune responses (see p.24), it is obvious that even a mildly 
hypoactive form of this molecule may have drastic consequences. Activation ofIRAK-M 
has a powerful anti-inflammatory effect through inhibition ofTLR signaling. An 
individual in whom IRAK-M was hypoactive would be unable to fully 'dampen' TLR-
mediated signaling. If an event occurred that necessitated the recruitment of 
gastrointestinal mucosal macrophages (e.g. mild injury or infection), exposure of these 
innate immune effector cells to normal bowel luminal contents would provoke an 
inflammatory response of an inappropriate magnitude. If this pattern were to be repeated 
over a prolonged period, it is logical to hypothesize that such an individual could develop 
the type of chronic inflammation characteristic of IBD. 
A number of criticisms of this hypothesis do, however, need to be addressed. 
Firstly, given that IRAK-M appears to be important in developing LPS tolerance, why are 
IBD patients not more susceptible to developing endotoxic shock ifIRAK-M dysfunction 
is indeed involved in IBD pathogenesis? Secondly, why is it that IBD patients do not 
mount inappropriate inflammatory responses to stimuli that cause TLR-activation in other 
organs? Both questions can be partially answered by considering the type of genetic 
variation found in complex diseases. It is unlikely that a mutated gene would be 
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completely non-functional in a complex disorder such as IBD (this situation is more 
likely to be the case in Mendelian disorders). Genes involved in complex disorders such 
as IBD are more likely to display more subtle functional abnormalities. Such a gene 
product may fulfill its normal biological role, but at a different level of functionality. In 
LPS tolerance, lRAK-M hypoactivity may be adequately compensated for by other 
mechanisms and LPS hyper-responsiveness would not be a feature ofIBD. When 
considering the absence of inappropriate inflammatory responses in other organ systems 
in IBD, it should be remembered that the human gastrointestinal tract is exposed to 
chronically high microbial levels. If lRAK-M mutation were indeed involved in the IBD 
pathogenic process, the alimentary tract would be the most likely site of inappropriate 
inflammatory responses owing to the persistently high bacterial load present in the bowel 
lumen. lRAK-M under-activity in this type of environment could lead to chronic 
inflammation, whereas, other organ systems lacking similar levels of pathogen exposure 
would be apparently disease-free. 
A two-fold approach will be used to test this hypothesis and to assess the 
feasibility of lRAK-M as an IBD candidate gene. Firstly, colonic mucosal expression 
levels of lRAK-M will be measured in both healthy and IBD-affected mucosa. Although 
abnormal gene expression levels in disease-affected mucosa are by no means categorical 
evidence of gene involvement in disease pathogenesis, it does imply that regulation of 
gene expression is abnormal, which in turn may be due to mutation of regulatory regions 
within that gene. This approach basically provides further evidence that the candidate 
gene is a prudent choice, and that more detailed characterization may be warranted. 
Analysis of gene expression will be performed using real-time peR. 
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The second approach is to screen coding and regulatory genetic regions for single 
nucleotide polymorphisms (SNPs). SNPs located within such regions may be of great 
interest since they may cause abnormal gene function. Ideally, non-synonymous coding 
SNPs that cause changes in the amino-acid sequence of the encoded protein, or 
polymorphisms that may interfere with gene regulatory region functionality such as those 
within the promoter or 3' -untranslated region (3' -VTR) will be defined. Although of less 
interest, SNPs in intronic regions flanking exons will also be considered for further study 
since they may possess some form of regulatory role. 
Once the screening process has been completed, identified polymorphisms will be 
defined in the entire study population. Statistical analysis methods similar to those used 
in the susceptibility loci studies will be employed to analyze polymorphism allele 
frequency data (i.e. population- and family-based methods). 
Hypothesis #4 
Mutation of MyD88 in IBD limits its ability to induce apoptosis upon TLR 
stimulation, thereby allowing inflammation to continue for an abnormal period of 
time. 
As discussed above, MyD88 is not only involved in NF-KB activation following 
TLR and/or IL-IR stimulation. Aliprantis et al (71) demonstrated that MyD88 is an 
intermediary in a pathway leading to macrophage apoptosis in response to TLR2 
stimulation by its ligand, bacterial lipoprotein. The TLR signaling pathway appears to 
bifurcate at the level of MyD88. TLR2 stimulation has been demonstrated to activate the 
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proinflammatory transcription factor NF-KB by binding IRAK-l and IRAK-4. However, 
in certain circumstances MyD88 can bind Fas-associated death domain protein (F ADD), 
a universal apoptotic adapter protein that mediates signaling between all known death 
domain-containing members of the TNF receptor superfamily (72). A number of 
plausible explanations for this intriguing finding have been suggested, the most likely of 
which is that activation of programmed cell-death in immune effector cells may serve to 
limit the inflammatory response. That is, to resolve inflammation, immune effector cells 
must be eliminated through apoptosis (73). It is easy to see that if this process were to be 
disrupted, immune effector cells would not be cleared following elimination of the 
pathogenic threat. Indeed, the hypothesis presented here states that this is the case in IBD. 
Immune effector cells within the bowel wall are not cleared in IBD since TLR-mediated 
apoptosis is defective. Inflammation will therefore continue for an abnormal length of 
time due to the prolonged stimulation and subsequent production of inflammatory 
mediators by immune effector cells. 
It should be noted, however, that the case for MyD88 as an IBD candidate gene 
does not appear to be as strong as for lRAK-M. This primarily relates to the genomic 
location of MyD88. The existence of an inflammatory bowel disease locus, IBD9, on 
chromosome 3p26 is supported by significant linkage, transmission/disequilibrium and 
partitioning of linkage evidence (25). MyD88 is also located on the short arm of 
chromosome 3, although it is some distance from the peak region of linkage in IBD9, 
being located at 3p22. A significant genetic distance therefore lies between IBD9 and 
MyD88, and it is for this reason that MyD88 appears the least likely candidate gene, 
despite appearing to be biologically plausible. 
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The approach taken to assess MyD88 as an IBD candidate gene will be the same 
as for lRAK-M. The feasibility of MyD88 as a candidate gene will be assessed by 
determining its colonic mucosal expression levels, and by screening coding and 
regulatory regions for SNPs. Following this, identified SNPs will be characterized in the 
entire population and SNP frequencies analyzed using population- and family-based 
statistical approaches. 
Biological Plausibility and Candidate Gene Selection 
To reiterate, biological plausibility is considered the most important factor in 
deciding which genes are to be the focus of this research. Indeed, biological plausibility 
should be assessed in all candidate gene studies by giving consideration to both the 
relevance of the proposed candidate in the pathogenesis of the particular disease, and to 
the functional effects (if any) of a polymorphism (95). The argument for the biological 
plausibility of genes included in this study is outlined above. Functionally significant 
polymorphisms rather than random polymorphisms in a gene of interest offer 
considerable advantages in terms of detecting disease-associated genes (95;96). It is for 
this reason that candidate genes will be screened for polymorphisms primarily within the 
coding and regulatory regions (i.e. promoter and 3' -VTR). 
The major disadvantage of the candidate gene approach is that in any given 
complex disorder, numerous genes may appear to be biologically plausible candidates. It 
is, however, likely that the vast majority of such genes will not be disease-associated. 
Analyzing candidate expression levels in colonic mucosa of IBD patients will therefore 
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be used to narrow the choice of genes. If there is no significant difference in candidate 
gene expression (i.e. :::: 2-fold change in either direction in IBD-affected colonic mucosa 
when compared to nonnal colonic mucosa), that gene will be excluded from further 
study. Gene expression analyses will be perfonned for each biologically plausible 




MATERIALS AND METHODS 
Patient Population and Study Participation 
A population of IBD patients was recruited from a University surgical practice for 
study participation. These patients have been referred to a surgeon because their disease 
has not responded to medical therapy and they may therefore be classified as having 
severe disease. Patients originate from a relatively small geographical area, consisting of 
Kentucky and southern Indiana. These areas are predominantly rural, which is unusual 
since IBD is more prevalent in urban populations (13). 
The initial diagnosis of IBD was determined through conventional radiological, 
endoscopic, and/or histopathologic findings. Histology was available in all cases. 
Following the initial diagnosis, a single gastrointestinal pathologist with a particular 
interest in IBD reviewed all histology. Previous studies have shown that interobserver 
variation in histological diagnosis can be a significant confounding variable (97). If there 
was disagreement between the initial diagnosis and that of the specialist pathologist, the 
latter diagnosis was used for purposes of this study. The approach used here was 
intended to maximize diagnostic consistency, thus increasing the clinical homogeneity of 
IBD subgroups. 
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Individuals without IBD also participated in this study. Information regarding 
race, ethnicity, and family history ofIBD was obtained in a similar manner to IBD 
patients. These individuals will be derived from the same geographic area as the IBD 
patient population and will be recruited from patients without a family history of IBD 
who present for a screening colonoscopy. Since they are derived from the same practice, 
they should be similar to the IBD popUlation with respect to geographic and 
socioeconomic variables. Due to the fact that they are presenting for cancer screening, 
many of these individuals will be older than the IBD patients. While this does represent a 
significant selection bias, it does have one important advantage. Specifically, since IBD 
may have a late age of onset, having controls from an older age group minimizes the 
chance that these patients will subsequently develop IBD, and therefore be misclassified 
as "unaffected". 
Patients with biopsy or surgically confirmed IBD, available histology, complete 
personal and family history, and signed written informed consent will be eligible for 
study participation. The following information will be documented for IBD patients: age, 
race, gender, age of diagnosis, family history ofIBD and colon cancer, smoking history, 
number and type of previous operations, presence of extra-intestinal manifestations, and 
presence of colonic dysplasia or cancer. Disease behavior (uncomplicated, stenosing, or 
fistulizing disease) (98), presence and location of fistulae, presence or absence of perianal 
disease, and disease recurrence will also be assessed for CD patients. Such data will be of 
vital importance to this study since the overall aim is to define genotype-phenotype 
relationships for susceptibility loci and candidate genes. 
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IC was considered as a distinct IBD phenotype in this study. Strong evidence (99) 
has shown that IC should be considered a distinct clinical entity. IC patients have been 
shown to suffer from more fulminant disease and have a higher incidence of 
complications following surgery. One could argue that with sufficient follow-up, the 
majority of these patients will eventually be categorized as either CD or UC. This IC 
population has, however, been observed for a significant length of time, with an average 
5.6 year follow-up and maximum follow-up of 12 years. IC patients exhibiting diagnostic 
features of either UC or CD are promptly re-categorized, thus increasing group 
homogeneity. 
Eight milliliters of peripheral whole blood will be obtained for each study 
participant. Leukocyte DNA will be extracted (Puregene DNA isolation kit, Gentra 
Systems, Inc., Minneapolis, MN), quantified spectrophotometrically (Gene Quant, 
Pharmacia, Dublin, OR), and stored at 4°C until analysis. In patients undergoing surgery, 
1cm2 colonic mucosal samples will be harvested. Ralfthe sample will be sent to 
pathology for hematoxylin and eosin staining and the other half immediately placed in 
RNLater (Quiagen, Valencia, CA) and stored at 4°C until analysis. In "control" patients 
who undergo hemorrhoidectomy, 1cm2 "control" mucosal samples will be obtained and 
similarly processed. 
Characterization of IBD Susceptibility Loci STR Markers 
The primary goal of this part of the study is to perform case-control and family-
based tests of association using STR markers within a number of IBD susceptibility loci. 
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Choice of STR markers for the preliminary IBD susceptibility loci study, and for the 
more detailed characterization of IBD2 will be discussed in Chapters V and VI 
respectively. 
Polymerase chain reaction (PCR) primers will be custom synthesized (Proligo 
Corp, La Jolla, CA) and STRs amplified using a standard PCR protocol (Perkin-Elmer 
Thermocycler, Norwalk, CT) at amplicon-specific annealing temperatures and reagent 
concentrations. These conditions will be discussed in detail in the relevant chapter. 
Amplicons will be analyzed using high performance liquid chromatography 
(HPLC [WA VE®, Transgenomic, Omaha, NED. Larger PCR fragments are eluted from 
the DNAsep cartridge (WAVE®, Transgenomic, Omaha NE) less rapidly than smaller 
alleles. 
Statistical Analysis 
Case-Control Tests of Association: Two-way contingency table analysis will be used to 
test for differences in allele and genotype frequencies among groups. Each marker will 
be tested separately for homogeneity of allele-genotype frequencies across groups by 
two-way contingency table analysis. Since there are many rare alleles and genotypes, 
alleles and genotypes with a frequency of less than 5% are pooled into one class for 
analysis. 
The Mehta-Patel (100) extension of Fisher's exact test for two-way tables was 
used for computing P values. Case-control tests will be conducted in a three-step fashion. 
First, a Monte Carlo estimation of the global exact test for overall allele-genotype 
homogeneity will be calculated using 2 x c contingency tables for disease group versus 
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control populations (or disease versus disease in the case of CD disease behavior 
subgroups, and age category versus age category in the case of age of disease onset). 
Second, these P-values will be combined using Fisher's method (101) as a global test of 
allele-genotype homogeneity. Individual genotypes or alleles will only be tested when 
both the global and disease versus control comparisons achieve statistical significance 
following Bonferroni correction, thus accounting for the problem of multiple analyses 
and compounding of a type I error. Individual genotypes or alleles are compared using 
Fisher's exact test on a 2x2 table. Computations are performed using Statistical Analysis 
Software 9.0 (SAS Institute, Cary, NC). 
Haplotype Estimations: Haplotype estimations will only be performed when appropriate 
i.e. when STR markers are on the same chromosome and are in close enough genetic 
proximity for linkage disequilibrium to exist between STRs. Haplotype frequencies for 
STR pairs will be estimated using an EM maximum likelihood method. The Markov test 
(Arlequin 2.0 software (102)) is used to test the differentiation between disease and 
control populations in haplotypic data. Maximum-likelihood estimates of haplotype 
frequencies will be calculated from genotypes of unknown phase, and standard deviations 
of estimates are obtained using a Monte Carlo method. The Markov chain will consist of 
10,000 steps. 
Family-Based Tests: Family-based tests of association are used to compare transmission 
of alleles from parents to affected siblings in different family units. They can also be used 
to compare allele transmission between affected and unaffected (phenotypically 
discordant) siblings. The Pedigree Disequilibrium Test (PDT) and a likelihood ratio test 
as implemented in the computer program TRANSMIT will be employed in this study. 
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The PDT allows for the use of genotype data from extended pedigrees, including 
triads and discordant sibling pairs, related nuclear families, and larger sibships from 
pedigrees. The PDT provides a valid test of both linkage and association (103). The PDT 
is a valid test of association, even if population substructure is present. Use of the PDT is 
expected to result in substantial gains in power. The PDT will remain robust, even when 
sample sizes as small as 25 pedigrees are used. The PDT -sum statistic, which will be 
utilized in this study, is a variation of the PDT used to correct for potential bias (104). 
A likelihood ratio test as implemented in the computer program TRANSMIT will 
also be used as a method of family-based testing (105). It can deal with the transmission 
of multilocus haplotypes, even if the phase is unknown. If parental genotypes are 
unknown, data from unaffected or siblings of unknown status can be used to narrow the 
range of possible parental genotypes. For cases in which no information on parental 
genotype is available, the likelihood ratio test can be performed using data from either 
affected or non-affected siblings. 
Apparent disease associations can occur in population-based studies due to either 
true disease association or spurious associations due to the effects of population 
substructure (106). Population substructure may occur if there are, for example, multiple 
population subtypes in what is assumed to be a homogeneous population. Family-based 
studies, unlike population-based approaches, have the advantage of not being affected by 
popUlation substructure. Case-control studies are however superior in a number of ways, 
notably that they permit analysis of larger groups of patients than would typically be 
possible in linkage studies. Confirmation of results from the case-control population 
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study utilizing family-based testing will indicate if linkage and association are indeed 
present. 
Characterization of TLR Pathway IBD Candidate Genes 
Colonic Mucosal Expression of Candidate Genes 
Candidate gene expression will be compared between colonic mucosa obtained 
from IBD patients and from subjects without IBD or colon cancer. These non-IBD, non-
cancer mucosal samples will be obtained from individuals undergoing 
hemorrhoidectomy. In order to conclusively demonstrate a trend in gene expression, 
these experiments will be performed using tissue samples from several individuals with 
each type of IBD as well as in controls. 
Following informed written consent, lcm2 of colonic mucosa will be obtained 
from IBD patients immediately following bowel resection, and placed in RNLater® 
(Quiagen, Valencia, CA) and stored at 4°C. To ensure accurate disease assessment and 
uniformity of sampled tissue, matched tissue sections will be obtained for routine 
histological examination. Analyses will be performed only after a specialist 
gastrointestinal pathologist has verified the diagnosis. 
Real-time PCR quantification will be performed in order to determine differential 
expression of candidate genes. Primers will be custom-designed using VectorNTI 
software (107) and will be weighted to the 3' UTR of candidate genes. Colonic mucosal 
tissue (lOOmg) from DC, CD, and normal mucosa will be subjected to total RNA 
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extraction following homogenization and cell lysis in guanidine isothiocyanate-
containing buffer using an affinity column technique (Qiagen RNeasy® Midi purification 
kit, CA). Collected cellular RNAs will then be converted to cDNA. All reactions will be 
performed on an ABI Prism® 7700 Sequence Detection System using Stratagene® 
Brilliant® Quantitative PCR kit with fi-actin as an internal standard. Each reaction will be 
performed in triplicate and reactions without cDNA will be included as negative controls. 
Cycle threshold (Ct) values will be obtained graphically for each gene of interest and the 
fi-actin internal standard. Standard curves will be constructed for all genes before 
calculation of gene-specific mRNA levels, and gene expression normalized to fi-actin. 
For each sample, the mean ofthree Ct values will be calculated. Comparison of gene 
expression between control and disease samples is derived from the standard curve 
method. Relative gene expression will be compared to controls set as normal. 
Complete methods used for RNA extraction, cDNA synthesis, and real-time PCR 
quantification of candidate gene expression are given in Chapter VII. 
Polymerase Chain Reaction Primer Design and Amplification Procedure 
Candidate gene sequence data are obtained from the National Center for 
Biotechnology Information (NCBI) human genome public database 
(http://www.ncbi.nlm.nih.gov/). Sequence data are then imported into VectorNTI 
software (107) for PCR amplicon design. PCR protocols are derived from amp licon-
specific analyses performed using VectorNTI software (107), with touchdown 
thermocycling protocols typically being employed. The primary focus of this part of the 
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study will be on SNP discovery within candidate gene exons ad regulatory regions 
including the promoter and 3' -untranslated region (3' -UTR). Amplicons for candidate 
gene exons will include approximately 100bp ofintronic DNA on both the 5' and 3' sides 
of coding regions. These intronic regions will be included since polymorphisms here may 
be involved in binding of regulatory proteins (e.g. transcriptional enhancers), or may alter 
mRNA alternative splicing patterns. 
Germline DNA extracted from peripheralleucocytes will form the template for 
PCR amplification of candidate genes. Specific details of PCR methodology will be 
described in Chapter VII. 
Candidate Gene Polymorphism Discovery 
Overview: Polymorphism discovery is an integral part of this part of the study. Although 
gene polymorphism data within human genome databases (e.g. the NCB I dbSNP 
databases) is useful, it does have limitations. Many of the described polymorphisms have 
been characterized in a small number of individuals (often from fewer than 20 
chromosomes). It is likely that the frequency of disease-associated mutations within 
susceptibility genes would be low in healthy populations such as those used in the Human 
Genome Project. It is extremely unlikely that a disease-associated polymorphism would 
be detected in such a low number of unaffected individuals. Screening for 
polymorphisms plays an important role given the low level of polymorphism 
characterization, especially within the proposed candidate genes. 
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Candidate Gene Amplicon Design: Candidate gene sequence data are obtained from 
public databases such as the National Center for Biotechnology Information web page 
(http://www.ncbi.nlm.nih.gov/). Sequence data are then imported into VectorNTI 
software (107) for PCR amplicon design. A number of amplicon design parameters are 
set, and are based around optimal denaturing high performance liquid chromatography 
(dHPLC [Trans genomic WAVE@, Omaha, NED amplicon analysis. Desired amplicon 
characteristics are as follows: 
1) Ideal amplicon size is between 200-700bp. Sizes of up to 1500bp can be 
adequately analyzed. Analysis of amplicons <200bp is not feasible. 
2) Ideal amplicon GC content is between 48-68% GC. Fragments with a higher or 
lower GC content can be used, but will require dHPLC heteroduplexing 
temperature optimization. 
Mutation Analysis: PCR amplicons will be screened for mutations using dHPLC. This 
method compares two or more chromosomes as a mixture of denatured and re-annealed 
PCR amplicons. A sample dHPLC chromatogram is shown in Figure 5. 
The presence of a polymorphism within one of the two genomic copies of an 
amplicon (i.e. when an individual is heterozygotic for a polymorphism) is indicated by 
differential retention ofhetero- and homoduplex DNA on reversed-phase 
chromatography supports under conditions of partial denaturation (108). DNA fragments 
are eluted from the stationary phase of the HPLC column (DNASep@ cartridge, 
Transgenomic, Omaha, NE) by creating a buffer gradient. Buffers used in this process are 
O.lM triethylammonium acetate (TEAA) solution (,Buffer A') and O.1M TEAA 
containing 25% acetonitrile (,Buffer B'). Acetonitrile interferes with the interaction 
53 
Figure 5. Example of a polymorphic and non-polymorphic dHPLC chromatogram used 
for screening candidate gene amplicons for polymorphisms. Chromatograms from two 
separate samples are shown here: 
Sample 1: One major peak evident. This pattern is seen when there is no amplicon 
heteroduplexing. The candidate gene amplicon from this individual is not polymorphic. 
Sample 2: Two major peaks evident. This pattern is seen when there is amplicon 
heteroduplexing. Heteroduplexed amplicons are eluted from the dHPLC column earlier 
than the homoduplexes. These data imply that there is a polymorphism within that 
amplicon, although it does not confer the position or nature (i.e. insertion, deletion, 
missense) of the polymorphism. Sequence analysis of the polymorphic amplicon must 
now be performed. 
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between the negatively charged DNA molecule, the positively charged TEAA ion-pairing 
reagent, and the hydrophobic stationary phase of the DNASep® Cartridge. Thus as 
acetonitrile concentration (i.e. buffer B) increases with time, differentially sized DNA 
molecules are eluted. Hetero- and homoduplex DNA are resolved in this manner, with 
heteroduplexes being eluted from the column at an earlier time period. Single nucleotide 
substitutions, deletions, and insertions can be detected by on-line UV monitoring within 
2-3 minutes in unpurified amplicons as large as 1.5kbp. The sensitivity and specificity of 
this method consistently approaches 100% (108). 
The process ofheteroduplex resolution is very temperature sensitive. Optimal 
temperature for mutation analysis is dependant on the helicity of the amplicon being 
studied. Optimal helicity for dHPLC mutation analysis is between 50% and 98% i.e. 50-
98% of the amplicon is double stranded at the experimental temperature. The helicity of 
an amplicon at a given temperature is determined by its G-C ¢ontent. Different parts of an 
amplicon will likely have different G-C contents, and owing to the higher stability of G-C 
as compared to A-T bonds, higher G-C content amplicon domains will require more 
energy to disrupt nucleotide pair hydrogen bonding than lower G-C domains. Thus the 
helicity of G-C rich amplicon domains will be higher than that of A-T rich domains at 
increasing temperatures. Any given amplicon can therefore be divided into domains 
based on its G-C content. The location of these domains within an amplicon, and the 
temperature at which dHPLC experiments must be performed in order for amplicons to 
have optimal helicity, are predicted by Transgenomic Wavemaker software (109). It is 
therefore highly probable that an amplicon will have to be analyzed at a variety of 
temperatures to effectively screen all domains for polymorphisms. 
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Screening Protocol: A protocol whereby a limited, although representative proportion of 
the total population are screened for polymorphisms is required for a number of reasons. 
Firstly, although the total study population consists of over 1000 individuals, many study 
participants have limited amounts of stock genetic material available. Secondly, the 
length of time required to screen each of the numerous candidate gene amplicons would 
be considerable if performed for every member of study cohort. The 'screening' cohort 
will therefore consist of 96 individuals comprising a representative proportion of the total 
study population (32 population controls, 32 ulcerative colitis, and 32 Crohn's disease 
individuals). Every attempt will be made to include individuals in the screening process 
that have disease-associated STR polymorphisms. Whether this is possible will depend 
on the amount of stock DNA available for such patients. Ideally, a large quantity of stock 
genetic material will be available for individuals included in the screening stage of the 
study. 
There are two possible outcomes from dHPLC screening: 
1) A polymorphism is identified within a candidate gene amplicon. In this instance, 
the SNP is likely to be of a high enough frequency in the entire population to 
warrant further study. DNA sequencing of apparently polymorphic amplicons will 
therefore need to be performed. 
2) There may be no evidence of polymorphism within an amplicon in the screening 
population. This will probably be due to the fact that the studied amplicon truly 
does not contain a polymorphism, or because a polymorphism is too rare to be 
detected (i.e. likely total population frequency <1 %). In the instance of an 
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infrequently occurring polymorphism, further analysis would not be warranted 
since it is unlikely to make a significant contribution to disease susceptibility. 
DNA Sequencing: Following dHPLC screening of candidate genes, apparently 
polymorphic amplicons will be sequenced. To ensure complete characterization of 
wildtype and mutant alleles, DNA sequencing will be performed on several individuals 
with both polymorphic and non-polymorphic candidate gene amplicons. DNA fragments 
are sequenced using fluorescent cycle sequencing and analyzed on a DNA sequencer 
(model CEQ2000XL; Beckman-Coulter, Fullerton, CA). These data will in turn, be used 
to design fluorogenic probes for SNP-specific PCR, as described below. 
Given current data, the number of SNPs in the human genome likely exceeds 3 
million (or 1 SNPlkbp) (110). It is therefore highly likely that many polymorphisms will 
be identified in both candidate genes through the use of this screening process. 
SNP Genotyping 
Following polymorphism discovery, TaqMan-based genotyping methods will be 
employed to characterize polymorphisms in the entire study population. 
peR Primer and Oligonucleotide Probe Design: Candidate gene SNP-specific PCR 
primers and fluorogenic probes will be designed using Primer Express (version 1.5, 
Applied Biosystems, Foster City, CA). The fluorogenic minor groove binder (MGB) 
TaqMan probes are labeled with a reporter dye (either FAM [5-(&6)-carboxyfluorescein] 
or VIC® [a proprietary fluorescent dye produced by Applied Biosystems]) specific for the 
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wildtype and variant alleles of each candidate gene SNP. For consistency, F AM will 
always label the wildtype probe and VIC the mutant probe. 
Fluorogenic probe and PCR primer design have been described elsewhere (111). 
Briefly, fluorogenic probes are designed to have a melting temperature between 65°C and 
67°C, and with the SNP located in the center of the oligonucleotide. Melting 
temperatures of each SNP-specific probe-pair will not differ by more than 1°C. PCR 
primers will have a melting temperature between 58°C and 60°C and will contain less 
than three G'S and C's within the last five bases at their 3'-end. 
peR Amplification and SNP-Genotyping: PCRs will be carried out using a two 
temperature PCR protocol (Perkin-Elmer Thermocycler, Norwalk, CT). Reactions 
lacking template DNA will be included as controls to ensure that there is no amplification 
of contaminating DNA. The fluorescence of each sample will be read post-PCR on an 
ABI Prism® 7900HT sequence detection system (Applied Biosystems, Foster City, CA). 
An example of the type of output given by this apparatus is given in Figure 6. 
Fluorescence is detected when the probe with the exact sequence match binds to the 
complementary region of the single-stranded DNA template and is digested by the 5' -3'-
exonuclease activity of AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster 
City, CA). Probe digestion releases the fluorescent reporter dye from the quencher 
located on the 3' end of the probe. Homozygote wildtype samples fluoresce with F AM, 
whereas homozygote mutants fluoresce with VIC, and heterozygotes with both F AM and 
VIC. 
PCR primers and SNP-specific probe sequences for each SNP included in the 
study are shown in Chapter VIII. 
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Figure 6. Post-PCR detennination of fluorescence from SNP-specific PCR reactions-
typical read-out. Following PCR amplification of a polymorphism, the ABI 7900HT 
apparatus detennines the relative fluorescence of the 6-F AM and VIC marker dyes in 
each sample. Each data point represents the fluorescence from one reaction. Five groups 
are apparent: 
1) Allele X - These samples only fluoresce with the allele X dye. By convention, 
this is always VIC, the dye bound to mutant probes. These individuals are 
therefore homozygote mutants for the SNP of interest. 
2) Allele Y - These samples only fluoresce with the allele Y dye, 6-FAM. These 
individuals are therefore homozygote wildtypes for the studied SNP. 
3) Both - Both marker dyes fluoresce with approximately equal intensity. These 
individuals are heterozygotes for the mutant SNP allele. 
4) NTC - 'No Template Control'. These are negative controls that contain all 
reagents apart from template DNA. They control against the presence of 
contaminating (e.g. microbial) DNA. As expected, fluorescence is not detected for 
either dye in the samples shown here. 
5) Undetermined - These are either samples where PCR amplification has failed or 
the position of the data point on the graph is ambiguous. A number of failed 
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Case-Control Association Studies: A case-control approach will be employed for 
comparison of candidate gene SNP frequencies between IBD populations and the control 
population. Comparisons will be made using the using chi-squared and/or Fishers Exact 
tests with use of the Bonferroni method to correct for compounding of type 1 when 
appropriate. Analyses will be performed in racially matched disease and control 
populations. Case-control analyses will initially be performed using CD, UC, and IC 
groups. 
Other Statistical Analysis: Haplotype and family-based methods will be used in a 
similar manner for candidate gene SNPs as were used for STR analysis (see p. 45-47). 
Linkage disequilibrium is far more likely to exist between SNPs within the same 
candidate gene owing to their likely closer genetic proximity. It is therefore likely that the 
use of haplotype estimations will be far more extensive in candidate gene studies than 
was the case for STR data. 
Analysis of Genotype-Phenotype Correlations 
Subset analysis will form an essential part of this proposal. The importance of 
such analyses has been underlined by experience with the IBD susceptibility gene NOD2. 
NOD2 disease-causing mutations have been shown to be associated with fibrostenosing 
ileocolic CD in Caucasian populations (31;33;35;36). Recent data from these as well as 
other association studies conclusively demonstrate that IBD consists of more than the two 
traditionally described phenotypes (i.e. CD and UC) (32). Analysis of genotype-
phenotype relationships in IBD will likely improve statistical power by increasing group 
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homogeneity. In a similar manner, ethnic differences are another important factor that 
must be taken into consideration. For example, NOD2 mutations playa prominent role in 
CD susceptibility in Caucasians, but not in Japanese populations (38; 112). 
The CD and UC groups will therefore be subdivided on the basis of ethnicity, 
gender, age of diagnosis and presence of extra-intestinal disease manifestations. The IC 
population will not be subdivided in such a manner owing to the low number of subjects 
currently in the study (n=82). Analyses performed at the sub-phenotype level in such a 
population would lack statistical power and likely be of little value. The CD popUlation 
will also be subdivided on the basis of the Vienna classification (98) in order to permit 
disease location and disease behavior to be considered as distinct CD subgroups. 
Following subgroup division, the methods described above (i.e. case-control, 
haplotype and family-based analyses) will be employed to analyze genotype-phenotype 
relationships. Each phenotypic variable will be considered separately and analyzed in 
isolation to other disease characteristics. 
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CHAPTER V 
CHARACTERIZATION OF GENOTYPE-PHENOTYPE RELATIONSHIPS FOR 
INFLAMMATORY BOWEL DISEASE SUSCEPTIBILITY LOCI USING 
MULTIPLE SHORT TANDEM REPEAT GENETIC MARKERS 
Overview 
BACKGROUND: The genetic basis ofIBD is well founded and susceptibility 
loci have been identified on a number of different chromosomes. Previous genome-wide 
scans have produced highly variable results, with reproduction of linkage demonstrated at 
some loci proving difficult or impossible. The most likely sources of these variable 
outcomes are intrinsic popUlation differences and inconsistent IBD phenotyping as a 
result of differing diagnostic criteria. HYPOTHESIS: A variable number of previously 
described IBD susceptibility loci will be associated with disease in this population. 
METHODS: The aim of this study was to improve disease characterization by defining 
genotype-phenotype relationships for various IBD susceptibility loci (IBD1, IBD2, 
IBD5-7, chromosome 4) by characterizing previously described peak logarithm of odds 
(LOD) score short tandem repeat markers. The study population consisted of 484 
severely affected Caucasian patients with IBD, 144 unrelated population controls, and 
348 non-affected first-degree relatives of IBD patients. Markers were amplified from 
peripheral leukocyte DNA using polymerase chain reaction and analyzed using high-
performance liquid chromatography. Case-control association studies were performed 
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using the Mehta-Patel extension of Fisher's exact test. Family-based association studies 
were used to confirm associations from case-control tests. RESULTS: IBDl, IBD2, and 
IBD5 markers were associated with disease in the study population. Following 
correction for mUltiple analyses, association was evident in terminal ileal CD for IBDI 
(P=O.012), and in indeterminate colitis for IBD5 (P=O.008). There was also a trend 
towards significant association in colonic CD for IBDI (P=O.022), in both indeterminate 
colitis (P=O.027) and terminal ileal CD (P=O.014) populations for IBD2, and finally in 
colonic CD for IBD5 (P=O.017). Family-based studies confirmed IBD2 association in 13 
indeterminate colitis families (P=O.005) as well as in 35 ulcerative colitis families 
(P=O.048). CONCLUSIONS: These results show that IBDl, IBD2, and IBD5 playa role 
in disease susceptibility in this IBD population. 
Introduction 
As discussed in Chapter II, both UC and CD are complex, polygenic disorders 
that share some, but not all, susceptibility genes (10). Genome-wide linkage studies 
using non-informative STR markers have defined chromosomal regions where the 
presence of a certain marker/loci increases an individual's risk of developing IBD. Thus 
far, nine such IBD susceptibility loci with a relatively high likelihood oflinkage to IBD 
have been identified. These loci have subsequently been named IBDl-9 (5;18-25). In 
addition to IBDI-9, a number of studies have produced evidence for the existence of 
other loci, including a chromosome 4 susceptibility locus (23). 
Replication of linkage exhibited by the majority ofIBD susceptibility loci has 
been relatively inconsistent. Only IBD 1-4 have shown any level of consistent 
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reproducibility (5;113-116). Confirmation oflinkage at other IBD susceptibility loci has 
often only proved possible within small, homogenous populations. An example of this 
type of phenomenon is the finding of association with the IBD7 locus in an American 
Chaldean IBD population (93). 
The aim of this study is to characterize IBD susceptibility loci in a phenotypically 
well-defined rural population through the use of previously described STR markers. The 
studied STR markers possess peak LOD scores with respect to previously described 
susceptibility loci. The overall goal of this study was to define IBD genotype-phenotype 
correlations that could eventually lead to improved disease classification, as well as to 
define disease-associated genomic regions in the study population as a means to 
commence more detailed mapping and candidate gene studies. 
Materials and Methods 
Study Design 
Study design has been described in detail in Chapter IV. Briefly, the primary 
approach was to perform a case-control association study using STR markers with the 
highest LOD score with respect to previously described IBD susceptibility loci. STR 
allele and genotype frequencies were compared between well-defined disease populations 
and an unrelated control population with no clinical evidence or family history oflBD. 
The CD population was subdivided into populations with distinct phenotypes based on 
the Vienna classification (98). 
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In addition to characterizing peak LOD score STR markers, a non-IBD STR from 
a genomic region that has never displayed linkage to IBD was defined. If associations 
were evident with this marker, it would imply that associations observed with IBD 
markers might be spurious. Conversely, ifno associations were observed with this "non-
IBD" STR, more strength would be afforded to the argument that any association 
observed with IBD susceptibility loci STRs were valid (117). 
Family-based tests of association were performed to confirm the findings of case-
control studies, in addition to accounting for the possible confounding effects of 
population substructure. Family-based tests were performed using non-affected first-
degree relatives of IBD probands. 
Setting and Participants 
The University of Louisville Institutional Review Board approved this study. 
Written informed consent was obtained from all subjects. Patients were derived from a 
University-based colon and rectal surgery practice. These patients were referred for 
surgical consultation by their treating gastroenterologists due to the severity of their 
symptoms or lack of response to medical therapy, and are therefore classified as having 
severe disease. Patients originated from a relatively small rural geographical area 
consisting of Kentucky and southern Indiana. This is atypical since IBD is more 
prevalent in urban populations (13). 
The patient population consisted of a total of 628 Caucasians, including 254 
unrelated individuals with CD (63% women), 165 with UC (53% women), 65 with IC 
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(70% women), and 144 population controls (74% women). About one third of the IBD 
patients studied did not require surgery (25% of CD patients, 33% ofUC patients). The 
average duration of clinical follow up for the CD population was 4.6 years (range, 0-16 
years), 4.3 years for the UC population (range, 0-14 years), and 5.6 years for the IC 
population (range, 0-12 years). 
For the purposes of more accurate phenotyping, the CD group was subdivided 
based on the Vienna classification (98). This classification categorizes CD patients based 
on their age of onset (A), location of disease (L), and disease behavior (B). With regard 
to age of onset, 175 of254 (69%) CD patients were diagnosed at < 40 years of age (AI 
group), 47 of 254 (18%) at 2: 40 years old (A2 group), and information regarding age of 
onset was not available for the remaining 32 patients (13%). Regarding disease location, 
70 of254 (28%) had terminal ileal disease (Ll group), 152 of254 (60%) had purely 
colonic and/or terminal ileal (ileal and colonic) disease (L2/L3 groups), and 32 of254 
(12%) had disease located proximal to the terminal ileum (L4 group). The L2 and L3 
groups were combined in this study since colonic disease constitutes the primary focus of 
research in this cohort. Due to the relatively low numbers of individuals with CD 
proximal to the terminal ileum (L4 group), this disease subgroup was excluded from 
case-control analyses. Regarding disease behavior, 96 of254 patients (38%) had 
uncomplicated inflammatory disease (B 1 group), 28 of 254 (11 %) had stricturing disease 
(B2 group), and 130 of254 (51 %) had penetrating disease (B3 group). This pattern of 
disease behavior is consistent with the severe affection status of this patient cohort. 
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Three hundred forty-eight non-affected first-degree relatives ofIBD patients were 
available for this study. There were 63 CD families (29 triads, 30 discordant sibling pairs 
[DSPsD, 4 triadlDSP combinations), 43 DC families (11 triads, 24 DSPs, 8 triadIDSP 
combinations), and 14 IC families (5 triads, 5 DSPs, 4 triadIDSP combinations). In 
addition, there were 17 CD families, 18 DC families, and 9 IC families who could not be 
classified as either a triad or DSP. CD families included probands with ileal disease, 
probands with colonic CD, as well as probands with proximal small bowel disease. 
Genetic Marker Characterization 
STR markers with the highest LOD scores were selected from the original studies 
describing the IBD susceptibility loci IBDl, IBD2, IBD6, IBD7, and the chromosome 4 
susceptibility locus (5;18;19;22;23). The IBD5 marker D5S1984 was chosen from a fine-
mapping study (118) of the 5q31 cytokine cluster performed by the group that initially 
described IBD5. The non-IBD STR marker D13S252, which is located in the 
peri centromeric region of chromosome 13, was selected from the NCB I human genome 
database (http://www.ncbi.nlm.nih.gov). The genetic markers used in this study and the 
associated polymerase chain reaction (PCR) primers are shown in Table 1. 
PCR primers were custom-synthesized (Proligo, La Jolla, CA) and STRs were 
amplified from genomic DNA using a standard PCR protocol (Perkin-Elmer 
Thermocycler, Norwalk, CT). PCR mixtures consisted of lOOng genomic DNA, 70nM of 
each dNTP, 2.51-11 Thermophilic DNA lOx reaction buffer (Promega, Madison, WI), 




Locus Annealing PCR Primer Sequence 
Marker Score 
Temperature 
IBDI D16S419 3.17 57°C ATTTTTAAGGAATGTAAAGNACACA 
GACGTTAGACCAGGAGTCAG 
IBD2 D12S83 5.47 59°C TTTTTGGAAGTCTATCAATTTGA 
TAGCAGAGAAAGCCAATTCA 
IBD5 05S1984 3.00 68°C CCAGCCCGCTTAGTGT 
TAGGAGGCTTCCCACATCT 
IBD6 019S1166 4.60 54°C TTCCAGCCTAGGTAGCAGTG 
GCAACTGAGGAAATGCATCT 
IBD7 DlS1597 3.01 55°C TTTATTGAGATATATTTGACATGCA 
AAGGAGGAAAGCTTTTTGGA 
Chr.4 D4S1647 2.76 59°C TATTTCCAACACCCCTGCTA 
AAGCAAAGAGGATTGAAAGTG 
Non-IBD D13S252 N/A 57°C CTCAACCTGGCTTCTACT 
TACTCCTTAATAAACTCCCC 
Table 1. STR markers utilized in the IBD susceptibility loci study. Amplimer sequences, 
LOD score from previous linkage studies and PCR annealing temperatures are shown for 
each STR marker. 
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DNA polymerase (Promega, Madison, WI) in a final 25jJ.I reaction volume. Thermal 
cycling parameters comprised an initial denaturation step of 94°C for 10 min followed by 
25 cycles of denaturing at 94°C for 30 sec, annealing at the primer-specific temperature 
shown in Table 1 for 30 sec, extension at nOc for 30 sec, followed by a final extension 
phase at 72°C for 7 min. PCR products were analyzed using HPLC (W A VE®, 
Transgenomic, Omaha, NE). 
Statistical Analysis 
Methods for statistical analysis of STR data have been described in detail in 
Chapter IV. Case-control and family-based approaches have been used here. Individuals 
with CD proximal to the terminal ileum were excluded from case-control analyses owing 
to their relatively low numbers in the study population (L4 group, n=32). 
To account for multiple testing in case-control studies, individual STR genotype 
and allele frequencies were only examined when the global test of homogeneity of all 
groups and disease versus control pair-wise comparisons achieved statistical significance. 
Global tests of homogeneity of disease versus control pair-wise comparisons were 
corrected by the Bonferroni method, and were considered to have achieved statistical 
significance when P,:S0.0125. 
With regards to family-based testing, CD pedigrees were not analyzed based on 
disease location. All CD family data were pooled in order to maximize statistical power 
by allowing for the analysis of the maximum number of CD families. Haplotype analysis 
of these data was not applicable. 
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Results 
Allele and Genotype Frequencies 
Allele frequencies for STRs that were disease-associated on case-control analysis 
are shown in Table 2. Smaller alleles were eluted from the DNAsep cartridge 
(Transgenomic, Omaha, NE) earlier than larger alleles, and therefore were detected by 
the HPLC apparatus at earlier time intervals. Alleles were named on the basis of their 
size, with "1" representing the largest amplified fragment and consecutive numbers 
representing alleles of decreasing size. 
Case-Control Association Studies 
Results of global case-control analyses for all STRs are shown in Table 3. These 
P-values are uncorrected for multiple analyses. Each locus is now considered in tum. 
IBDl: The global test of homogeneity of all groups for the IBDI STR (DI6S419) alleles 
showed a statistical difference (P=0.004). Following this, the global test of homogeneity 
between disease and control groups demonstrated a statistically significant difference in 
allele frequencies between the ileal (L 1) CD groups when compared with the control 
population (P=0.012). This was significant at the Bonferroni-corrected significance level 
ofP<0.0125). Individual pair-wise disease versus control analyses showed over-
representation of allele 5 in the ileal (L 1) CD group (ileal CD frequency 10 of 50 alleles 
[20%], control frequency 5 of 118 alleles [4%], P=0.002). The uncorrected global test of 
homogeneity between disease and control groups demonstrated a statistically significant 




IBDI Ulcerative Indeterminate Crohn's Disease 
Dl6S419 Colitis Colitis Disease (LI) (L2/3) Controls 
Allele N % N % N % N % N % 
4 53 33% 28 33% 14 28% 31 28% 49 42% 
5 11 7% 8 10% 10 20% 18 16% 5 4% 
7 9 6% 2 2% 1 2% 9 8% 10 8% 
6 71 44% 36 43% 19 38% 42 38% 44 37% 
Pooled 16 10% 10 12% 6 12% 10 9% 10 8% 
--
160 84 50 110 118 
Terminal Colonic 
Ileal Crohn's 
IBD2 Ulcerative Indeterminate Crohn's Disease 
Dl2S83 Colitis Colitis Disease (LI) (L2/3) Controls 
Allele N % N % N % N % N % 
7 78 43% 33 43% 25 35% 57 38% 34 28% 
8 24 13% 7 9% 3 4% 16 11% 21 18% 
9 16 9% 14 18% 12 17% 20 13% 11 9% 
10 17 9% 8 11% 6 8% 14 9% 21 18% 
11 32 18% 11 14% 13 18% 34 23% 20 17% 
Pooled 15 8% 3 4% 13 18% 9 6% 13 11% 
182 76 72 150 120 
Terminal Colonic 
Ileal Crohn's 
IBD5 Ulcerative Indeterminate Crohn's Disease 
D5S1984 Colitis Colitis Disease (LI) (L2/3) Controls 
Allele N % N % N % N % N % 
2 14 11% 1 2% 2 4% 6 6% 8 10% 
4 54 43% 26 45% 21 40% 47 46% 37 46% 
5 39 31% 22 38% 16 31% 36 35% 13 16% 
6 11 9% 8 14% 11 21% 8 8% 14 18% 
Pooled 8 6% 1 2% 2 4% 5 5% 8 10% 
126 58 52 102 80 
Table 2. STR allele frequencies for !BD1, IBD2, and IBD5. Alleles with <5% frequency 
were pooled. 
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Disease vs. Control ComEarison Global P-value Global test 
Colonic of Terminal Crohn's homogeneity Ulcerative Indeterminate Ileal CD Disease (combined P STRMarker Colitis Colitis (L1) (L2/3) value) 
IBD1 Genotype 0.731 0.236 0.640 0.104 0.348 
D16S419 Allele 0.423 0.131 0.012 0.022 0.004 
IBD2 Genotype 0.283 0.102 0.502 0.032 0.053 
D12S83 Allele 0.090 0.027 0.014 0.051 < 0.001 
IBD5 Genotype 0.173 0.108 0.623 0.100 0.095 
D5S1984 Allele 0.082 0.008 0.159 0.017 < 0.001 
IBD6 Genotype 0.416 0.328 0.620 0.482 0.603 
D19S1166 Allele 0.568 0.523 0.596 0.547 0.792 
IBD7 Genotype 0.830 0.260 1.000 0.108 0.484 
D1S1597 Allele 0.973 0.517 1.000 0.348 0.900 
Chr.4 Genotype 0.908 0.414 0.335 0.706 0.774 
D4S1647 Allele 0.594 0.247 0.021 0.503 0.115 
Non-IBD Genotype 0.117 0.245 0.049 0.833 0.096 
D13S252 Allele 0.107 0.094 0.210 0.291 0.063 
Table 3. Case-control association test global P-values for IBD loci peak LOD score 
STRs. Statistically significant global tests prior to correction for multiple analysis are 
highlighted. 
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the control population (P=0.022). This, however, was not significant when applying the 
Bonferroni method for correction of multiple analyses. Some interesting associations 
were noted with individual pair-wise disease versus control analyses showed over-
representation of allele 5 (colonic CD frequency 18 of 110 alleles [16%], control 
frequency 5 of 118 alleles [4%], P=0.003) and under-representation of allele 4 in the 
colonic (L2/L3) CD population (colonic CD frequency 31 of 110 alleles [28%] compared 
to the control frequency 49 of 118 alleles [42%], P=0.038). These however can only be 
viewed as trends towards significance and not firm evidence of association. 
IBD5: The global test of homogeneity of all groups for the IBD5 STR (D5S1984) alleles 
showed a statistical difference (P<O.OOI). Following this, the Bonferroni-corrected 
global test of homogeneity between disease and control groups revealed a significant 
difference in allele frequencies between the IC groups when compared with the control 
population (P=0.008). Individual pair-wise disease versus control analyses showed over-
representation of allele 5 in the IC population (lC frequency 22 of 58 alleles [38%], 
control frequency 13 of 80 alleles [16%], P=0.005). 
In a similar manner to IBD 1, the uncorrected global test of homogeneity between 
disease and control groups demonstrated a significant difference in allele frequencies 
between colonic (L2/L3) CD groups when compared with the control population 
(P=0.017). This, however, was not significant when applying the Bonferroni method for 
correction of multiple analyses, and can consequently only be viewed as a trend towards 
association. Individual pair-wise disease versus control analyses showed over-
representation of allele 5 in the colonic (L2/L3) CD group (colonic CD frequency 36 of 
102 alleles [35%], control frequency 13 of80 alleles [16%], P=0.004). 
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IBD2: The global test of homogeneity of all groups for the IBD2 STR (DI2S83) alleles 
was statistically significant (P<O.OOI). Following this, the global test of homogeneity 
between disease and control groups revealed a statistically significant difference in allele 
frequencies between both IC and ileal (Ll group) CD when compared with the control 
population (P=0.027 and P=0.014, respectively). However, following application of the 
Bonferroni correction neither P-value was significant. Individual pair-wise disease versus 
control analyses showed over-representation of allele 7 in the IC group (IC frequency 33 
of76 alleles [43%], control frequency 34 of 120 alleles [28%], P=0.032) and under-
representation of allele 8 in the ileal CD population (ileal CD frequency 3 of 72 alleles 
[4%] versus control frequency 21 of 120 alleles [18%], P=0.006). 
Other markers: Case-control analyses for the IBD6, IBD7, and chromosome 4 
susceptibility loci markers did not reveal any evidence of association. As expected, no 
associations were observed with the "non-IBD" STR in any disease group. 
Disease Behavior and Age of Onset 
With regard to CD disease behavior characteristics, no correlation was evident 
between disease behavior and STR allele and/or genotype data. When analyzing age of 
onset, however, the IBDI STR (DI6S419) global test of genotype homogeneity showed a 
significant difference in distribution (P=0.032). Following this, the global test of 
homogeneity between different age of onset groups revealed a significant difference in 
the age of onset ofUC with respect to D16S419 genotype (P=O.OII). Individual pair-wise 
analyses of the 80 UC individuals who had both age of onset and genotype data showed 
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over-representation of genotype 6,6 in those UC patients with an age of disease onset :::: 
40 years (9 of 20 individuals [45%]) compared to those with an age of onset of < 40 years 
(8 of 60 individuals [13%]; P=0.009). 
Family-Based Association Studies 
Likelihood ratio testing showed evidence of association for DI2S83 in 13 IC 
families (i=16.6 [6 d.£]; P=0.005). This was primarily due to over-transmission of 
allele 11 (P=0.022). The same STR revealed evidence of association in 35 UC families 
(i=12.4 [8 d.f.]; P=0.048). Correction for multiple analyses was not performed. Other 
STRs did not exhibit evidence of association upon family-based testing. 
Discussion 
This study presents evidence for disease associations with peak LaD score STRs 
that have been shown to be linked to the IBD susceptibility loci IBDI, IBD2, and IBD5. 
Conversely, no association was evident in this population for IBD6, IBD7, and the 
chromosome 4 susceptibility loci. This is not entirely surprising, since there was a 
relatively low level of replication of linkage for the latter three susceptibility loci. It may 
well be that such susceptibility loci have either a limited effect on disease susceptibility, 
or their effects may be confined to isolated populations. Additionally, the "non-IBD" 
marker D13S252 did not demonstrate any disease group associations in this population, 
adding strength to the argument that the association exhibited by the IBD 1, IBD2, and 
IBD5 markers is not spurious. 
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This study has shown IBDI to be associated with terminal ileal CD. This result is 
not entirely surprising given that this finding is undoubtedly due to the presence of NOD2 
within IBDI. Gasche et al. (32) reviewed genotype-phenotype correlations for the IBDI 
susceptibility gene NOD2 and concluded that mutations within this gene were associated 
with AlILl or L3/B2 subgroups of the Vienna classification. These analyses confirm this 
observation with respect to disease location. Specifically, an association with Ll and 
L2/L3 CD is demonstrated. This is an important observation given the other STR disease 
associations that have been found in the current study. There was also some evidence of 
association with colonic CD (Vienna groups L2/L3). However, following correction for 
multiple analyses, this association appeared of uncertain significance. It should be noted 
that the current study has low numbers of participants and thus lacks somewhat in 
statistical power. The global comparison between colonic CD versus controls for IBDI 
alleles approached the significance threshold ofP~O.0125, with the estimation of the 
global exact test being P=O.022. With increased numbers, and consequently increased 
power, it is not improbable that this global test would become significant. 
An obvious criticism of this current study is that the number of individuals 
included is too low to provide convincing evidence of association, especially given the 
likely modest effects that would be observed with the type of genetic marker studied. 
Using the IBDl-linked STR D16S419, replication of the association observed in distinct 
phenotypic groups with NOD2 has been achieved in this relatively small but clinically 
homogenous population. It can therefore be argued that the additional case-control 
associations with IBD5, and to a lesser extent IBD2, are likely true in this cohort. 
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This study provides convincing evidence to show that IBD5 is associated with 
indeterminate colitis, with the global test of homogeneity of alleles for IC versus controls 
being significant (P=0.008). This appears to be a novel finding, the likes of which has not 
been described in other populations. Furthermore, the analyses presented here partially 
confirm the findings of recent studies with the IBD5 susceptibility locus. Recent studies 
have demonstrated that the IBD5 locus on chromosome 5q is involved in CD 
susceptibility (118; 119). The region of association has recently been refined to a 
conserved 250 kb haplotype on chromosome 5q31, which includes the STR studied here 
D5S 1984 (118). Specifically, such studies have shown an association with perianal CD. 
IBD5 was found to be associated with colonic CD (Vienna classification groups L2/L3). 
In fact, many of the patients with colonic disease in the study do also have perianal 
involvement, reflecting the severity of the disease process in this population. This 
finding should, however be viewed with caution since the global test of allele 
homogeneity between colonic CD and controls only approached significance (P=0.017). 
This again is likely a reflection of the low statistical power ofthis study. 
Case-control analyses demonstrated evidence of allelic association for the IBD2-
linked marker D12S83 in both IC and terminal ileal CD populations. Again, both these 
associations approached significance following correction for multiple analyses (P=0.027 
and P=0.014 respectively). However, the finding of association in the IC population upon 
family-based testing gives strength to the argument that case-control studies suffer from 
low statistical power. That is, the family-based study confirms the apparently non-
significant result from case-control analysis. In addition, family based testing showed 
evidence of association in the UC population, although this was not evident on case-
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control analysis. Previous studies showing that IBD2 appears to playa role in the 
pathogenesis of all forms ofIBD are thus confirmed (19;120). A number of novel 
findings are however presented for the IBD2 susceptibility locus. These include 
association of various D12S83 alleles with IC and possibly ileal CD. Since the most 
compelling evidence of IBD2 disease association was displayed in the IC population, it is 
possible that the IBD2 susceptibility gene plays an important role in the pathogenesis of 
this form of IBD. Previous studies in the same cohort have shown evidence of genetic 
heterogeneity between racial and ethnic populations with CD (94). IBD2 therefore 
appears to be a promising candidate for more detailed characterization by studying 
multiple STR markers. 
Family-based association studies played an integral role in the analytic process. 
These tests confirmed the presence of association in 13 IC families for the IBD2 STR 
(DI2S83). This result is particularly surprising given the low number of families 
available for analysis. This implies that the degree of association for this marker may be 
relatively high in the IC population. CD families were analyzed without accounting for 
disease location in order to maximize the number of families available. This may explain 
the lack of confirmation of association observed in case-control studies in the terminal 
ileal CD popUlation upon family-based testing for D12S83. The proband had terminal 
ileal CD in only 24 families. Since both the PDT and likelihood ratio tests require larger 
numbers of informative families to reveal associations, separate analysis of this small 
group would likely not yield useful data due to low power. Similarly, this probably 
accounts for the lack of association observed with the IBD 1 STR (D 16S419) in the CD 
population upon family-based testing. 
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A distinct strength of this current study is that a single gastrointestinal pathologist 
with an interest in IBD reviewed all of the IBD histology. Silverberg et al. (121) 
suggested that even low rates of diagnostic misclassification could lead to a significant 
loss of power to detect true linkage, particularly for loci with modest effects, as is likely 
the case in IBD. Inconsistent diagnoses are likely to account, at least in part, for the 
contradictory findings of previous linkage studies. It is logical to assume that diagnostic 
misclassification also would reduce the power to detect association. Minimizing 
interobserver variation in the diagnosis of IBD should increase the probability that the 
associations presented herein are true. 
The choice of only one STR from each susceptibility locus may be a point of 
criticism. This is especially true given that previous studies have demonstrated that most 
susceptibility loci display linkage over broad chromosomal regions. The aim of this 
study, however, was not to re-define entire susceptibility loci through association studies, 
but to determine IBD genotype-phenotype relationships, and to define possible starting 
points for the fine mapping of susceptibility loci. This aim is considered to have been 
adequately achieved with respect to the IBD2 and IBD5 susceptibility loci. Kaplan and 
Morris (122) demonstrated that the use of a single marker in an outbred popUlation is a 
valid approach to define starting points for fine mapping. This provides further evidence 
to suggest that the genetic region in surrounding the IBD2 STR (DI2S83) and the IBD5 
S TR (D5 S 1984) will be a useful starting point in this type of study. 
The importance of defining IBD genotype-phenotype relationships is becoming 
increasingly apparent. Descriptions of such relationships will be important in the 
characterization of the genetic defects that increase susceptibility to the development of 
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IBD. A number of studies have, for example, correlated the presence of CD-associated 
NOD2 mutations in Caucasians with distinct IBD phenotypes (31;33;35;36). Specific 
NOD2 mutations have been shown to be associated with a higher incidence of ileal 
disease, a lower likelihood of colonic involvement, as well as an increased likelihood of 
developing fistulae and strictures. In a similar manner, IBD1, IBD5, and to some extent 
IBD2 have been demonstrated to be associated with equally distinct IBD phenotypes. 
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CHAPTER VI 
CHARACTERIZATION OF GENOTYPE-PHENOTYPE RELATIONSHIPS 
WITHIN THE INFLAMMATORY BOWEL DISEASE SUSCEPTIBILITY 
LOCUSIBD2 
Overview 
BACKGROUND: The IBD2 susceptibility locus, initially described by Satsangi 
et al (1996), spans the majority of chromosome 12, with the peak region of linkage being 
at 12q13. Subsequent studies showed that IBD2 appears to be more strongly linked to UC 
than to CD. Although a number of plausible candidate genes have been considered, the 
identity of the IBD2 susceptibility gene remains unknown. HYPOTHESIS: The IBD2 
susceptibility locus is associated with disease in the Kentucky and Southern Indiana IBD 
patient population. METHODS: The aim of this study is to perform a detailed 
characterization of the IBD2 susceptibility locus and to define genotype-phenotype 
correlations. This will aid characterization of the lRAK-M candidate gene that lies within 
the 12q 13 genetic region. The studied population consisted of 484 Caucasian IBD 
patients, 144 population controls, and 348 non-IBD patients whose first-degree relatives 
are diagnosed with IBD. Three short tandem repeat (STR) markers were used to 
characterize the IBD2 locus. Case-control, haplotype, and family-based association tests 
were used to define genotype-phenotype relationships. RESULTS: Using family-based 
and case-control methods, novel evidence is provided to show that IBD2 is associated 
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with IC. Family-based testing showed evidence ofSTR D12S83 allelic association in 13 
IC families (P=O.005), and evidence oflinkage disequilibrium between the 
D12S10561D12S83 STRs in the IC family population (P=O.OOl). Case-control analyses 
partially confirmed these results, with D12S83 alleles being differentially distributed 
between IC and controls (P=O.027). However, this was not significant following 
correction for multiple analyses. Additionally, following correction for multiple analyses 
one STR was associated with the development of colonic CD based on the results of 
case-control studies (P=O.OII). Family-based analyses of data from one STR also showed 
association 38 UC families (P=O.030). CONCLUSION: The results presented here 
confirm previous studies showing involvement of IBD2 in susceptibility to all forms of 
IBD. In contrast to this, IBD2 is demonstrated to be more strongly associated with IC 
than with UC. This study forms the basis for characterization of the IBD candidate gene 
lRAK-M, which lies in very close genetic proximity to the peak region oflinkage within 
IBD2. 
Introduction 
The IBD2 susceptibility locus, described by Satsangi et al. (19) in a Northern 
European cohort, is the focus of the current study. IBD2 spans the majority of 
chromosome 12 (12p13.2-q24.l). A peak LOD score of 5.47 was obtained with the STR 
marker D12S83 (located on chromosome 12q13). Parkes et al. (123) further 
characterized this susceptibility locus and demonstrated linkage heterogeneity between 
UC and CD. IBD2 was found to have a major role in UC susceptibility, but only a 
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relatively minor effect in CD. To date, the identity of the IBD2 susceptibility gene 
remains unknown (124). 
The aim ofthis study was to define the IBD2 susceptibility locus in CD, UC, and 
IC populations by characterizing the STR marker D12S83, which had the highest LOD 
score in previous linkage studies, as well as two flanking markers. Disease populations 
were sub-classified into distinct phenotypic groups in an attempt to ensure clinically 
homogenous populations. This study was performed in order to define IBD genotype-
phenotype correlations, which could eventually lead to improved disease classification 
and aid future candidate gene studies. 
Materials and Methods 
Study Design 
Study design has been described in detail in Chapter IV. Briefly, a case-control 
association study was designed in which the IBD2 susceptibility locus was characterized 
using three STR markers. The principal marker chosen was D12S83, which is the STR 
marker with the highest LOD score within IBD2 (19). Two further markers were chosen 
on the basis of their physical and genetic proximity to D12S83 (D12S1056 and 
D2S 1 022). STR allele and genotype frequencies were compared between well-defined 
disease populations and an unrelated control population with no clinical evidence or 
family history oflBD. Both populations were derived from the same geographic area. 
The CD population was sub-divided into distinct phenotypic groups based on the Vienna 
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classification (98), which classifies patients according to their age of onset, disease 
location, and disease behavior. 
Two additional analytical approaches were then applied to the STR data: (1) 
haplotype estimation and (2) family-based tests of association. Family-based tests 
enabled confirmation of associations identified in case-control studies, accounting for the 
effects of population substructure. 
Setting and Participants 
This study was performed prospectively and had the approval of the University of 
Louisville Institutional Review Board. Written informed consent was obtained from all 
subjects. The patient population consisted of a total of 484 Caucasians, including 254 
unrelated individuals with CD (63% women), 165 with UC (53% women), and 65 with 
IC (70% women). For comparative purposes 144 population controls (74% women) and 
348 non-IBD patients whose first-degree relatives are diagnosed with IBD were included 
in the study. The mean patient age was 46 years for UC (range, 11-80 years), 38 years 
for IC (range, 17-61 years), 40 years for CD (range, 15-81 years), and 55 years for the 
control population (range, 9-87 years). The mean age of disease onset in UC was 33 years 
(range, 9-75 years), 30 years in IC (range, 12-59 years), and 30 years in CD (range, 6-81 
years). Although the majority of patients had prior surgery, 25% of CD patients and 33% 
ofUC patients were medically managed. The average duration of clinical follow-up for 
the CD population was 4.6 years (range 0-16 years), 4.3 years for the UC population 
(range, 0-14 years), and 5.6 years for the IC population (range, 0-12 years). 
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For the purposes of categorizing disease phenotype more accurately, the CD 
group was subdivided based on the Vienna classification (98). This classification 
categorizes CD patients based on age of onset (A), location of disease (L), and disease 
behavior (B). With regard to age of onset, 175 of254 (69%) CD patients were diagnosed 
at < 40 years of age (AI group) and 47 of254 (18%) had disease diagnosed at 2:40 years 
of age (A2 group). Information regarding age of onset was not available for 32 of 254 
patients (13%). Regarding disease location, 70 of254 (28%) had terminal ileal disease 
(Ll group), 152 of254 (60%) had purely colonic andlor terminal ileal (ileal and colonic) 
disease (L2/L3 groups), and 32 of 254 (12%) had disease located proximal to terminal 
ileum (L4 group). The L2 and L3 groups were combined for the purposes of this study, 
since colonic disease constitutes the primary focus of research in this population. 
Regarding disease behavior, 96 of254 (38%) had uncomplicated inflammatory disease 
(Bl group), 28 of254 (11%) had stricturing disease (B2 group), and 130 of254 (51%) 
had penetrating disease (B3 group). 
A total of 348 non-affected first-degree relatives of IBD patients were available 
for the study. There were 63 CD families (29 triads, 30 discordant sibling pairs [DSPsD, 
4 triadIDSP combinations), 43 UC families (11 triads, 24 DSPs, 8 triadIDSP 
combinations), and 14 IC families (5 triads, 5 DSPs, 4 triadiDSP combinations). In 
addition, there were 17 CD families, 18 UC families, and 9 IC families who could not be 
classified as either a triad or DSP. CD families included pro bands with ileal disease, 
probands with colonic CD, as well as probands with proximal small bowel disease. 
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STR Characterization 
Two markers in close proximity to 012S83 ([AC]n) were selected from the 
Fondati6n Jean Dausset database (http://cephb.fr/cgi-binlwdb/ceph/systeme/form). The 
tetranuculeotide STRs D12S1056 (GATA)n and D12S1022 (GAAT)n were chosen for 
study. These markers are 0.35Mbp proximal and 2.70Mbp distal ofD12S83, respectively 
(http://www.ncbi.nlm.nih.gov). 
Polymerase chain reaction (PCR) primers were custom-synthesized (Proligo, La 
Jolla, CA) and had the following sequences: 
D12S83 
5'-TTTTTGGAAGTCTATCAATTTGA-3' and 5'-TAGCAGAGAAAGCCAATTCA-3' 
D12S1022 
5'-AAGATCAGGTCAGTTGCGAA-3' and 5'-CACTTCAAGGAGCCAGTGGA-3' 
D12S1056 
5' -CAAA TTCAACCATCATCACT -3' and 5' -GCAGCATTGAACATTT AACA-3' 
STRs were amplified using a standard PCR protocol (Perkin-Elmer 
Thermocycler, Norwalk, CT). PCR mixtures for all markers consisted of 100ng of 
genomic DNA, 70nM of each dNTP, 2.5 J..tl of thermophilic DNA lOx reaction buffer 
(Promega, Madison, WI), 1.51lM of magnesium chloride, 1.0/lM of both forward and 
reverse primers, and 1 unit ofTaq DNA polymerase (Promega, Madison, WI) in a final of 
25111 reaction volume. Thermal cycling parameters for STRs comprised an initial 
denaturation step of 94°C for 10 min, followed by 25 cycles of denaturing at 94°C for 30 
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sec, annealing at the primer-specific temperature (59°C for D12S83, 58°C for D12Sl022, 
and 55°C for D12Sl056) for 30 sec, extension at nOc for 30 seconds, followed by a final 
extension phase at 72°C for 7 min. 
STR amplicons were analyzed using HPLC (WA VE®, Transgenomic, Omaha, 
NE). Two independent observers blinded to disease diagnosis and patient identity 
determined genotypes. 
Statistical Analysis 
Statistical analysis methods for STR data have been described in detail in Chapter 
IV. Case-control and family-based approaches have been used here. Individuals with CD 
proximal to the terminal ileum were excluded case-control analyses owing to their 
relatively low numbers in the study population (L4 group, n=32). 
To account for multiple testing in case-control studies, individual STR genotype 
and allele frequencies were only examined when the global test of homogeneity of all 
groups and the disease versus control pair-wise comparisons achieved statistical 
significance. The global tests of homogeneity for disease versus control pair-wise 
comparisons were corrected by the Bonferroni metlaod, and were considered to be 
statistically significant when P::::0.0125. 
Haplotype analysis was performed using twb methods. Firstly, haplotype 
frequencies were estimated using an expectation m~imization method as described in 
Chapter IV. In addition to this phase unknown approach, haplotype frequencies were 
estimated using transmission disequilibrium test (TDT) analysis (TRANSMIT [105]). 
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This approach has the important advantage of corre~ting for population substructure. 
Haplotype analyses were performed for D12S83 and D12S1056 STR genotype data 
(inter-SNP distance = 350kbp), since previous studies have shown that linkage 
disequilibrium can span several hundred kbp (125). Since D12S1022 was 2.70 Mbp distal 
to D12S83, haplotype analyses were not performed for these markers. 
With regards to family-based testing, CD pedigrees were not analyzed based on 
disease location and all CD family data were pooled. This maximized statistical power by 
allowing for the analysis of the maximum number of CD families. 
Results 
Allele and Genotype Frequencies 
Alleles were named numerically according to molecular weight, with "I" 
representing a larger allele than "2," etc. Larger PCR fragments were eluted from the 
DNAsep cartridge (W A VE®, Transgenomic, Omaha NE) less rapidly than smaller alleles. 
Allele and genotype frequencies for D12S83, D12S1056, and D12S1022 are shown in 
Tables 4 (alleles) and 5 (genotypes). 
Case-Control Association Tests 
Results of global case-control analyses for all STRs are shown in Table 6. The P-
values shown are uncorrected for multiple analyses. 
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Table 4. Allele frequencies for the short tandem repeats (STR) D12S83, D12S1056, and 





STR Ulcerative Indeterminate Disease Disease 
D12S83 Colitis Colitis (Ll) (L2/3) Controls 
Allele N % N % N 0/0 N % N 0/0 
7 78 43% 33 43% 25 35% 57 38% 34 28% 
8 24 13% 7 9% 3 4% 16 11% 21 18% 
9 16 9% 14 18% 12 17% 20 13% 11 9% 
10 17 9% 8 11% 6 8% 14 9% 21 18% 
11 32 18% 11 14% 13 18% 34 23% 20 17% 
Pooled* 15 8% 3 4% 13 18% 9 6% 13 11% 




STR Ulcerative Indeterminate Disease Disease 
D12S1056 Colitis Colitis (Ll) (L2/3) Controls 
Allele N % N 0/0 N % N % N % 
3 54 22% 23 25% 28 32% 38 19% 53 23% 
4 121 50% 39 42% 32 36% 83 42% 95 41% 
5 54 22% 25 27% 23 26% 63 32% 67 29% 
Pooled* 15 6% 5 5% 5 6% 14 7% 15 7% 
--




STR Ulcerative Indeterminate Disease Disease 
D12S1022 Colitis Colitis (Ll) (L2/3) Controls 
Allele N % N 0/0 N % N % N % 
3 29 12% 8 8% 7 7% 30 14% 34 14% 
4 203 81% 85 82% 82 82% 172 79% 176 75% 
Pooled* 18 7% 11 11% 11 11% 16 7% 26 11% 
250 104 100 218 236 
92 
Table 5. Genotype frequencies for the short tandem repeats (STRs) D12S83, D12S1056, 





STR Ulcerative Indeterminate Disease Disease 
D12S83 Colitis Colitis (Ll) (L2/3) Controls 
Genotype N % N 0/0 N 0/0 N % N % 
7,7 17 19% 9 24% 6 17% 15 20% 4 7% 
7,8 7 8% 2 5% 0 0% 2 3% 4 7% 
7,9 8 9% 6 16% 4 11% 8 11% 4 7% 
7,10 9 10% 1 3% 4 11% 3 4% 7 12% 
7,11 14 15% 3 8% 3 8% 11 15% 7 12% 
8,11 5 5% 2 5% 1 3% 2 3% 5 8% 
9,11 4 4% 2 5% 1 3% 7 9% 1 2% 
Pooled* 27 30% 13 34% 17 47% 27 36% 28 47% 
-- --




STR Ulcerative Indeterminate Disease Disease 
D12S1056 Colitis Colitis (Ll) (L2/3) Controls 
Genotype N % N % N % N % N % 
3,3 6 5% 2 4% 6 14% 3 3% 6 5% 
3,4 20 16% 12 26% 11 25% 19 19% 26 23% 
3,5 17 14% 6 13% 5 11% 10 10% 15 13% 
4,4 36 30% 5 11% 6 14% 19 19% 17 15% 
4,5 23 19% 14 30% 5 11% 21 21% 27 23% 
5,5 6 5% 2 4% 6 14% 13 13% 9 8% 
Pooled* 14 11% 5 11% 5 11% 14 14% 15 13% 
--




STR Ulcerative Indeterminate Disease Disease 
D12S1022 Colitis Colitis (Ll) (L2/3) Controls 
Genotype N 0/0 N 0/0 N % N % N 0/0 
2,4 8 6% 10 19% 9 18% 11 10% 10 8% 
3,4 24 19% 6 12% 6 12% 28 26% 17 14% 
4,4 83 66% 34 65% 33 66% 65 60% 72 61% 
Pooled* 10 8% 2 4% 2 4% 5 5% 19 16% 
--
125 52 50 109 118 
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D12S83 Genotype 0.283 
Allele 0.090 
D12S1022 Genotype 0.188 
Allele 0.179 






































Table 6. Case-control association global P-values for disease group versus control 
comparisons for IBD2 STRs. 
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When case-control analyses were performed for IBD2 STRs, the global test of 
homogeneity between all groups showed a statistically difference only for D 12S 1 022 
genotypes (P<O.OOI) and D12S83 alleles (P<O.OOI). 
Following this, global testing of homogeneity between disease and control groups 
indicated difference in D12S1022 genotype frequencies (P=O.OII) between colonic CD 
(L2/L3 groups) and IC when compared to the control population (P=0.024). The global 
test of genotype homogeneity was significant at the Bonferroni-corrected significance 
level ofP:::;0.0125 for the colonic CD versus control comparison. The same cannot be said 
for the IC population, and as a consequence individual allelic associations in this group 
should be approached with caution. Individual pair-wise disease versus control analyses 
showed over-representation of genotype 3,4 in the colonic CD group (colonic CD 
frequency 28 of 109 genotypes [26%] versus control frequency 17 of 118 genotypes 
[14%]; P=0.045). Despite a significant global P value for the IC versus control genotype 
comparison, no single causative genotype could be identified. 
The global test of homogeneity between disease and control groups indicated a 
statistically significant difference in D12S83 allele frequencies between both IC and ileal 
CD (Ll group) when compared to the control population (P=0.027 and P=0.014 
respectively). Following correction for multiple testing using the Bonferroni method, 
with a correct significance level ofP:::;0.0125, neither was significant. Therefore 
individual allelic associations should be approached with some caution. Individual pair-
wise disease versus control analyses showed over-representation of allele 7 in the IC 
group (lC frequency 33 of76 alleles [43%], control frequency 34 of 120 alleles [28%]; 
P=0.032) and under-representation of allele 8 in the ileal CD population (ileal CD 
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frequency 3 ofn alleles [4%] versus control frequency 21 of 120 alleles [18%]; 
P=0.006). 
Family-Based Tests 
Family-based association studies were employed to confirm associations 
identified in case-control analyses. Correction for multiple analyses was not performed. 
Likelihood ratio testing confirmed evidence of allelic association for D12S83 in 13 IC 
families (global X2=14.7 [4 d.f.]; P=0.005). Individual allele distributions among families 
for this marker are shown in Table 7. These showed significant over-transmission of 
D12S83 allele 11 in IC families (P=0.02). 
Significant evidence of association was detected for the STR D12S1056 in 38 UC 
families based on PDT analysis (global sum PDT i=12.8 [5 d.f.]; P=0.030). Individual 
allele distributions among families for this marker are shown in Table 8. Analysis of 
individual alleles indicated that this was caused by over-transmission of allele 4 (P=0.03) 
and under-transmission of allele 3 (P=O.OI). The STR D12S1022 did not identify 
evidence of association as based on family-based testing. 
Haplotype Analysis 
TDT analysis ofD12S10561D12S83 haplotypes revealed evidence of linkage 
disequilibrium between these markers in the IC population. Haplotype frequencies are 
shown in Table 9. An initial global test of homogeneity showed a statistically significant 
difference in haplotype frequency in the IC population (P=O.OOl). Analysis of individual 
haplotype frequencies revealed over-transmission of the haplotype consisting of 
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Allele* Observed Expected 
7 10 11.81 
9 6 4.59 
10 2 2.52 

















Table 7. Transmission disequilibrium test analysis ofD12S83 alleles among 
indeterminate colitis families. * Only those alleles with a frequency ~ 5% are shown. 
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Parental Contribution Discordant Sibs 
Not Z p Allele* Transmitted Transmitted Affected Unaffected 
2 1 1 1 0 0.82 0.41 
3 2 9 7 14 -2.52 0.01 
4 17 10 22 25 2.12 0.03 
5 2 5 6 10 -1.41 0.16 
6 2 1 2 2 0.58 0.56 
7 0 0 0 1 -1.00 0.32 
Table 8. Pedigree disequilibrium test analysis ofD12S1056 alleles among ulcerative 
colitis families. * Only those alleles with a frequency> 5% are shown. 
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Haplotype* Variance 
(D12S1056-D12S83) Observed Expected (O-E) p 
3-7 4.26 4.73 0.96 0.22 0.64 
4-7 2.30 2.55 0.46 0.14 0.70 
5-7 1.94 3.50 0.73 3.33 0.07 
4-9 4.31 2.95 0.70 2.65 0.10 
5-9 2.09 1.57 0.36 0.77 0.38 
3-10 1.05 1.72 0.71 0.63 0.43 
3-11 3.06 1.99 0.30 3.76 0.05 
Table 9. Haplotypes for the short tandem repeat markers D12S1056 and D12S83 in the 
indeterminate colitis population. * Only those haplotypes with a frequency> 5% are 
shown. 
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D12S1056 allele 3 and D12S83 allele 11 (P=0.05). These analyses are uncorrected for 
compounding of type 1 error. 
Discussion 
These data provide evidence of STR association within the IBD2 locus using 
family-based and population-based techniques. IBD2 disease-association was evident 
when using family-based analysis in the UC population. The STR D12S1056 showed 
disease association upon PDT analysis with over-transmission of allele 4 in UC families. 
Under-transmission of allele 3 was evident in the same family cohort. Given the robust 
nature of PDT analysis, this is an especially significant result. 
Evidence of association between CD and IBD2 was less compelling than for UC. 
In case-control analyses, colonic CD (L2 and L3 groups) patients showed significant 
over-representation ofD12S1022 genotype 3,4 compared to controls following correction 
of the global test for multiple analysis. Terminal ileal CD (L1 group) patients showed 
under-representation ofD12S83 allele 8. The latter association appeared of uncertain 
significance, however, following correction of the global test for of allele homogeneity 
multiple analyses, with the global comparison between terminal ileal CD versus controls 
for Dl2S83 alleles only approaching the significance threshold ofP::s0.0125, with 
estimation of the global exact test being P=0.014. It should be noted that the current study 
has low numbers of participants and thus lacks somewhat in statistical power. With 
increased numbers, and consequently increased power, it is not improbable that this 
global test could become significant. 
101 
Neither of these associations between D12S83 and CD subgroups could be 
confIrmed using family-based studies of association, and thus may be due to the 
confounding effects of population substructure. This finding is however in agreement 
with previous studies, including Parkes et al. (123), who found that IBD2 appears to play 
a more significant role in DC susceptibility than in CD susceptibility. 
One possible reason, however, for the lack of correlation between population-
based and family-based testing may be that the CD family cohort has a rather 
heterogeneous nature. Owing to the small numbers of families for each CD subgroup, 
data from CD families were combined. An increased number of first-degree relatives of 
CD-affected individuals will therefore be required to absolutely confirm or refute the 
findings of disease association observed in the case-control association studies presented 
here. Such individuals are currently being actively accrued in order to address this 
problem. 
In contrast to many earlier studies, evidence is presented for association of IBD2 
with IC. Indeed, many groups have chosen to omit this population from genetic studies 
owing to the apparent diagnostic ambiguity that leads to a patient being classified with 
IC. There is strong evidence to suggest that IC should be considered a distinct clinical 
entity (99). IC patients have been shown to suffer from more fulminant disease, as well as 
have a higher incidence of complications following surgery. IC is considered as a 
separate and distinct IBD phenotype in the current study primarily based on clinical 
observations, long-term follow-up (average follow-up, 5.6 years), and the findings of a 
single specialist gastrointestinal pathologist's review. These data provide evidence that 
IBD2 is strongly associated with IC. D12S83 allele 11 is significantly over-transmitted 
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in IC families on likelihood ratio testing. Further strength to this argument is added by 
the finding oflinkage disequilibrium between D12S1056 and D12S83 in the IC 
population based upon TDT analysis. This haplotype that displayed over-transmission 
included D12S83 allele 11, the same allele over-transmitted on likelihood ratio testing. 
Case-control studies partially confirmed this result with over-representation of allele 7 in 
the IC group. As with the case-control test discussed above, the global test of allele 
homogeneity only approached significance when using the Bonferroni method to correct 
for multiple testing (P=O.027). Therefore, the apparent allelic association should be 
viewed cautiously. As before, low study participant numbers does raise the possibility of 
type 2 statistical error, and it may therefore prove advantageous to repeat these analyses 
when further patients have been accrued. 
Agreement between results from case-control studies, TDT, and other family-
based tests in the IC population is important, since associations detected in case-control 
studies could be spurious due to the presence of population substructure. Given these 
data, it appears feasible to speCUlate that IC is genetically more similar to UC than to CD. 
Characterization of further genotype-phenotype relationships will lead to an increased 
understanding of the genetic basis ofIBD. The majority of such relationships thus far 
have been described with the IBDI susceptibility gene NOD2. Here, the presence of any 
of the three well-characterized disease-causing mutations has been shown to increase 
susceptibility to developing fibrostenosing ileocolic CD (31 ;33;35;36). There are 
however very few studies that have aimed to define genotype-phenotype relationships for 
IBD susceptibility loci. The majority of susceptibility loci studies have used patient 
groups that appear to be somewhat heterogeneous, in which variables such as disease 
103 
location and severity have not been adequately accounted for. In addition, few studies 
have considered Ie as a separate IBD phenotype. 
The overall aim of this study has been to improve IBD2 characterization by 
defining genotype-phenotype correlations. This in turn may aid the characterization of the 
IBD2 susceptibility gene(s). There essentially are two approaches to elucidating 
susceptibility genes: positional cloning and candidate gene approaches. Although 
positional cloning is a powerful means of locating a susceptibility gene, it suffers in that 
it is an extremely time consuming process. To date, there are no studies published 
relating to positional cloning attempts to define the IBD2 susceptibility gene. In contrast, 
candidate gene methods are relatively simple, but do suffer from a number of significant 
drawbacks, the most prominent of which is that there may be a large number of 
biologically plausible candidate genes within genomic region displaying a high degree of 
disease linkage (Le. in close proximity to D12S83 in the case ofIBD2). Many plausible 
IBD2 candidates have been identified (124), and genes studied to date include AVIL, 
which codes for the advillin protein and is involved in microvilli morphogenesis (126), 
and ~7 integrin, which is involved in enteric lymphocyte chemotaxis and retention of 
intraepitheliallymphocytes (127). None of these has as yet displayed convincing 
evidence of disease association, and the underlying cause of linkage/association within 
IBD2 remains unknown. 
Future studies of IBD2 in this laboratory will follow a candidate gene approach, 
and will involve characterization of lRAK-M, a gene that is in close proximity to the peak 
region of linkage in IBD2. IRAK-M is a negative regulator of the Toll-like receptor 
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pathway, a key proinflammatory pathway of the innate immune system, and integral in 
the recognition of bacterial products such as lipopolysacceride (58). 
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CHAPTER VII 
PRELIMINARY ASSESSMENT OF INTERLEUKIN-l RECEPTOR 
ASSOCIATED KINASE-M AND MYELOID DIFFERENTIATION FACTOR 88 
AS INFLAMMATORY BOWEL DISEASE CANDIDATE GENES 
Overview 
BACKGROUND: The discovery of IBD susceptibility genes has proven 
extremely difficult, and to date only one such gene, NOD2, has been definitively 
implicated in disease pathogenesis. Definition of further susceptibility genes remains of 
vital importance in understanding the pathophysiological mechanisms underlying IBD 
susceptibility. The aim of this study is to determine whether further assessment of two 
biologically plausible IBD candidate genes, lRAK-M and MyD88, is worthwhile. 
HYPOTHESES: 1) lRAK-M and MyD88 are differentially expressed in IBD-affected 
colonic mucosa. This may be caused by mutation of regulatory elements within each 
gene. 2) lRAK-M and MyD88 contain polymorphisms within coding, regulatory and 
adjacent genetic regions in a sizeable proportion of the study population. METHODS: 
Candidate gene expression was measured from mRNA extracted from IBD-affected and 
disease free colonic mucosal samples using real-time PCR. Following quantification of 
gene expression, candidate gene coding and regulatory regions were screened for 
germline polymorphisms in a representative proportion of the entire study population. 
One-third ofthe screening cohort of96 individuals had Crohn's disease, one-third had 
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ulcerative colitis, and one-third were population controls. PCR amplicons were designed 
to contain candidate gene coding and regulatory regions. Amplicons were then screened 
for polymorphisms using dHPLC. Polymorphic amplicons were sequenced to determine 
the nature of the variation. RESULTS: Both candidate genes were significantly over-
expressed in IBD-affected colonic mucosa when compared to disease-free samples. 
lRAK-M was found to contain four relatively commonly occurring variations. Two 
variations were within coding regions: a missense mutation within exon 5 and a 
synonymous single nucleotide polymorphism (SNP) within exon 12. SNPs were also 
discovered within introns 1 and 2, both of which were in close proximity to exon 2. 
MyD88 contained three polymorphisms, all of which were non-coding. Two were located 
in the regulatory 3'-untranslated region, and one adjacent to exon 3, within intron 3. 
CONCLUSIONS: Both lRAK-M and MyD88 appear to be feasible candidate genes since 
they are differentially expressed in IBD-affected tissue and contain a number of 
commonly occurring polymorphisms. Polymorphisms defined in this study will 
eventually be characterized in the entire study population. The aim of the follow-up study 
will be to assess whether candidate gene polymorphisms identified here are associated 
with disease, and therefore increase susceptibility to IBD development. 
Introduction 
Identification of IBD susceptibility genes remains of paramount importance to 
understanding the mechanism of disease development. Many promising candidates have 
been studied, but only one gene, NOD2, has been conclusively proven to be involved in 
IBD pathogenesis. 
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Cytokine dysregulation is a prominent feature of all forms of IBD, with mucosal 
synthesis of pro-inflammatory cytokines, including interleukin (IL )-l~, IL-6, IL-8, IL-16, 
and tumor necrosis factor-alpha (TNFa) being increased in both UC and CD. Despite of 
our poor understanding of the specific abnormalities leading to this pro inflammatory 
cytokine excess, it is clear that inappropriate activation transcription factor nuclear factor 
KB (NF-KB) is a prominent feature of IBD (48). NF-KB is involved in up-regulation of a 
variety of key regulators of the inflammatory response including pro-inflammatory 
cytokines, chemokines, inflammatory enzymes, adhesion molecules, and receptors. 
Activation ofNF -KB is normally induced by a variety of sources including cytokines and 
pathogens. However, the cause ofNF-KB over-activity in IBD is again, poorly 
comprehended. Inappropriate NF-KB activation is likely a leading cause of the 
characteristic chronic gastrointestinal inflammation in IBD. 
The Toll-like receptor (TLR) pathway is a receptor-mediated signaling cascade 
that is currently subject to a fair amount of scrutiny with respect to inappropriate NF-KB 
activation in IBD. Toll-like receptors are a key component of the innate immune system 
and are involved in initiation of inflammatory responses through recognition of a wide 
variety of pathogens. Two promising IBD candidate genes within this pathway have been 
identified, each of which having already been discussed in great detail. The first is lRAK-
M, a molecule that inhibits signaling through the TLR pathway (58). The hypothesis here 
is that disruption lRAK-M function could lead to uninhibited TLR stimulation in 
response to normal bowel luminal contents. Over a period of time, this would lead to the 
type of chronic inflammation characteristic of IBD. The second candidate is the adaptor 
protein MyD88. MyD88 serves as a link between TLRs and the serine threonine kinases 
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lRAK-l and lRAK-4 (56). Activation of these kinase molecules is required to initiate 
downstream components ofthe signaling pathway leading to NF-KB up-regulation. 
However, MyD88 has also been shown to interact with a number of other death-domain 
containing proteins other than lRAK-I/-4 following macrophage TLR stimulation. An 
example of such a protein is F ADD, an intermediary in an apoptotic signaling cascade 
(71). To resolve inflammation, immune effector cells must be eliminated through 
apoptosis (73), and if this process were to somehow become disrupted (e.g. by mutation 
ofMyD88), immune effector cells would persist and inflammation would continue for an 
abnormal period of time. It is therefore hypothesized that mutation of MyD88 leads to the 
type of chronic inflammation characteristic ofIBD. 
The aim of this study is to gather further evidence to prove that lRAK-M and 
MyD88 are feasible IBD candidate genes. Compelling evidence has already been 
provided, at least for lRAK-M, to show that this gene may be involved in IBD 
pathogenesis. Data outlined in Chapters V and VI has shown that STR markers on 
chromosome 12q 13, the genomic region containing lRAK-M, are associated with 
different forms ofIBD. In this chapter, candidate gene colonic mucosal expression will 
defined in both IBD-affected and normal tissue. Abnormal gene expression may well be 
indicative of mutation of a regulatory region within a candidate gene. Following this, 
candidate gene coding and regulatory regions will be screened using dHPLC. If a 
polymorphism is detected through this screening process, DNA sequencing will be used 
to fully characterize the candidate gene amplicon. This will allow sufficient information 
to be gathered for polymorphism genotyping in the entire population in future studies. 
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Materials and Methods 
Gastrointestinal Mucosal Gene Expression 
Methods for determining candidate gene colonic mucosal expression levels have 
been discussed in detail in Chapter IV. Briefly, colonic mucosal samples were obtained 
from two individuals with UC, two individuals with CD and two individuals with no 
history of IBD or colorectal, with the latter serving as controls. IBD-affected individuals 
in expression studies were not treated with immunosuppressive therapy prior to 
harvesting of mucosal samples. This is especially important given that 
immunosuppression may drastically alter gene expression patterns. mRNA was isolated 
from total RNA extracted from each mucosal sample. This mRNA was then used as a 
template for the cDNA synthesis, which was subsequently used in real-time PCR 
experiments. These experiments were performed in the following manner: 
1) RNA Extraction 
100mg of colonic mucosal tissue from UC, CD and normal mucosa was subjected 
to total RNA extraction following homogenization and cell lysis in guanidine 
isothiocyanate-containing buffer using an affinity column technique (RNeasy® Midi 
purification kit, Qiagen, Valencia, CA). 
2) cDNA Synthesis 
Collected cellular RNAs were then converted to cDNA using Invitrogen 
Superscript® First Strand Synthesis System for real-time RT-PCR (Invitrogen, Carlsbad, 
CA). l~g of total cellular RNA was mixed with poly dT Primer 1~1 (50~M 0Iigo[dT]20) 
and 1 ~l of 10mM dNTP mix, and the total volume adjusted to 1 O~l with DEPC-treated 
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water. Reaction mixtures were then incubated at 65°C for 5 min and subsequently placed 
on ice for 1 min. The following were then added to mixtures: 2111 of lOx RT buffer, 4111 
of25mM MgCh, 2111 ofO.1M DTT, 1 III ofRNaseOVT (40 VII) and 1 III of SuperScript II 
RT (200V/I). Reactions were incubated for 50 min at 50°C. Termination of reactions was 
performed by incubating at 70°C for 15 min followed by chilling on ice. 1 III of RNaseH 
is then added and reactions were incubated for 20 min at 37°C. 
3) Real-Time peR Expression Analysis 
Real-time PCR quantification was performed to compare candidate gene 
expression in diseased and disease-free colonic mucosal samples. 
Primers were designed for the candidate genes MyD88 and lRAK-M using Vector 
NT! software (107), and weighted to the 3' VTR. Primer sequences were as follows: 
MyD88 
5' AGCTGGCTCTGCTGGTCCTTCT3' and 5'TCCTGCATGGAACCAGTGGC3' 
lRAK-M 
5'TGTCCTCTCCATCTCCTCAGTGTG3' and 5 'TTCCTACAACCCGTGCAAGCA3' 
All reactions were performed on an ABI Prism 7700 Sequence Detection System 
(Applied Biosystems, Foster City, CA) using Brilliant® Quantitative PCR Kit 
(Stratagene, La Jolla, CA). p-actin was used as an internal standard (Proligo, La Jolla, 
CA). Primer sequences were as follows: 
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p-Actin 
5' -AA TCAAAGTCCTCGGCCACATTG-3' 
and 5' -AAACTGGAACGGTGAAGGTGACAG-3' 
Each reaction was performed in triplicate and contained 150nM of gene specific 
primers, 1 x mastermix, and 1 III of cDN A (2nM final concentration) in a 25111 reaction. 
Reactions without cDNA were included as negative controls. Reaction conditions were as 
follows: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 20 sec, 1 
min annealing at primer-specific temperatures (IRAK-M 54°C, MyD88 55°C, p-actin 
54°C) and extension nOc for 1 min. Signals were detected at annealing and extension 
phases. 
Cycle threshold (Ct) values were obtained graphically for candidate genes as well 
as for the p-actin internal standard. Standard curves were constructed for all genes before 
calculation of gene-specific mRNA levels. Gene expression was normalized to p-actin. 
For each sample the mean of the three Ct values was calculated. Comparison of gene 
expression between control and disease samples was performed using a standard curve 
method, with gene expression in controls considered as normal. Candidate gene 
expression is given as a fold-change from this "normal" value. 
peR Amplification of Candidate Gene Coding and Regulatory Regions 
PCR primers for lRAK-M and MyD88 coding and regulatory were designed using 
the parameters discussed in Chapter IV. Primer sequences and a number of other 
characteristics of these amplicons are shown in Tables 10 and 11. 
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Table 10. PCR amplicons designed for lRAK-M using VectorNTI software. a Feature too 
large to be analyze as one fragment using dHPLC. b Exons 9 &10 analyzed as one 
amplicon due to their proximity. 
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Position of 
Size Feature PCR GC Feature (bp) within Annealing % Upstream Primer Downstream Primer Amplicon Temp (OC) 
{b~) 
Promoter 537 1-537 67.0 45.3 TGTATGGAGGAGAGGCCGCC CAGCTCACGGAGCCTCCACC 1 a 
Promoter 770 1-663 67.0 62.6 AACGACACTCCCTCTCTACGAA GTCGCAGCTGTCCAGAACAG 2 a 
Exon 1 720 102-234 65.0 62.1 TGCCGTCGTGGAAGCAGGAT CCGCGTTCATTGCAAACCGT 
Exon2 527 165-347 53.0 35.1 CAGAAGGCAGGTGAATATAT AGGGAAGAAAGTGTCACAAG 
Exon3 330 125-189 54.0 34.8 CATGGGAATGAAACTTTAGA ATAATGAGAGAACAAAGGCA 
Exon4 798 315-369 58.0 30.2 TGCATGTCACTGTTAGTTTT GGAAAGTTGATATGGAAGAT 
Exon5 705 101-252 58.0 40.0 CTTCCACTGGACTCTGATTTG CAGCCTCTTCTTCCTGTGCT 
- Exon6 762 242-306 60.0 34.9 GTTAACATGGCGATACACTG TCTCCAAGGACTCTCAGACT 
-..J::>. 
Exon 7 275 101-215 55.0 41.1 GCCTATTCCCCATCCCACCTTAC GCAGCTCTCCCAGGGATTCAAG 
Exon8 392 168-286 55.0 40.8 GAAACCCATCTGGAATTAAA CACATACATACCAGGAGAAC 
Exon 9 b 790 102-300 54.0 35.2 CGAATTAACCAGATATGAAG GGAGGCACTTTCTTATCTAG Exon 10 b 564-626 
Exon 11 420 123-287 62.0 41.2 GAGTAGTGTTAGATGATCCAA TATGTTGGAATTCTCTGTTG 
Exon 548 160-548 56.0 37.6 GGGCGTTAGCTAATCTTTAA GGAGCTTCTGAAGAAGGATC 12.1 a 
Exon 769 1-669 58.0 40.6 GGACAAAAAGCCAGAGAGCA ACAAGCAGGCTAGTCAGGGA 12.2 a 
3'UTR 642 33-468 58.0 39.9 GGGATGAATATGAACAGTACA AGGATAGATCTTGGGAAGAA 
Table 11. PCR amplicons designed for MyD88 using VectorNTI software. a Feature too 
large to be analyze as one fragment using dHPLC. 
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Position of Optimized Feature 
Feature Size within PCR GC Upstream Primer Downstream Primer (bp) Annealing % Amplicon Temp (OC) (bp) 
Promoter 581 1-581 62.0 53.4 GGCTCTAATTCCTCTACCCA GGGACGTCATGACACTAGGT 1 8 
Promoter 811 1-700 63.0 63.7 GGCCATGTCTTCACCTGAGA TCAAGAACAGAGACAGGCGG 2 8 
Exon 1 536 109-436 63.0 67.4 CTTCTCGGAAAGCGAAAGCC GCAGGAAATGGGGTCTCTCC 
Exon2 458 97-257 
....... 
65.0 55.7 CCTTCCAGAAAGCCAGAACA ACTTGCCCAAGGTCTCACAG 
....... 
0"1 
Exon3 506 112-292 68.0 58.5 ATCTTGGGAAGGGTGCAGGG AGACAACCACCACCATCCGG 
Exon4 494 101-192 64.0 55.7 CTGTCCAGCCTGGGCACAGT GTCGCTTCTGATGGGCACCT 
Exon5 405 101-255 64.0 55.1 TAGATGGGGGATGGCTGTTG GCTGCTGCAGACGTGTCTGT 
3'-UTR 836 155-836 64.0 54.6 GTGCCCATCAGAAGCGACTG GAAGGTTGGGCAGAAGCTGG 1 8 
3'-UTR 678 1-678 62.0 51.6 ACTGATGCTTCAGTGCCTCT GGGACACAAGAGAAAAGGAA 2 8 
3'-UTR 816 1-649 62.0 46.3 CTCCCAGGAACAGCTAGGTG GTATTCCTGGTTCTGCCTGC 3 8 
Primers were custom-synthesized (Proligo, La Jolla, CA) and STRs amplified 
from genomic DNA using standard PCR apparatus (Perkin-Elmer Thermocycler, 
Norwalk, CT). PCR mixtures consisted of lOOng genomic DNA, 200nM of each dNTP, 
2.5JlI Thermophilic DNA lOx reaction buffer (Promega, Madison, WI), 1.5JlM 
magnesium chloride, 1.0JlM of both forward and reverse primers, and 2 units Taq DNA 
polymerase (Promega, Madison, WI) in a final 25 JlI reaction volume. A touchdown PCR 
protocol was used to amplify candidate gene features, with thermal cycling parameters 
comprising an initial denaturation step of 95°C for 10 min followed by 2 cycles of 
denaturing at 94°C for 20 sec, annealing at 4°C above the primer-specific annealing 
temperature shown in Tables 10 or 11 for 60 sec and extension at 72°C for 45 sec. This 
was then followed by 2 cycles of denaturing at 94°C for 20 sec, annealing at the primer-
specific temperature + 3.5°C for 60 sec and extension at 72°C for 45 sec. The primer 
annealing temperature was decreased in this manner until the cycle annealing temperature 
equaled the annealing temperature shown in Table 10 or 11. This was followed by 20 
cycles of denaturing at 94°C for 20 sec, annealing at the primer-specific temperature for 
60 sec and extension at 72°C for 45 sec, followed by a final extension phase at 72°C for 5 
min. PCR products were screened for polymorphisms using dHPLC mutation analysis. 
Polymorphism Discovery Protocol 
The screening population consisted of 96 Caucasian individuals. Thirty-two were 
population controls, 32 had UC and 32 had CD. Of the CD popUlation, 18 had colonic 
CD (Vienna classification groups L2/L3). Individuals with colonic CD were included in 
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SNP screening since IBD2 appears to increase susceptibility to developing colonic CD in 
this population. 
Following PCR amplification, 5111 of the total reaction volume was taken from 
each individual sample and combined into 12 groups of 8 pooled samples. dHPLC 
mutation analysis was then performed at amplicon domain-specific heteroduplexing 
temperatures (see Table 12 below for heteroduplexing temperatures of polymorphic 
amplicons). If a polymorphism was evident in one pooled samples, the unpooled samples 
were analyzed individually to determine which reaction contained a polymorphic 
amplicon. Amplicon sequencing was then performed to determine the nature of the 
polymorphism. 
PCR amplification of amplicons found to be polymorphic on dHPLC mutation 
analysis was performed prior to sequencing. PCR mixtures consisted of 150ng genomic 
DNA, O.5mM dNTP mixture, 10111 lOx Cloned Pfu reaction buffer (Stratagene, La Jolla, 
CA), 1.5mM magnesium chloride, 0.5mM of the same forward and reverse primers used 
in screening experiments, and 5 units Cloned Pfu polymerase (Stratagene, La Jolla, CA), 
in a final 100111 reaction volume. Amplification was performed using the same amplicon-
specific PCR protocols as outlined above. Amplicons were subsequently purified using 
the Wizard® PCR Preps DNA Purification System (Promega. Madison, WI). Following 
amplicon purification, their concentration was quantified spectrophotometrically 
(GeneQuant, Pharmacia, Dublin, OH). DNA fragments were sequenced using fluorescent 
cycle sequencing and analyzed on a DNA sequencer (model CEQ2000XL; Beckman-
Coulter, Fullerton, CA). 
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Results 
Gastrointestinal Mucosal Gene Expression 
lRAK-M: Expression of lRAK-M was up regulated in both CD and UC colonic mucosa 
when compared to normal, un-inflamed mucosa from controls. Real-time PCR (RT-PCR) 
amplification illustrated lRAK-M to be expressed an average of 8 times more in both CD 
and UC colonic mucosa as opposed to un-inflamed tissue. This was based on RT-PCR 
analysis of two CD colonic mucosal samples, two UC colonic mucosal samples, and 2 
"control" colonic mucosal samples. 
MyD88: Expression of MyD88 was up regulated in both CD and UC colonic mucosa 
when compared to uninflamed colonic mucosa. Real-time PCR amplification showed 
MyD88 to be expressed an average of 3 times more in CD and 13 times more in UC 
colonic mucosa compared to uninflamed control tissue. These data are based on RT-PCR 
data from two CD colonic mucosal samples, two UC colonic mucosal samples, and 2 
"controls" colonic mucosal samples. 
dHPLC Mutation Analysis 
Apparently polymorphic lRAK-M and MyD88 amplicons using dHPLC mutation 
analysis are shown in Table 12. Also shown here are the temperatures and dHPLC buffer 
gradients at which heteroduplexing was evident, and the total number of amplicons from 
each group displaying polym~rphisms. 
Five candidate gene ainplicons appeared to be polymorphic using dHPLC 
mutation screening. It should be noted however that the MyD88 3' -UTR3 amplicon 
appeared to contain polymorphisms within two different dHPLC domains (i.e. 
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Number of 
dHPLC Gradient Details Polymorphic 
Heteroduplexing Sam~les 
Amplicon Temperature Length 
0/0 0/0 
(OC) 
of Buffer Buffer Con UC CD 
Gradient Bat Bat Start End 
lRAK-M 52.1 2 min 64 68 2 3 5 Exon2 
lRAK-M 53.6 2 min 65 65 2 3 6 Exon5 
lRAK-M 53.2 2 min 64 68 3 6 5 Exon 12.2 
MyD88 62.9 2 min 62 66 5 6 13 Exon3 
MyD883' 
57.2 2 min 62 72 7 8 17 
UTR3 
58.l 2 min 62 72 7 3 14 
Table 12. Polymorphic candidate gene amplicons on dHPLC analysis of the screening 
population. Note that the MyD88 3' -UTR3 amplicon displayed different distributions of 
polymorphisms at two different heteroduplexing temperatures, implying that more than 
one polymorphism may exist within this amplicon. 'Buffer B' - 0.1M triethylammonium 
acetate solution containing 25% acetonitrile. 
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heteroduplexing was observed at two temperatures), with different individuals possessing 
polymorphic chromatograms at these two different temperatures. This is strongly implies 
that this amplicon contains two distinct polymorphisms. Other amplicons did not display 
heteroduplexing on dHPLC analysis and were therefore non-polymorphic. These 
candidate gene regions were therefore excluded from further analysis. 
Sequence Analysis of Polymorphic Amplicons 
Following dHPLC candidate gene polymorphism screening, individual amplicons 
were sequenced to define the nature of polymorphisms. Seven polymorphisms were 
discovered. Sequencing chromatograms, the position of the mutation within the candidate 
gene amplicon and the effect of the polymorphism on the protein sequence (if any) are 
shown in Figures 7 - 11. 
121 
Figure 7. Polymorphisms within the 527bp lRAK-M exon 2 amplicon. 
A: The presence of two roughly equally sized peaks at the same position on the 
sequencing chromatogram denotes the presence of a polymorphism. This sequencing 
chromatogram has two peaks at position 81 bp, one representing an adenosine and one 
representing a thymidine. This means that this individual is heterozygous for an AfT 
polymorphism at this position within the sequenced amplicon. Following sequence 
alignment with Vector NTI software, this was found to correspond to a previously 
described T ---+A polymorphism within intron 1 of lRAK-M (NCBI designation 
rsI185630). The position of this SNP within the 527bp exon 2 amplicon is shown in 
B. The rs 1185630 SNP is 72bp upstream of exon 2. 
B: Diagrammatic representation of the 527bp exon 2 amplicon. The coding region is 
displayed as the orange arrow. 
C: A second polymorphism was discovered in the lRAK-M exon 2 amplicon. This 
individual is heterozygous a CIT polymorphism at position 387bp. This was shown to 
correspond to a previously described C---+T SNP within intron 2 of lRAK-M(NCBI 
designation rs1882200) following sequence alignment. The position ofthis SNP in 
relation to exon 2 is shown in B. The rs 1882200 SNP is 28bp downstream of exon 2. 
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Figure 8. Polymorphism within the 705bp lRAK-M exon 5 amplicon. 
A: A polymorphism was discovered in the exon 5 amplicon. The individual shown is 
heterozygous for AlG polymorphism at position 65bp. Following sequence alignment 
using Vector NT! software, this was shown to correspond to the previously described 
502G--.A SNP within exon 5 of lRAK-M (NCBI designation rsl152888). The position 
of this SNP within exon 5 is shown in B. 
B: Diagrammatic representation of the 705bp exon 5 amplicon. The coding region is 
displayed as the orange arrow. 
C: Diagram ofthe IRAK-M protein. The 502G--.A polymorphism causes a change in 
amino acid sequence ofIRAK-M at position 147 in the amino acid chain. The 
wildtype residue at this position is a valine and the mutant is an isoleucine. This 
mutation therefore has the designation V 1471. 
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Figure 9. Polymorphism within the 769bp amplicon containing the 3' -end of lRAK-M 
exon 12 (exon 12.2). 
A: A polymorphism was discovered in the exon 12.2 amplicon. The individual shown is 
heterozygous for an AfT polymorphism at position 101 bp. Following sequence 
alignment using Vector NT! software, this within exon 12 of lRAK-M. Based on the 
position of the mutation within the lRAK-MmRNA, the polymorphism is given the 
designation 1752T ~A. The 1752T ~A SNP does not correspond to any previously 
described polymorphism and consequently has no NCBI designation. The position of 
the polymorphism within exon 12 is shown in B. 
B: Diagrammatic representation ofthe 769bp exon 12.2 amplicon. The coding region is 
displayed as the orange arrow. 
C: The 1752T ~A polymorphism is a non-coding synonymous change and does not alter 
the amino acid sequence ofIRAK-M. Both the wildtype T allele and the mutant A 
allele code for a proline at position 563 within IRAK-M. This mutation is therefore 
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Figure 10. Polymorphism within the 705bp MyD88 exon 3 amplicon. 
A: A polymorphism was discovered in the exon 3 amplicon. The individual shown is 
heterozygous for C/G polymorphism at position 358bp. Following sequence 
alignment using Vector NT! software, this was shown to correspond to a previously 
described C-G SNP within intron 3 of MyD88 (NCB I designation rs4988457). The 
position of this SNP in relation to exon 3 is shown in B. The rs4988457 SNP is 76bp 
downstream of exon 3. 
B: Diagrammatic representation of the 705bp exon 3 amplicon. The coding region is 
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Figure 11. Polymorphisms within the 816bp amplicon containing the 3' -end of the 3'-
untranslated region of MyD88 (3'-UTR3). 
A: A polymorphism was discovered in the 3' end of the 3' -UTR. The individual shown 
here is heterozygous an AlG polymorphism at position 122bp. Following sequence 
alignment, this was shown to correspond to a previously described A--+G SNP within 
the 3'-UTR of MyD88 (NCBI designation rs7744). The position of this SNP within 
the 3'-UTR is shown in B. 
B: Diagrammatic representation of the 816bp amplicon containing the 3'-end of the 3'-
UTR. The untranslated region is displayed as the green arrow. 
C: A second polymorphism was discovered in the 3' end ofthe 3'-UTR. The individual 
shown here is heterozygous an AlG polymorphisms at position 587bp. Following 
sequence alignment, this was shown to correspond to a previously described A--+G 
SNP within the 3' -UTR of MyD88 (NCBI designation rs6853). The position of this 
SNP within the 3' -UTR is shown in B. 
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Discussion 
Differential candidate gene expression has been identified in CD and UC colonic 
mucosal samples, with both lRAK-M and MyD88 being significantly over-expressed in 
disease-affected colonic mucosal samples when compared to disease-free colonic 
mucosal samples. The magnitude of increased expression was significant in all IBD-
affected tissues. For MyD88 this ranged from a three-fold increase in expression in CD-
affected colonic mucosa to thirteen times greater expression in UC-affected colonic 
mucosa. lRAK-M was over-expressed eight-fold in both CD- and UC affected colonic 
mucosa. The magnitude of this over-expression implies a significant degree of 
dysregulation of both candidate genes in IBD-affected colonic mucosa. There are likely 
two causes of this: an intrinsic genetic abnormality that leads to increased candidate 
expression (i.e. mutation of regulatory elements); or over-expression is a secondary 
phenomenon caused by dysregulation of another proinflammatory system. Obviously, at 
this stage there is insufficient evidence to implicate either as the cause of the candidate 
gene dysregulation in IBD. This question will be addressed through a process of 
elimination i.e. by screening genetic regions involved in regulation of candidate gene 
expression and characterizing polymorphisms within such regions. 
Screening candidate gene amplicons for polymorphisms using dHPLC mutation 
analysis has proven an extremely powerful tool with seven SNPs being discovered using 
this methodology. All the polymorphisms discovered had a relatively high heterozygote 
frequency (i.e. heteroduplexing seen on chromatogram) in this small screening sample. 
Heterozygote frequency ranged from 10% (10/96 lRAK-M exon 2 samples showed 
heteroduplex formation, see Table 12) to 33% (32/96 MyD88 3'-UTR3 samples). 
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Therefore, all polymorphisms, at least at this stage of the study, appear to be relatively 
common. 
The use of this screening protocol does raise a number of important criticisms. 
Firstly, rare polymorphisms may be overlooked when using a small screening population 
(i.e. 96 patients). Secondly, the composition of the screening population may well affect 
the outcome of screening, espe¢ially if a candidate gene polymorphism were to be 
involved in susceptibility to a ~ery distinct phenotype. The first criticism is addressed 
when one considers the total study population. The screening population of 96 patients is 
derived from a total population of approximately 1000 subjects. The cohort used for 
dHPLC mutation screening therefore represents around 10% of the entire population. If a 
polymorphism was discovered, for example, in fewer than five individuals in the 
screening cohort, it is probable that the mutant allele frequency in the entire popUlation 
would be extremely low. A murtant allele with such a low frequency is highly unlikely to 
have any major impact on disease susceptibility (at least in a cohort of 1000 patients) and 
further characterization of such a polymorphism would likely prove worthless. Attempts 
have been made to address the second criticism by including individuals with disease-
associated IBD2 STR alleles in the screening population (see Chapter VI). The remainder 
of the screening population is made up of individuals with a broad array of different IBD 
manifestations. In this manner endeavors have been made to screen a population that is 
both tailored towards previous findings in this cohort, as well as being representative of 
the IBD population as a whole. In summary, dHPLC mutation analysis has proven to be 
an accurate and efficient means of detecting polymorphisms, and has significant 
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advantages over more cumbersome and costly techniques such as screening by 
sequencing. 
A total of seven candidate gene polymorphisms were characterized using 
sequence analysis, four within lRAK-M and three within MyD88. Of the four 
polymorphisms in lRAK-M, two were within coding regions, one within exon 5 and one 
within exon 12. The 1752T ~A polymorphism within exon 12 is a synonymous change 
and does not alter the amino acid sequence of the IRAK-M protein. Both the wildtype T 
allele and mutant A alleles code for a proline at position 563 within IRAK-M. Further 
consideration will therefore not be given to the P563P mutation since the 1752T ~A 
polymorphism within lRAK-M exon 12 will have no effect on the functionality of the 
encoded IRAK -M protein. 
In contrast, the 502G~A polymorphism within exon 5 (rsI152888) does cause a 
change in the IRAK -M protein, with the mutant A allele coding for an isoleucine instead 
ofa valine at position 147. The structures ofthese two amino acids are shown in Figure 
12. The position of the V147I mutation within IRAK-M is shown in Figure 8C. This 
mutation lies in the region connecting the kinase domain and the protein-protein 
interaction death-domain of IRAK -M. When the position of this is considered together 
with the nature of the mutation (i.e. hydrophobic valine ~ hydrophobic isoleucine), the 
likely functional effects of the change in amino acid sequence caused by the 502G~A 
SNP are likely minimal. However, IRAK-M is a protein that exists within the cytosol of 
macrophages and is therefore likely to be water-soluble. Hydrophobic amino acids in 
regions connecting the two functional motifs, such as the residue found at position 147, 











Wildtype IRAK-M Mutant IRAK-M 
Figure 12. Molecular structure of valine and isoleucine. A valine residue is found at 
position 147 of the wildtype IRAK-M and an isoleucine is found in the same position in 
mutant IRAK-M. Both valine and isoleucine are classed as hydrophobic amino acids. 
135 
residues exposed to the water-rich cytosol. A mutation at such a position could alter the 
shape of the protein and thus modify its functionality. As illustrated in Figure 12, 
isoleucine contains more methyl side chains than valine. The increased 'bulkiness' of 
isoleucine in mutant IRAK-M may therefore alter the conformation of the protein. This in 
turn may affect its interaction with other signaling molecules, its ability to be activated 
and so on. Whether this mutation appears to predispose individuals to developing IBD 
will be assessed in Chapter VIII. 
The two SNPs identified within the 3'-UTR of MyD88 (rs7744 and rs6853) also 
appear to be of great interest. The 3' -UTR is an integral component of an mRNA, and is 
heavily involved in regulation of gene expression. These regulatory functions appear to 
be both diverse and numerous, and include control of nuclear export, polyadenylation 
status, subcellular targeting, and rates of translation and degradation ofmRNA (128). It is 
very possible that mutation of a 3' -UTR may affects on gene expression. Indeed, a 
number of human diseases have been linked to disruption of 3 ' -UTR mediated events. An 
example of such a disease is myotonic dystrophy, an autosomal-dominant multi-system 
disorder that has an incidence of about 1 :8500. This disease is caused by an expanded 
number oftrinucleotide (CTG) repeats in the 3'-UTR ofa cAMP-dependent protein 
kinase gene (128). Other examples of "3'-UTR-mediated diseases" include Cl-
thalassemia, Fukuyama-type congenital muscular dystrophy, and possibly acute 
myelogenous leukemia (128). The mutations within the 3' -UTR of MyD88 may also 
influence disease pathogenesis by altering gene expression. Differential expression of 
MyD88 has been identified in IBD-affected colonic mucosa. Therefore, the distribution of 
mutant rs7744 and rs6853 SNP alleles in the entire study cohort will be of great interest. 
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Three intronic mutations were also discovered. Two were within lRAK-M: one 
was 72bp upstream of exon 2 in intron 1 (rsl185630), and the other was 28bp 
downstream of exon 2 in intron 2 (rs 1882200). The final SNP (rs4988457) was in intron 
3 of MyD88, being located 76bp downstream of exon 3. Although intronic SNPs do not 
appear to be as 'exciting' as coding SNPs at first glance, there is growing evidence to 
suggest that like the 3' -UTR, introns play an important role in the regulating gene 
expression (129;130). lntrons, and the act of their removal by the spliceosome, can 
influence many stages of the mRNA metabolism, including initial rates of gene 
transcription, pre-mRNA editing and polyadenylation, and nuclear export, translation and 
decay of the mRNA (130). These functions are dependant on the nucleotide sequence of 
the intron, and mutation of intronic sequences could alter gene expression, which in turn 
may lead to disease susceptibility. It is therefore possible that the three candidate gene 
polymorphisms residing within introns may be involved in IBD susceptibility. 
In summary, initial assessment of lRAK-M and MyD8'8 show that they both 
appear to be reasonable IBD susceptibility gene candidates . .Both are over-expressed in 
IBD-affected colonic mucosa. Furthermore, both genes contain commonly occurring 
mutations within coding regions or gene elements that could be involved in regulation of 
expression. The next phase of this study will be to characterize candidate gene 
polymorphisms in the entire study population. The aim here will be to define SNP 
associations in specific IBD sub-phenotypes. Six of the seven discovered SNPs will be 
characterized. The seventh SNP, lRAK-M 1752T -A will not be characterized. As 
mentioned previously, this polymorphism is a synonymous c~ange within lRAK-M exon 
12, and consequently will have no effect on lRAK-M function. 
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CHAPTER VIII 
IS THERE A ROLE FOR lRAK-M AND MYD88 IN SUSCEPTIBILITY TO 
INFLAMMATORY BOWEL DISEASE? 
Overview 
BACKGROUND: Six SNPs have been identified within the two candidate genes 
using dHPLC mutation analysis and sequencing. Three ofthese lie within the gene 
encoding the anti-inflammatory inhibitor ofTLR pathway signaling, IRAK-M, and three 
lie within the gene encoding MyD88, an adaptor protein shown to be an intermediary in a 
macrophage apoptotic pathway and therefore presumably involved in limitation of 
inflammatory responses. HYPOTHESIS: Mutation(s) of the genes encoding IRAK-M 
and MyD88 cause abnormal functioning of their respective gene products, which in turn, 
leads to the type of chronic inflammation characteristic of IBD. METHODS: The study 
population consisted of 422 Caucasian IBD patients, 101 popUlation controls with no 
history ofIBD or colorectal cancer and 275 first-degree relatives ofIBD patients. The six 
candidate gene polymorphisms were genotyped using SNP-specific PCR. Mutant allele 
frequencies were examined initially in unstratified IBD populations, and then in groups 
stratified on the basis of disease characteristics. Population- and family-based methods 
were used to analyze candidate gene SNP data. RESULTS: Preliminary evidence is 
provided to suggest that MyD88 may be involved in susceptibility to late onset CD in 
patients with a family history of IBD. The frequency of the 3' -UTR rs7744 mutant allele 
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was significantly higher in late onset CD than in both early onset CD (mutant allele 
frequencies 30% and 15% respectively; P=0.005) and controls (mutant allele frequency: 
13%; P=0.003). Furthermore, the 3' -UTR rs6853 SNP was significantly more frequent in 
CD patients with a family history of IBD than in CD patients with no family history of 
IBD (mutant allele frequency: 15% vs. 7%; P=0.015). Both results were significant 
following correction for multiple analyses. In contrast to MyD88 SNPs, no evidence of 
lRAK-M SNP association was found in this IBD population. CONCLUSIONS: These 
results provide preliminary evidence to suggest that MyD88 may be involved in 
susceptibility to late onset CD in patients with a family history ofIBD. This finding is 
however viewed with some caution given the relatively small IBD population size and 
the lack of corroboration of the positive findings from population-based methods by 
additional statistical methodology. IRAK-M however plays no role in IBD susceptibility 
in this population 
Introduction 
The rationale for further study of the two IBD candidate genes has been discussed 
in depth in the previous chapter. Both lRAK-M and MyD88 contain commonly occurring 
mutations within coding regions and/or gene elements with potential regulatory effects. 
Furthermore, each candidate is over-expressed in IBD-affected colonic mucosa. For these 
reasons, lRAK-M and MyD88 are believed to be reasonable IBD susceptibility gene 
candidates. The polymorphisms identified in the previous chapter therefore require 
characterization in the entire study population. 
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The aim of this study is to determine whether the candidate gene SNPs identified 
in Chapter VII are associated with IBD. This will be assessed by performing population-
and family-basedi testing in well-defined phenotypic groups. Phenotypic characteristics 
studied will include age of disease onset, presence or absence of extra-intestinal disease 
manifestations and family history of IBD. Furthermore, the CD population will be 
subdivided both on the basis of the Vienna Classification (98), as well on a number of 
other disease behavior characteristics (presence of perianal disease, fistulae not involving 
the perianal region and fibrostenosing behavior patterns). The importance of analysis at 
the sub-phenotype level has been proven by studies of the IBD susceptibility gene NOD2, 
where the degree of association is much stronger in CD subgroups than in the entire CD 
population (31 ;35;36). Increasing subgroup clinical homogeneity therefore seems to 
increase the strength of association, at least in the instance of NOD2. It is for this reason 
that candidate gene SNPs will only be characterized in Caucasians, given that this ethnic 
group comprises over 95% of the entire IBD population. 
Candidate gene SNPs will be genotyped in individuals with IBD, as well as in 
population and family controls. The frequency of mutant SNP alleles will then be 
compared between disease and control populations (or between disease populations in the 
instance of the sub-phenotypic groups). A positive outcome would be a significantly 
increased frequency of one or more mutant SNP alleles in disease-affected populations 
when compared to controls. This would mean that the SNP is associated with IBD and 
the candidate gene is likely involved in IBD susceptibility. 
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Materials and Methods 
Patients and Families 
The University of Louisville Institutional Review Board approved this study. 
Written informed consent was obtained from all subjects. Patients were derived from the 
same population as described in previous chapters. The population-based association 
study cohort consisted of a total of 523 Caucasian individuals, including 208 unrelated 
individuals with CD (61% women), 159 with UC (53% women), 55 with IC (68% 
women), and 101 population controls (65% women). Demographic data for this 
population are shown in Table 13. For the purposes of more accurate phenotyping, the 
CD population was subdivided based on the Vienna classification (98). The CD 
population was also divided in an alternative manner, in order to include the following as 
distinct phenotypes: perianal fistulae, fistulae not involving the perianal region and 
gastrointestinal obstruction with or without the presence of fistulae. CD phenotype data 
are shown in Table 14. 
Two hundred seventy-five non-affected first-degree relatives of Caucasian IBD 
patients were available for this study. There were 64 CD families (28 triads, 30 
discordant sibling pairs [DSPsD, 6 triadIDSP combinations), 38 UC families (8 triads, 22 
DSPs, 8 triadlDSP combinations), and 14 IC families (4 triads, 6 DSPs, 4 triadIDSP 
combinations). In addition, there were 16 CD families, 14 UC families, and 9 IC families 
who could not be classified as either a triad or DSP. The UC and CD family cohorts 
were subdivided on the basis of the same proband phenotypic characteristics, as 
described above. Subgroup analysis was not performed in the IC family cohort owing to 
the low frequency of these families in the study (n=14). 
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Crohn's Disease Ulcerative Indeterminate 
n=208 Colitis n=159 Colitis n=55 
Average Length of Clinical 
4.6 (0-16) 4.3 (0-14) 5.6 (0-12) 
Follow-Up (Range) (yrs) 
Age of IBD Onset (Range) 
29.2 (6-81) 
(yrs) 
34.4 (10-75) 29.7 (12-64) 
Surgical Treatment for IBD 
75% 67% 82% 
Complications 
First-Degree Relative with 
36% 20% 22% 
IBD 
Extra-intestinal 
43% 36% 49% 
Manifestations a 
Table 13. Demographic data for IBD patients in the candidate gene study. 
a Extra-intestinal manifestations are defined as IBD-related disease outside the 
gastrointestinal tract involving joints, eyes, hepatobiliary system or the skin. 
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Age of Diagnosis 
< 40 years (AI) 
> 40 years (A2) 
Unknown 
Disease Behavior 
Non-stricturing, non-penetrating (B 1) 
Stricturing without penetration (B2) 
Penetrating (B3) 
Disease Location 
Terminal ileum (Ll) 
Colon (L2) 
Ileocolon (L3) 
Upper gastrointestinal tract (L4) 
Unknown 
Alternative Classification of Disease Characteristics 
Perianal disease 
































Table 14. Disease characteristics of the CD population used in candidate gene studies. 
Patients are subdivided using the Vienna Classification (98), as well as a number of other 
CD characteristics. 
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The initial diagnosis of IBD was determined through conventional radiological, 
endoscopic, and/or histopathologic findings. Histology was available in all cases. 
Following the initial diagnosis, a single gastrointestinal pathologist with a particular 
interest in IBD reviewed all histology. Previous studies have shown that interobserver 
variation in histological diagnosis can be a significant confounding variable (97). If there 
was disagreement between the initial diagnosis and that of the specialist pathologist, the 
latter diagnosis was used for purposes of this study. The approach used here is likely to 
maximize diagnostic consistency, thus increasing the clinical homogeneity ofIBD 
subgroups. 
Characterization of Candidate Gene Polymorphisms 
lRAK-M and MyD88 SNP-specific PCR primers and fluorogenic probes were 
designed as per the specifications given in Chapter IV. The sequences of primers and 
probes are shown in Table 15. Reaction mixtures consisted of300nM of each 
oligonucleotide primer, 100nM fluorogenic probes, 50ng template DNA, and 2x TaqMan 
Universal PCR Master Mix (Applied Biosystems, Foster City, CA) in a total volume of 
111ll. The amplification reactions were performed on a Perkin-Elmer Thermocycler 
(Norwalk, CT) with two initial hold steps (50°C for 2 min, followed by 95°C for 10 min) 
and 40 cycles ofa two-step PCR (92°C for 15 sec, 60°C for 1 min). The fluorescence 
intensity of each sample was measured post-PCR in an ABI Prism 7900HT sequence 
detection system (Applied Biosystems, Foster City, CA), and candidate gene SNP 
genotypes were determined by the fluorescence ratio of the nucleotide-specific 
fluorogenic probes. 
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SNP Oligonucleotide Oligonucleotide Sequence 
lRAK-M 
Forward Primer 5'-ACATTAGCAGAAGGCAGGTGAATAT-3' 
Intron 1 Reverse Primer 5'-TCTCTGCTGTGGAAA TTGCAA-3' 
T~A Wildtype Probe FAM-AATAAAACATTAGGTACACAAA 
rs1185630 
Mutant Probe VIC-AATAAAACATAAGGTACACAAA 
lRAK-M Forward Primer 5'-TCGAGCTATTCATTTAATTACAAACTATGGT3' 
Intron 2 Reverse Primer 5'-AA TGTCTTGGATAAAATGCAA TATTCG-3' 
C~T Wildtype Probe F AM-CAGATT AAGAGCCACATTA 
rs1882200 
Mutant Probe VIC-TTACAGATT AAAAGCCACATTA 
lRAK-M Forward Primer 
5'-GGTTATAATGGTGATGTTCCTTCTTAGC-3' 
Exon5 Reverse Primer 5'-TCTCTCCTTCTCCAATTAGGAAGTCT -3' 
502G~A Wildtype Probe VIC-CCTTCCT AAGGAGTACTGCT 
rs1152888 
Mutant Probe F AM-CCTTCCTAAGGAATACTGCTT 
MyD88 Forward Primer 5'-CATCGAAAAGAGGTTGGCTAGAA-3' 
Intron 3 Reverse Primer 5'-TTCAGGAAGGGCCCACTGT -3' 
C~G Wildtype Probe F AM-CATCTCCTCCTAGCTGT 
rs4988457 
Mutant Probe VIC-CATCTCCTGCTAGCTG 
MyD88 
Forward Primer 5'-CTGGAAAGGACCCAA TGTACCA-3' 
3'-UTR Reverse Primer 5'-TGTTGTGTGAGTTT AAGCAGCTCTCT -3' 
A~G Wildtype Probe FAM-TTTATACCTCTAATGAAGCACAG 
rs7744 
Mutant Probe VIC-TACCTCTAGTGAAGCACA 
MyD88 
Forward Primer 5'-GCACCTGTCCCCCTTT AA TACTG-3' 
3'-UTR Reverse Primer 5'-TTGAAA TTATTTTAATGCGTACAAAACATG-3' 
A~G Wildtype Probe FAM-CATCTCAAGAGGCATC 
rs6853 
Mutant Probe VIC-CCATCTCGAGAGGCA 
Table 15. Primers and fluorescently labeled oligonucleotide probes used in candidate 
gene SNP-specific PCR genotyping experiments. The position of the SNP within each 
probe is marked in red. F AM: 5-(&6)-carboxyfluorescein. VIC®: a proprietary 
fluorescent dye produced by Applied Biosystems (Foster City, CA). 
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Statistical Analysis 
Statistical analysis of candidate gene SNP data has been discussed at length in 
Chapter IV. Briefly, SNP data will be analyzed in two manners. First, candidate gene 
polymorphism frequency data will be analyzed in order to attempt to define associations 
between SNP alleles and IBD. The primary approach will be to perform case-control 
analyses to examine allele frequencies in CD, UC, IC, and in the IBD population when 
considered as a whole. Case-control will be augmented by estimation of candidate gene 
haplotype frequencies and family-based approaches. Correction for compounding of type 
I error will be performed using the Bonferoni method. 
Following case-control analyses, attempts will be made to define genotype-
phenotype correlations for candidate gene SNPs. This may be a powerful means of 
detecting association given the relatively small size of the study cohort. That is, 
stratifying the patient population into more clinically homogenous sub-groups may 
increase the degree of SNP association. Again, population-based, haplotype and family-
based tests to study candidate gene genotype-phenotype correlations will be used. 
Correction for multiple analyses will be performed in a similar manner as described 
above. 
Results 
Candidate gene SNP genotype and allele frequencies and P-values for comparison 
of allele frequencies using case-control methods are shown in Table 16. The overall 
frequency of each candidate gene mutant SNP allele varied widely in the study 
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population, with the lRAK-Mintron 2 rs1882200 mutant allele being most common (28% 
IBD patients, 26% controls) and the MyD88 intron 3 rs4988457 mutant allele being least 
common (6% IBD patients, 7% controls). Population-based approaches were initially to 
compare candidate gene mutant allele disease frequencies between the IBD, UC, CD, and 
IC groups and the control population. As shown in Table 16, no associations were evident 
between disease populations and controls for the six candidate gene SNPs using 
population-based methods. 
Following SNP analysis using population-based approaches, haplotype and 
family-based analyses were performed in IBD, UC, CD, and IC groups. Haplotype 
frequencies were estimated from SNP allele data using an expectation maximization 
method (see Chapter IV for a detailed description of these methods). These analyses did 
not yield any evidence of SNP association. Similarly, family-based approaches (PDT and 
likelihood ratio testing) did not reveal any evidence of association. 
Analysis of Genotype-Phenotype Relationships 
Population-Based Association Tests: Frequencies of candidate gene mutant alleles were 
calculated for the disease characteristics listed in Tables 13 and 14 in CD and UC 
populations. This was not performed in the IC population owing the low numbers of 
individuals in this population (n=55). Population-based analyses at the sub-phenotype 
level using a cohort of this size would be meaningless. Mutant allele frequencies for the 
lRAK-M and MyD88 sub-phenotypes described in Table 13 are shown in Tables 17 and 
18 respectively. 
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Table 16. lRAK-M and MyD88 genotype and allele frequencies for patients and controls. 
-/- Homozygous wildtype; +/- Heterozygous; +/+ Homozygous mutant 
a P-value for comparison of allele frequencies between controls and patients. 
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Genotype Mutant 
SNP Cohort Allele pI 
-/- +/- +/+ Fre9.uenc~ 
IBD 334 55 5 8% 0.164 
lRAK-MExon 5 CD 166 28 1 8% 0.168 
rs1152888 UC 120 19 1 8% 0.181 
IC 48 8 3 12% 0.934 
Control 81 15 4 12% 
IBD 227 65 2 12% 0.257 
lRAK-MIntron 1 CD 109 26 1 10% 0.262 
rs1185630 UC 81 31 1 15% 0.909 
IC 37 8 0 9% 0.239 
Control 57 16 3 14% 
IBD 170 145 23 28% 0.692 
lRAK-MIntron 2 
CD 87 65 11 27% 0.987 
rs1882200 UC 61 55 10 30% 0.519 
IC 22 25 2 30% 0.667 
Control 38 39 1 26% 
IBD 285 36 1 6% 0.575 
MyD88 Intron 3 
CD 139 15 1 5% 0.617 
UC 105 15 0 6% 0.888 
rs4988457 
IC 41 6 0 6% 0.977 
Control 67 9 1 7% 
IBD 221 104 5 17% 0.410 
MyD88 3' -UTR 
CD 99 52 4 19% 0.225 
UC 85 42 1 17% 0.534 
rs7744 
IC 37 10 0 11% 0.508 
Control 58 21 1 14% 
IBD 250 61 4 11% 0.370 
MyD883'-UTR 
CD 122 28 1 10% 0.651 
UC 90 28 2 13% 0.158 
rs6853 
IC 38 5 1 8% 0.827 
Control 63 10 1 8% 
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Allele frequencies were compared using Fishers Exact test. One significant 
difference was evident for MyD88: the frequency of the 3'-UTRrs6853 A~G mutant 
allele was significantly more common in individuals with a family history of IBD when 
compared to those with no history ofIBD (221144 alleles [15%] vs. 181246 alleles [7%] 
respectively; P=0.015). This was significant following at the Bonferroni-corrected 
significance level ofP:sO.0167. This significance level was used since three comparisons 
are made to test the null hypothesis "there is no difference in MyD88 SNP mutant allele 
frequency when considering presence or absence of family history of IBD in CD" (i.e. 3 
SNPs, 2 comparison groups, 1 disease group, :.P=0.05/3). The rs6853 mutant allele 
frequency did not differ when comparing the family history positive CD group to the 
control popUlation (rs6853 frequency in CD with family history ofIBD: 22/144 vs. 
control frequency: 141168; P=0.07). This result should therefore be viewed with some 
caution. In contrast, none of the lRAK-M mutant SNP alleles appeared to be associated 
with any of the phenotypic variables outlined in Table 13. 
Following this, the additional CD phenotypic characteristics described in Table 14 
were considered. Mutant allele frequencies were calculated for each sub-phenotype 
(allele frequencies not shown) and comparisons were made in the same pair-wise fashion 
as described above. The MyD88 3'-UTR A~G SNP (rs7744) mutant allele was 
significantly more frequent in the A2 Vienna group (age of disease onset ;::40 yr) than in 
the Al group (age of onset <40 years) group (21170 alleles [30%] vs. 37/250 alleles 
[15%] respectively; P=0.005). This was significant at the Bonferroni-corrected level of 
P:S0.0167. Furthermore, the rs7744 mutant allele in the late onset CD group was also 
significantly more frequent than in the control population (rs7744 frequency in late onset 
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Table 17. lRAK-M mutant allele frequencies for CD and UC populations at the sub-
phenotype level. Comparisons of mutant allele frequencies were performed between 
different subgroups of the same phenotypic variable (i.e. CD patients with a family 
history oflBD vs. CD patients with no family history of IBD) using Fishers Exact test. 
Allele frequency is given as: "mutant allele frequency / total number of alleles". None of 
these comparisons were statistically significant. 
a Early age of onset in this instance was defined as ~ 20 years for CD and ~ 40 for UC. 
The frequency ofUC with onset ~ 20 years was low (13% of total UC population) and 
comparisons would have been meaningless. Comparisons for CD with onset ~ 40 years 







Intron 1 Intron 2 
rs1185630 rs1882200 
N % N 0/0 
First Degree Relative With IBD 
Yes 15/138 11% 37/146 25% 
No 26/224 12% 821262 31% 
Presence of Extra-intestinal Manifestations 
Yes 19 
No 22/202 


















Exon5 Intron 1 
rs1152888 rs1185630 
N % N % 
111206 5% 8/62 13% 
20/260 8% 361224 16% 
14 8% 15/104 14% 










































Table 18. MyD88 mutant allele frequencies for CD and DC populations at the sub-
phenotype level. Comparisons of mutant allele frequencies were performed between 
different subgroups ofthe same phenotypic variable (i.e. CD patients with a family 
history ofIBD vs. CD patients with no family history ofIBD) for the same disease group 
using Fishers Exact test. Allele frequency is given as: "mutant allele frequency / total 
number of alleles". Statistically significant differences in mutant allele frequencies are 
highlighted in red. 
a Early age of onset in this instance was defined as :s 20 years for CD and :s 40 for DC. 
The frequency of DC with onset:s 20 years was low (13% of total DC population) and 
comparisons would have been meaningless. Comparisons for CD with onset :s 40 years 
are described below (see Vienna Classification). 
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Crohn's Disease Ulcerative Colitis 
MyD88 MyD88 MyD88 MyD88 MyD88 MyD88 
Intron 3 3'-UTR 3'-UTR Intron 3 3'-UTR 3'-UTR 
rs4988457 rs7744 rs6853 rs4988457 rs7744 rs6853 
N 0/0 N 0/ 0 N 0/ 0 N % N 0/ 0 N 0/ 0 
First Degree Relative With IBD 
Yes 1111 44 8% 311144 22% 22/144 15% 1/60 2% 10/62 16% 6/60 10% 
No 13/250 5% 441252 17% 18/246 7% 16/2 18 7% 38/240 16% 33/238 14% 
V> 
..,. 
Presence of Extra-intestinal Manifestations 
Yes 10/1 70 6% 311168 18% 2011 70 12% 9/1 10 8% 22/110 20% 16/106 15% 
No 141224 6% 40/228 18% 20/220 9% 8/168 5% 26/192 14% 23/1 88 12% 
Age of Disease Onset · 
Early 911 00 9% 14/96 15% 1511 00 15% 811 42 6% 2711 48 18% 1611 44 11 % 
Late 111228 5% 44/224 20% 191216 9% 6/62 10% 11164 17% 10/64 16% 
CD 21170 [30%] vs. control frequency 241180 [13%]; P=0.003). In contrast, none of the 
lRAK-M mutant alleles appeared to be associated with any of the phenotypic variables 
outlined in Table 14. 
Estimation of Haplotype Frequencies: Haplotype frequencies were estimated using the 
expectation maximization method as described previously, and were considered for all 
the phenotypic variables listed in Tables 13 and 14. Estimated haplotype frequencies 
were compared in a similar manner as in the population-based tests described above. 
None of the haplotype frequency comparisons were significant for lRAK-M. However, 
one MyD88 haplotype appeared to have a significantly different distribution between CD 
patients subdivided on the basis of age of onset (Vienna Classification groups Al and 
A2). Estimated haplotype frequencies for the early onset (group AI) and late onset CD 
(group A2) are shown in Table 19. The global test of the null hypothesis for the 
comparison between the two age of CD onset groups was rejected (P=0.049), suggesting 
that one or more of the haplotypes have different frequencies in the two groups. Four 
individual tests were performed to identify haplotypes with different frequencies between 
the two groups (see Table 19). These showed that the haplotype consisting of the mutant 
rs7744 (3' -UTR) allele and wildtype rs4988457 (intron 3) and rs6853 (3' -UTR) alleles 
was significantly more common in the late onset (A2) group than in the early onset (AI) 
CD group (frequency 0.28 vs. 0.14; P=0.025). However, following application of the 
Bonferroni correction for 4 individual tests (i.e. adjusted significance level P=0.0125), 
this result was not significant. Type 1 error therefore cannot be excluded in this instance. 
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Early Onset Late Onset 
MyD88 Haplotype CD n=138 CD n=32 
'1: (Group AI) (Group A2) p 
( rs4988457-rs7744-rs6853) Freq. s.d. Freq. s.d. 
-/-/- 0.73 0.03 0.64 0.06 1.87 0.171 
-/+/- 0.14 0.02 0.28 0.06 5.0] 0.025 
-/-/+ 0.06 0.02 0.05 0.03 0.25 0.617 
+/-/- 0.01 0.Ql 0.02 0.02 0.00 0.965 
Table 19. Estimated haplotype frequencies for MyD88 SNPs in early and late onset CD 
populations (Vienna Classification groups A I and A2). Haplotypes were estimated from 
a total population of 170 CD patients. Estimated MyD88 haplotype frequencies and 
standard deviations are given as a proportion of the group total. Haplotypes with a 
significantly different di stribution between groups are highl ighted in red. 
+ Mutant allele, - Wi ldtype allele. 
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Family-Based Tests of Association: Family-based tests were performed in the same 
phenotypic groups. Two PDT analyses showed evidence for MyD88 mutant allele 
association in the CD population (Table 20). Firstly, there was over-representation of the 
MyD88 intron 3 rs4988457 mutant allele in probands with fistulizing CD when compared 
to their unaffected siblings in 17 families (P=0.045). Secondly, there was over-
transmission of the 3'-UTR rs7744 mutant allele from parents to CD-affected individuals 
in 11 families where the disease process was not complicated by extra-intestinal 
manifestations (P=0.039). However, neither of these analyses were significant following 
application of the Bonferroni method, using a corrected significance level ofP,::::0.0167. 
The opposite situation was evident for analysis of MyD88 mutant allele frequencies in 
UC families with a disease process uncomplicated by the presence of extra-intestinal 
manifestations. PDT analysis of 11 families showed under-representation of the 3'-UTR 
rs7744 mutant allele in UC patients with no extra-intestinal manifestations (P=0.033). 
This was not significant following correction for multiple analyses. In a similar manner, 
the global test of differentiation for MyD88 SNP haplotypes using the likelihood ratio test 
was significant for in a cohort of26 families where the proband had UC uncomplicated 
by extra-intestinal manifestations (P=0.044) (Table 21). Analysis of transmission of 
individual haplotypes showed under-transmission of the haplotype consisting of the 
rs7744 mutant allele, and the rs4988457 and rs6853 wildtype alleles in this UC subgroup 
(P=0.018). As with all other family-based analyses this was not significant at the 
corrected significance level, and type 1 error can therefore not be excluded. 
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Table 20. Significant Pedigree Disequilibrium Test analyses for MyD88 sub-phenotypic 
groups. These analyses appear to show over-transmission of the two MyD88 SNPs in 
both CD with a fistulizing behavior pattern and disease uncomplicated by extra-intestinal 
disease manifestations. The opposite pattern is seen in UC with the absence of extra-
intestinal disease, where mutant alleles are significantly under-transmitted. 
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Mutant Allele Frequency 
Disease Group SNP Number of Parental Contribution Discordant Sibs 1: P Families 
Transmitted Not Affected Unaffected Transmitted 
Fistulizing (B3) rs4988457 17 0 0 5 2 4.00 0.045 (Intron 3) 
-VI CD \0 
Absence of 
rs7744 Extra-intestinal (3'-UTR) 11 4 1 5 1 4.26 0.039 Manifestations 
Absence of 




(rs4988457 -rs77 44- Variance P 
Frequency Frequency 
rs6853)* 
-/-/- 44 40.92 2.30 4.13 0.042 
-/+/- 6 9.70 2.44 5.61 0.018 
-/-/+ 0.69 0.10 0.93 0.336 
+/-/+ 0.69 0.11 0.87 0.350 
Table 21. MyD88 haplotype frequencies for families where the proband has UC without 
the presence of extra-intestinal mani festations. Analyses were performed using 25 
families using a likelihood ratio test as implemented in the computer program 
TRANSMIT. Haplotypes with a sign ificantly different di stribution between groups are 
highlighted in red. ·Only haplotypes with ~5% frequency are shown. 
+ Mutant al lele; - Wildtype allele. 
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Discussion 
Three SNPs in both lRAK-M and MyD88 have been characterized in order to 
assess whether either gene has a role in IBD susceptibility in the study population. 
Following SNP-specific PCR analysis, candidate gene allele data was analyzed using 
population- and family-based statistical methodology. Initial results from case-control 
analyses, where candidate gene allele frequencies were compared between disease and 
control populations, proved disappointing. No allelic associations were demonstrated for 
the six characterized candidate gene SNPs in CD, ue or Ie disease populations as a 
whole. This absence of association in these major IBD categories was confirmed by 
comparison of estimated haplotype frequencies for candidate gene SNPs, and by 
performing family-based studies. It must therefore be conclude that neither lRAK-M nor 
MyD88 are involved in IBD susceptibility when considering CD, ue and IC as a whole. 
Analysis of candidate genes at the sub-phenotypic level did provide some more 
promising results. Specifically, analysis of MyD88 3'-UTR SNP mutant allele 
frequencies suggested that this gene might playa role in susceptibility to late onset CD in 
patients with a family history of IBD. Population based methods showed over-
representation of 3' -UTR rs6853 alleles in CD patients with a family history of IBD 
(P=O.015), and over-representation of 3' -UTR rs7744 alleles in CD patients with an age 
of disease onset over forty years of age (P=O.005). Importantly, both these results 
appeared to remain valid following correction for compounding of type 1 statistical error, 
making them particularly exciting findings. 
Correction for multiple testing has proven an extremely troublesome problem 
throughout this study, as well as other parts of this dissertation. A prime example of this 
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problem is given when considering results from estimation of MyD88 SNP haplotypes. 
These showed that the haplotype consisting ofthe mutant rs7744 (3' -UTR) allele and 
wildtype rs4988457 (intron 3) and rs6853 (3' -UTR) alleles was significantly more 
common in the late onset (A2) group than in the early onset (AI) CD group (P=O.025). 
On first examination, this result appears to corroborate the findings of population-based 
association tests i.e. that the 3' -UTR rs7744 mutant allele is associated with late onset 
CD. However, following application of the Bonferroni correction for 4 individual tests, 
this result is not significant and type 1 error therefore cannot be excluded. 
The problem of mUltiple testing again arises when one considers results from 
family-based association tests. These suggested that in addition to late onset CD in 
patients with a family history of IBD, MyD88 might be involved in susceptibility to both 
fistulizing CD and CD with the absence of extra-intestinal manifestations. Specifically, 
there appeared to be over-transmission of intron 3 rs4988457 and 3' -UTR rs7744 mutant 
alleles in each of these CD sub-phenotypes. The possible involvement of MyD88 mutant 
SNPs in development of extra-intestinal manifestations in IBD was complicated still 
further when one considers the findings oflikelihood ratio analysis in UC families. In this 
instance there was significant under-transmission of a haplotype containing the mutant 
rs7744 allele in families where the proband had UC without extra-intestinal disease. 
However, as was the case with comparisons of the estimated haplotypes described above, 
correction for multiple testing rendered these apparent associations non-significant, again 
implying that they probably have occurred as a result oftype 1 error. All these should 
therefore only be viewed as trends and by no means conclusive evidence of the 
involvement of MyD88 in susceptibility to these sub-phenotypes. However, before 
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dismissing these results as type 1 error it is worthwhile considering the size of the study 
cohort. Analysis at the sUb-phenotype level in this study cohort involves consideration of 
very low number of families. It is therefore somewhat remarkable that any associations 
were evident on PDT and TRANSMIT analysis given the stringency and robustness of 
these tests. It will therefore be very interesting to repeat these analyses when more 
patients have been accrued. 
Given all the issues relating to compounding of type 1 error and correction for this 
serious problem, it appears that the associations of MyD88 3' -VTR rs6853 and rs7744 
SNPs with late onset CD in patients with a family history ofIBD are of particular 
interest. Despite the apparent association of the two 3'-VTR SNPs following population-
based testing and correction for multiple analyses, a number of prominent reservations do 
exist in proclaiming MyD88 as the "next CD susceptibility gene". Firstly, since the sub-
phenotype populations contain relatively few subjects, any testing performed in these 
groups will lack statistical power. Low statistical power interferes with the accuracy of 
statistical comparisons, and it will therefore be of great interest to see if the associations 
evident for the two 3' -VTR SNPs remain apparent in a larger cohort. Secondly, one 
would expect linkage disequilibrium to exist between the two 3' -VTR SNPs since they 
are in extremely close generic proximity (rs7744 and rs6853 are separated by 348bp). 
Subsequently, one would expect the same associations to be found for both SNPs. This 
was not the case, with the finding of association of rs6853 alleles for CD patients with a 
family history ofIBD not being reciprocated with rs7744. The same can be said with the 
association ofrs7744 alleles in CD patients with an age of disease onset over forty years 
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of age not being reciprocated with rs6853 alleles. These results must therefore be viewed 
cautiously. 
An obvious criticism of this work is the absence of association with mutant 3' -
UTR SNP alleles in the unstratified CD population. Indeed, case-control studies were far 
from significant for both 3' -UTR SNPs for CD versus control comparisons of mutant 
allele frequencies (rs7744 P=O.225, rs6853 P=O.651). Studies with the CD susceptibility 
gene NOD2 in other populations have shown a relatively strong association with 
unstratified CD populations and extremely high levels of association at the sub-
phenotype level (i.e. with fibrostenosing ileocolic CD) (31 ;35;36). This criticism is 
addressed when previous experiences with NOD2 in this laboratory are considered. 
Associations were only found for one of the three NOD2 disease-causing mutations in the 
unstratified CD cohort in this study population (unpublished data). However, all three of 
the disease-causing SNPs were strongly associated with fibrostenosing ileocolic CD. This 
is really a reflection on the size of this cohort, and the power of statistical analyses in 
such a population. The ability to detect association in a small cohort at the unstratified 
level is somewhat limited given the likely small effect of any susceptibility gene 
(including NOD2) combined with relatively low subject numbers. However, a particular 
strength of this study is the depth and quality of phenotype data available for all subjects. 
All patients are derived from a single surgeons practice and have clinical follow-up of 
significant duration, thus allowing for consistency of phenotyping and accurate 
information regarding changes in the course of disease. Furthermore, a single GI 
pathologist with a particular interest in IBD has reviewed all pathology, again increasing 
the accuracy and consistency of phenotyping. Therefore, any analysis of genetic data at 
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the sub-phenotype level will likely be highly accurate. This, taken together with the 
previous study of NOD2 in this population, gives strength to the argument that MyD88 
may be involved in susceptibility to late onset CD in patients with a family history of 
IBD. 
Another point of concern is the use of the notoriously conservative Bonferroni 
method to correct for compounding of type 1 error in this study. Indeed, some have 
started to question the rationale for using such stringent correction methods in genetic 
association studies, and have suggested that guarding against a single false positive 
occurring in genetic association studies is often going to be much too strict and will lead 
to many missed findings (131). Furthermore, some have suggested that assessing the 
likelihood of chance association should be considered in the light of the biological 
plausibility of any observed associations (95; 132). A number of possible SNP 
associations for the regulatory 3' -UTR of MyD88 have been rejected using the 
Bonferroni correction method. It may therefore prove worthwhile to re-analyze the 
current data set by applying a less stringent means of correcting for multiple analyses. 
The case of lRAK-M is much more clear-cut. No associations were evident in 
either the unstratified or stratified disease populations, and it is therefore probably true 
that this gene plays no role in IBD susceptibility in the study population. It could be 
argued that low sample size could have led to type 2 statistical errors in the instance of 
lRAK-M. This is, however, unlikely to be the case here since there was not even evidence 
of trends towards association for any lRAK-MSNP in any disease group. It may therefore 
prove prudent to exclude lRAK-M from further study as an IBD susceptibility gene. 
Negative studies such as this are an unfortunate consequence of the candidate gene 
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approach. When the biological nature of a disease is uncertain, as is the case with IBD, 
researchers are required to make "educated guesses" as to mechanisms underlying 
pathogenesis of the disorder. Although lRAK-M appeared to be a biologically plausible 
candidate that is located in an IBD-associated susceptibility locus, it did not turn out to be 
involved in disease susceptibility. The cause ofIBD2 disease association in this 
population therefore remains unclear. 
In summary, preliminary evidence is provid¢d to suggest that the adaptor protein 
MyD88 may be involved in susceptibility to late onset CD in patients with a family 
history ofIBD. The next step in this study will be to increase the size of the cohort and 
thus increase MyD88 genotype data. If the associations shown here hold true in a larger 




Summary of Findings 
This dissertation presents new, albeit somewhat preliminary, evidence to suggest 
that MyD88 is involved in susceptibility to late onset Crohn's disease in patients with a 
family history oflBD. Furthermore, IRAK-M has been conclusively excluded from IBD 
susceptibility in this population. 
The aim of the first series of experiments was to characterize a number of IBD 
susceptibility loci in the study population. The overall aim here was to improve study 
population disease characterization by defining peak LOD score STRs from previously 
described susceptibility loci. A somewhat different approach was taken than has 
commonly been employed in previous studies. Firstly, a case-control approach was used, 
in contrast to the affected sib-pair linkage analyses of earlier work. Secondly, distinct 
IBD phenotypic groups were examined, rather than the clinically heterogeneous 'CD' and 
'UC' classification system conventionally employed. Disease associations were observed 
for the IBD1, IBD2 and IBD5 susceptibility loci in a variety ofIBD phenotypes. In 
addition, the other studied loci from IBD susceptibility in this population. 
The results from this study, as well as a previous study (94), formed the basis of 
the second set of experiments, where a more detailed characterization of the IBD2 
167 
susceptibility locus was performed. This locus was chosen ahead ofIBDI since the 
susceptibility gene within this locus, NOD2, had already been defined (26;27). Similarly, 
IBD5 was not characterized any further since the region of susceptibility has already been 
narrowed down to a 250kb region of chromosome 5 (118). In contrast, the IBD2 locus 
remained less well characterized, and by employing the same methods as were used in 
the previous study, IBD2 was shown to be involved in susceptibility to indeterminate 
colitis, colonic Crohn's disease, and to some extent ulcerative colitis in the study 
population. 
This detailed characterization ofIBD2 formed the background for the next study, 
where a candidate gene approached was employed with the aim being to define new IBD 
susceptibility genes. Two genes were chosen for this purpose: lRAK-M, an inhibitor of 
the pro inflammatory Toll-like receptor signaling pathway, was chosen on the basis of its 
genomic location (within IBD2, close to the peak LOD score STR) and biological 
plausibility as an IBD candidate gene; MyD88, an adaptor protein involved in TLR-
mediated apoptotic signaling, was chosen on the basis of its biological plausibility and its 
genomic location within the IBD9 susceptibility locus. It should be noted, however, that 
the IBD9 locus was not characterized in this population. The first study essentially 
formed the groundwork for assessing these two candidates as IBD susceptibility genes. 
First, colonic mucosal expression levels in IBD-affected tissue were quantified for both 
candidate genes. This was performed to determine whether candidate genes exhibited 
dysregulation in IBD-affected colonic mucosa when compared to normal colonic mucosa. 
Second, candidate gene coding and regulatory regions were screened for polymorphisms. 
Mutation of these regions could have profound effects on candidate gene functionality, 
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which in turn could lead to the development ofIBD. Both candidates were found to be 
significantly over-expressed in both UC- and CD-affected colonic mucosa. Additionally, 
seven commonly occurring SNPs were defined within coding or potentially regulatory 
regions of the two candidate genes. Four of these SNPs were within lRAK-M and three 
were within MyD88. 
The series of experiments following this screening process involved 
characterization of six of the seven candidate gene SNPs in the entire study cohort. The 
seventh SNP, a T ~A polymorphism within exon 12 of lRAK-M, was not studied any 
further since it was a synonymous change and did not alter the amino acid sequence of 
the IRAK-M protein. Population- and family-based statistical methodologies were 
employed to examine the role of identified candidate gene SNPs in IBD susceptibility. 
MyD88 provided by far the more interesting results. Apparent associations were observed 
with two SNPs within the 3' -UTR of MyD88 in late onset CD in patients with a family 
history ofIBD. These associations are particularly interesting since 3'-UTRs have been 
shown to be extremely important in regulating gene expression, and mutations within the 
3' -UTRs of several genes have been implicated in the pathogenesis of a number of 
diseases (128). These associations are however only view these as preliminary evidence 
of involvement of MyD88 in IBD susceptibility for a number of reasons. This is primarily 
because associations were observed in a relatively small sample size, meaning that 
subsequent analyses lacked statistical power. lRAK-M, on the other hand, did not display 
any evidence of disease association in this population, and this gene is unlikely to be 
involved in IBD susceptibility in this population. 
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Directions of Future Research 
The most important question raised by this dissertation is whether MyD88 is 
really involved in susceptibility to late onset CD in patients with a family history of IBD. 
As mentioned previously, the statistical analyses used to derive this conclusion lacked 
statistical power. For example, the total number of patients in the comparative groups 
which led to the conclusion that the My D88 3' -UTR rs7744 SNP was associated with late 
onset CD was 125 in the Al Vienna Classification subgroup, and 35 in the A2 Vienna 
Classification subgroup. It is for this reason that the primary focus of this study was to 
define allelic associations, which enabled the use of increased numbers in analyses, as 
well as decreasing the total number of comparisons. These numbers are small, and 
despite the apparent level of association being relatively strong in this instance (P=0.005), 
it would be wise to conclude that the overall sample size is too small to be able to 
confidently state that MyD88 is an IBD susceptibility gene. In earlier studies involving 
the IBD susceptibility gene NOD2 that have employed this type of sub-phenotype 
analysis, and the smallest size of any subgroup included has been approximately double 
the size of the A2 Vienna Classification subgroup used here (31;35;36). For the apparent 
MyD88 associations presented here to be accepted by a wider scientific community, it is 
imperative that newly accrued patients are genotyped for the two MyD88 3'-UTR SNPs 
in the future. Indeed the problem of low sample size was apparent in family based 
studies, which showed association of 3' -UTR mutant SNP alleles with a number of other 
CD SUb-phenotypes. These were however, not significant after correction for multiple 
analyses. If these associations hold true in a larger population, it will indeed be an 
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important finding that will have great implications on our understanding of IBD 
pathogenesis. 
The lack of association of lRAK-M SNPs with IBD was disappointing, although 
not completely unexpected. Negative outcomes are inevitable in the majority of candidate 
gene studies given our lack of understanding of the pathophysiologic mechanisms 
underlying the deVelopment of most complex disorders. The cause of IBD2 association in 
this population, and consequently the identity of the IBD2 susceptibility gene remain 
unknown. There are essentially two approaches that can be taken to attempt to identify 
the IBD2 susceptibility gene(s): 1) to perform further candidate gene studies with the 
knowledge that most will have negative outcomes; 2) haplotype block mapping of the 
susceptibility locus. I believe for a number of reasons that the second option is by far the 
most appropriate approach to take in future studies. Firstly, high throughput genotyping 
techniques are now widely available and characterization of polymorphisms in an entire 
popUlation can be achieved relatively efficiently. Secondly, the analysis software 
available for haplotype block analysis is both powerful and widely available. Mapping of 
IBD2 could be performed at a relatively low resolution initially, for example by screening 
~ 1kb amplicons for polymorphisms at 100kb intervals within IBD2. In this manner, the 
region of association within IBD2 could be narrowed down to a much more manageable 
size to identify potential candidate genes than the 3.0SMbp region used in the current 
study. This approach does have a number of serious drawbacks however, the most 
notable of which is that the process is laborious, costly and by no means guarantees quick 
results. For example, the fine mapping study that defined the IBDI gene NOD2 took 
approximately six years to complete from start to finish (26). 
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The identification of IBD susceptibility genes is of crucial importance. Definition 
of such genes will give researchers fresh insights into the pathological basis of IBD and 
may aid the development of novel therapies to alleviate the often severe symptoms that 
accompany this disease. The aim of this study has been to define IBD susceptibility 
genes, and hopefully it may serve as a platform for future efforts to achieve this goal. 
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